<?xml version="1.0" encoding="UTF-8"?>
<GoldLabel drug="RISPERDAL">
  <Text>
    <Section id="S1" name="adverse reactions">  6 ADVERSE REACTIONS

  The following are discussed in more detail in other sections of the labeling:

 *  Increased mortality in elderly patients with dementia-related psychosis [see    Boxed Warning    and    Warnings and Precautions (5.1)  ]  
 *  Cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis [see    Warnings and Precautions (5.2)  ]  
 *  Neuroleptic malignant syndrome [see    Warnings and Precautions (5.3)  ]  
 *  Tardive dyskinesia [see    Warnings and Precautions (5.4)  ]  
 *  Metabolic Changes (Hyperglycemia and diabetes mellitus, Dyslipidemia, and Weight Gain) [see    Warnings and Precautions (5.5)  ]  
 *  Hyperprolactinemia [see    Warnings and Precautions (5.6)  ]  
 *  Orthostatic hypotension [see    Warnings and Precautions (5.7)  ]  
 *  Falls [see  Warnings and Precautions (5.8)  ]  
 *  Leukopenia, neutropenia, and agranulocytosis [see  Warnings and Precautions (5.9)  ]  
 *  Potential for cognitive and motor impairment [see  Warnings and Precautions (5.10)  ]  
 *  Seizures [see    Warnings and Precautions (5.11)  ]  
 *  Dysphagia [see    Warnings and Precautions (5.12)  ]  
 *  Priapism [see    Warnings and Precautions (5.13)  ]  
 *  Disruption of body temperature regulation [see    Warnings and Precautions (5.14)  ]  
 *  Patients with Phenylketonuria [see    Warnings and Precautions (5.15)  ].  
    The most common adverse reactions in clinical trials (&gt;5% and twice placebo) were parkinsonism, akathisia, dystonia, tremor, sedation, dizziness, anxiety, blurred vision, nausea, vomiting, upper abdominal pain, stomach discomfort, dyspepsia, diarrhea, salivary hypersecretion, constipation, dry mouth, increased appetite, increased weight, fatigue, rash, nasal congestion, upper respiratory tract infection, nasopharyngitis, and pharyngolaryngeal pain.
 

 The most common adverse reactions that were associated with discontinuation from clinical trials (causing discontinuation in &gt;1% of adults and/or &gt;2% of pediatrics) were nausea, somnolence, sedation, vomiting, dizziness, and akathisia  [see      Adverse Reactions, Discontinuations Due to Adverse Reactions (6.1)  ]  .

 The data described in this section are derived from a clinical trial database consisting of 9803 adult and pediatric patients exposed to one or more doses of RISPERDAL  (r)  for the treatment of schizophrenia, bipolar mania, autistic disorder, and other psychiatric disorders in pediatrics and elderly patients with dementia. Of these 9803 patients, 2687 were patients who received RISPERDAL  (r)  while participating in double-blind, placebo-controlled trials. The conditions and duration of treatment with RISPERDAL  (r)  varied greatly and included (in overlapping categories) double-blind, fixed- and flexible-dose, placebo- or active-controlled studies and open-label phases of studies, inpatients and outpatients, and short-term (up to 12 weeks) and longer-term (up to 3 years) exposures. Safety was assessed by collecting adverse events and performing physical examinations, vital signs, body weights, laboratory analyses, and ECGs.

   EXCERPT:   The most common adverse reactions in clinical trials (&gt;=5% and twice placebo) were parkinsonism, akathisia, dystonia, tremor, sedation, dizziness, anxiety, blurred vision, nausea, vomiting, upper abdominal pain, stomach discomfort, dyspepsia, diarrhea, salivary hypersecretion, constipation, dry mouth, increased appetite, increased weight, fatigue, rash, nasal congestion, upper respiratory tract infection, nasopharyngitis, and pharyngolaryngeal pain. (  6  )

   To report SUSPECTED ADVERSE REACTIONS, contact Janssen Pharmaceuticals, Inc.    at 1-800-JANSSEN (1-800-526-7736) or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch    

 

  6.1 Clinical Trials Experience

  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

     Commonly-Observed Adverse Reactions in Double-Blind, Placebo-Controlled Clinical Trials - Schizophrenia  

     Adult Patients with Schizophrenia  

 Table 8 lists the adverse reactions reported in 2% or more of RISPERDAL  (r)  -treated adult patients with schizophrenia in three 4- to 8-week, double-blind, placebo-controlled trials.

 Table 8. Adverse Reactions in &gt;=2% of RISPERDAL(r)-Treated Adult Patients (and greater than placebo) with Schizophrenia in Double-Blind, Placebo-Controlled Trials 
                                           Percentage of Patients Reporting Reaction   
                                             RISPERDAL  (r)                             
 System/Organ Class  Adverse Reaction      2-8 mg per day(N=366)  &gt;8-16 mg per day(N=198)     Placebo(N=225)      
  
   Cardiac Disorders                                                                                          
   Tachycardia                                      1                     3                     0             
   Eye Disorders                                                                                              
   Vision blurred                                   3                     1                     1             
   Gastrointestinal Disorders                                                                                 
   Nausea                                           9                     4                     4             
   Constipation                                     8                     9                     6             
   Dyspepsia                                        8                     6                     5             
   Dry mouth                                        4                     0                     1             
   Abdominal discomfort                             3                     1                     1             
   Salivary hypersecretion                          2                     1                     &lt;1            
   Diarrhea                                         2                     1                     1             
   General Disorders                                                                                          
   Fatigue                                          3                     1                     0             
   Chest pain                                       2                     2                     1             
   Asthenia                                         2                     1                     &lt;1            
   Infections and Infestations                                                                                
   Nasopharyngitis                                  3                     4                     3             
   Upper respiratory tract infection                2                     3                     1             
   Sinusitis                                        1                     2                     1             
   Urinary tract infection                          1                     3                     0             
   Investigations                                                                                             
   Blood creatine phosphokinase increased           1                     2                     &lt;1            
   Heart rate increased                             &lt;1                    2                     0             
   Musculoskeletal and Connective Tissue Disorders                                                                       
   Back pain                                        4                     1                     1             
   Arthralgia                                       2                     3                     &lt;1            
   Pain in extremity                                2                     1                     1             
   Nervous System Disorders                                                                                   
 Parkinsonism [note: Parkinsonism includes extrapyramidal disorder, musculoskeletal stiffness, parkinsonism, cogwheel rigidity, akinesia, bradykinesia, hypokinesia, masked facies, muscle rigidity, and Parkinson's disease. Akathisia includes akathisia and restlessness. Dystonia includes dystonia, muscle spasms, muscle contractions involuntary, muscle contracture, oculogyration, tongue paralysis. Tremor includes tremor and parkinsonian rest tremor.]            14                    17                    8             
   Akathisia                                        10                    10                    3             
   Sedation                                         10                    5                     2             
   Dizziness                                        7                     4                     2             
   Dystonia                                         3                     4                     2             
   Tremor                                           2                     3                     1             
   Dizziness postural                               2                     0                     0             
   Psychiatric Disorders                                                                                      
   Insomnia                                         32                    25                    27            
   Anxiety                                          16                    11                    11            
   Respiratory, Thoracic and Mediastinal Disorders                                                                       
   Nasal congestion                                 4                     6                     2             
   Dyspnea                                          1                     2                     0             
   Epistaxis                                        &lt;1                    2                     0             
   Skin and Subcutaneous Tissue Disorders                                                                       
   Rash                                             1                     4                     1             
   Dry skin                                         1                     3                     0             
   Vascular Disorders                                                                                         
   Orthostatic hypotension                          2                     1                     0             
              Pediatric Patients with Schizophrenia  
 

 Table 9 lists the adverse reactions reported in 5% or more of RISPERDAL  (r)  -treated pediatric patients with schizophrenia in a 6-week double-blind, placebo-controlled trial.

 Table 9. Adverse Reactions in &gt;=5% of RISPERDAL(r)-Treated Pediatric Patients (and greater than placebo) with Schizophrenia in a Double-Blind Trial 
                                           Percentage of Patients Reporting Reaction   
                                             RISPERDAL  (r)                             
 System/Organ Class  Adverse Reaction      1-3 mg per day(N=55)  4-6 mg per day(N=51)     Placebo(N=54)       
  
   Gastrointestinal Disorders                                                                                 
   Salivary hypersecretion                          0                     10                    2             
   Nervous System Disorders                                                                                   
   Sedation                                         24                    12                    4             
 Parkinsonism [note: Parkinsonism includes extrapyramidal disorder, muscle rigidity, musculoskeletal stiffness, and hypokinesia. Akathisia includes akathisia and restlessness. Dystonia includes dystonia and oculogyration.]            16                    28                    11            
   Tremor                                           11                    10                    6             
   Akathisia                                        9                     10                    4             
   Dizziness                                        7                     14                    2             
   Dystonia                                         2                     6                     0             
   Psychiatric Disorders                                                                                      
   Anxiety                                          7                     6                     0             
              Commonly-Observed Adverse Reactions in Double-Blind, Placebo-Controlled Clinical Trials - Bipolar Mania  
 

     Adult Patients with Bipolar Mania  

 Table 10 lists the adverse reactions reported in 2% or more of RISPERDAL  (r)  -treated adult patients with bipolar mania in four 3-week, double-blind, placebo-controlled monotherapy trials.

 Table 10. Adverse Reactions in &gt;=2% of RISPERDAL(r)-Treated Adult Patients (and greater than placebo) with Bipolar Mania in Double-Blind, Placebo-Controlled Monotherapy Trials 
                                                     Percentage of Patients Reporting Reaction   
 System/Organ Class  Adverse Reaction                RISPERDAL  (r)  1-6 mg per day(N=448)       Placebo(N=424)         
  
   Eye Disorders                                                                                            
   Vision blurred                                                2                          1               
   Gastrointestinal Disorders                                                                               
   Nausea                                                        5                          2               
   Diarrhea                                                      3                          2               
   Salivary hypersecretion                                       3                          1               
   Stomach discomfort                                            2                         &lt;1               
   General Disorders                                                                                        
   Fatigue                                                       2                          1               
   Nervous System Disorders                                                                                 
   Parkinsonism [note: Parkinsonism includes extrapyramidal disorder, parkinsonism, musculoskeletal stiffness, hypokinesia, muscle rigidity, muscle tightness, bradykinesia, cogwheel rigidity. Akathisia includes akathisia and restlessness. Tremor includes tremor and parkinsonian rest tremor. Dystonia includes dystonia, muscle spasms, oculogyration, torticollis.]              25                          9               
   Sedation                                                     11                          4               
   Akathisia                                                     9                          3               
   Tremor                                                        6                          3               
   Dizziness                                                     6                          5               
   Dystonia                                                      5                          1               
   Lethargy                                                      2                          1               
         Table 11 lists the adverse reactions reported in 2% or more of RISPERDAL  (r)  -treated adult patients with bipolar mania in two 3-week, double-blind, placebo-controlled adjuvant therapy trials.
 

 Table 11. Adverse Reactions in &gt;=2% of RISPERDAL(r)-Treated Adult Patients (and greater than placebo) with Bipolar Mania in Double-Blind, Placebo-Controlled Adjunctive Therapy Trials 
                                           Percentage of Patients Reporting Reaction   
 System/Organ Class                         RISPERDAL  (r)  + Mood Stabilizer   Placebo + Mood Stabilizer   
   Adverse Reaction                                      (N=127)                         (N=126)            
  
   Cardiac Disorders                                                                                        
   Palpitations                                             2                               0               
   Gastrointestinal Disorders                                                                               
   Dyspepsia                                                9                               8               
   Nausea                                                   6                               4               
   Diarrhea                                                 6                               4               
   Salivary hypersecretion                                  2                               0               
   General Disorders                                                                                        
   Chest pain                                               2                               1               
   Infections and Infestations                                                                              
   Urinary tract infection                                  2                               1               
   Nervous System Disorders                                                                                 
   Parkinsonism [note: Parkinsonism includes extrapyramidal disorder, hypokinesia and bradykinesia. Akathisia includes hyperkinesia and akathisia.]                   14                               4               
 Sedation                                                   9                               4               
   Akathisia                                                8                               0               
   Dizziness                                                7                               2               
   Tremor                                                   6                               2               
   Lethargy                                                 2                               1               
   Psychiatric Disorders                                                                                    
   Anxiety                                                  3                               2               
   Respiratory, Thoracic and Mediastinal Disorders                                                                     
   Pharyngolaryngeal pain                                   5                               2               
   Cough                                                    2                               0               
             Pediatric Patients with Bipolar Mania  
 

 Table 12 lists the adverse reactions reported in 5% or more of RISPERDAL  (r)  -treated pediatric patients with bipolar mania in a 3-week double-blind, placebo-controlled trial.

 Table 12. Adverse Reactions in &gt;=5% of RISPERDAL(r)-Treated Pediatric Patients (and greater than placebo) with Bipolar Mania in Double-Blind, Placebo-Controlled Trials 
                                           Percentage of Patients Reporting Reaction   
                                             RISPERDAL  (r)                             
 System/Organ Class  Adverse Reaction      0.5-2.5 mg per day(N=50)  3-6 mg per day(N=61)     Placebo(N=58)       
  
   Eye Disorders                                                                                              
   Vision blurred                                   4                     7                     0             
   Gastrointestinal Disorders                                                                                 
   Abdominal pain upper                             16                    13                    5             
   Nausea                                           16                    13                    7             
   Vomiting                                         10                    10                    5             
   Diarrhea                                         8                     7                     2             
   Dyspepsia                                        10                    3                     2             
   Stomach discomfort                               6                     0                     2             
   General Disorders                                                                                          
   Fatigue                                          18                    30                    3             
   Metabolism and Nutrition Disorders                                                                         
   Increased appetite                               4                     7                     2             
   Nervous System Disorders                                                                                   
   Sedation                                         42                    56                    19            
   Dizziness                                        16                    13                    5             
 Parkinsonism [note: Parkinsonism includes musculoskeletal stiffness, extrapyramidal disorder, bradykinesia, and nuchal rigidity. Dystonia includes dystonia, laryngospasm, and muscle spasms. Akathisia includes restlessness and akathisia.]            6                     12                    3             
   Dystonia                                         6                     5                     0             
   Akathisia                                        0                     8                     2             
   Psychiatric Disorders                                                                                      
   Anxiety                                          0                     8                     3             
   Respiratory, Thoracic and Mediastinal Disorders                                                                       
   Pharyngolaryngeal pain                           10                    3                     5             
   Skin and Subcutaneous Tissue Disorders                                                                       
   Rash                                             0                     7                     2             
              Commonly-Observed Adverse Reactions in Double-Blind, Placebo-Controlled Clinical Trials - Autistic Disorder  
 

 Table 13 lists the adverse reactions reported in 5% or more of RISPERDAL  (r)  -treated pediatric patients treated for irritability associated with autistic disorder in two 8-week, double-blind, placebo-controlled trials and one 6-week double-blind, placebo-controlled study.

 Table 13. Adverse Reactions in &gt;=5% of RISPERDAL(r)-Treated Pediatric Patients (and greater than placebo) Treated for Irritability Associated with Autistic Disorder in Double-Blind, Placebo-Controlled Trials 
                                                          Percentage of Patients Reporting Reaction   
 System/Organ Class                                       RISPERDAL  (r)  0.5-4.0 mg/day  Placebo                
   Adverse Reaction                                       (N=107)                    (N=115)                
  
   Gastrointestinal Disorders                                                                               
   Vomiting                                               20                         17                     
   Constipation                                           17                         6                      
   Dry mouth                                              10                         4                      
   Nausea                                                 8                          5                      
   Salivary hypersecretion                                7                          1                      
   General Disorders and Administration Site Conditions                                                      
   Fatigue                                                31                         9                      
   Pyrexia                                                16                         13                     
   Thirst                                                 7                          4                      
   Infections and Infestations                                                                              
   Nasopharyngitis                                        19                         9                      
   Rhinitis                                               9                          7                      
   Upper respiratory tract infection                      8                          3                      
   Investigations                                                                                           
   Weight increased                                       8                          2                      
   Metabolism and Nutrition Disorders                                                                       
   Increased appetite                                     44                         15                     
   Nervous System Disorders                                                                                 
   Sedation                                               63                         15                     
   Drooling                                               12                         4                      
   Headache                                               12                         10                     
   Tremor                                                 8                          1                      
   Dizziness                                              8                          2                      
   Parkinsonism [note: Parkinsonism includes musculoskeletal stiffness, extrapyramidal disorder, muscle rigidity, cogwheel rigidity, and muscle tightness.]   8                          1                      
   Renal and Urinary Disorders                                                                              
   Enuresis                                               16                         10                     
   Respiratory, Thoracic and Mediastinal Disorders                                                          
   Cough                                                  17                         12                     
   Rhinorrhea                                             12                         10                     
   Nasal congestion                                       10                         4                      
   Skin and Subcutaneous Tissue Disorders                                                                   
   Rash                                                   8                          5                      
             Other Adverse Reactions Observed During the Clinical Trial Evaluation of Risperidone  
 

 The following additional adverse reactions occurred across all placebo-controlled, active-controlled, and open-label studies of RISPERDAL  (r)  in adults and pediatric patients.

 Blood and Lymphatic System Disorders: anemia, granulocytopenia, neutropenia

 Cardiac Disorders: sinus bradycardia, sinus tachycardia, atrioventricular block first degree, bundle branch block left, bundle branch block right, atrioventricular block

 Ear and Labyrinth Disorders: ear pain, tinnitus

 Endocrine Disorders: hyperprolactinemia

 Eye Disorders: ocular hyperemia, eye discharge, conjunctivitis, eye rolling, eyelid edema, eye swelling, eyelid margin crusting, dry eye, lacrimation increased, photophobia, glaucoma, visual acuity reduced

 Gastrointestinal Disorders: dysphagia, fecaloma, fecal incontinence, gastritis, lip swelling, cheilitis, aptyalism

 General Disorders: edema peripheral, thirst, gait disturbance, influenza-like illness, pitting edema, edema, chills, sluggishness, malaise, chest discomfort, face edema, discomfort, generalized edema, drug withdrawal syndrome, peripheral coldness, feeling abnormal

 Immune System Disorders: drug hypersensitivity

 Infections and Infestations: pneumonia, influenza, ear infection, viral infection, pharyngitis, tonsillitis, bronchitis, eye infection, localized infection, cystitis, cellulitis, otitis media, onychomycosis, acarodermatitis, bronchopneumonia, respiratory tract infection, tracheobronchitis, otitis media chronic

 Investigations: body temperature increased, blood prolactin increased, alanine aminotransferase increased, electrocardiogram abnormal, eosinophil count increased, white blood cell count decreased, blood glucose increased, hemoglobin decreased, hematocrit decreased, body temperature decreased, blood pressure decreased, transaminases increased

 Metabolism and Nutrition Disorders: decreased appetite, polydipsia, anorexia

 Musculoskeletal and Connective Tissue Disorders: joint stiffness, joint swelling, musculoskeletal chest pain, posture abnormal, myalgia, neck pain, muscular weakness, rhabdomyolysis

 Nervous System Disorders: balance disorder, disturbance in attention, dysarthria, unresponsive to stimuli, depressed level of consciousness, movement disorder, transient ischemic attack, coordination abnormal, cerebrovascular accident, speech disorder, syncope, loss of consciousness, hypoesthesia, tardive dyskinesia, dyskinesia, cerebral ischemia, cerebrovascular disorder, neuroleptic malignant syndrome, diabetic coma, head titubation

 Psychiatric Disorders: agitation, blunted affect, confusional state, middle insomnia, nervousness, sleep disorder, listlessness, libido decreased, and anorgasmia

 Renal and Urinary Disorders: enuresis, dysuria, pollakiuria, urinary incontinence

 Reproductive System and Breast Disorders: menstruation irregular, amenorrhea, gynecomastia, galactorrhea, vaginal discharge, menstrual disorder, erectile dysfunction, retrograde ejaculation, ejaculation disorder, sexual dysfunction, breast enlargement

 Respiratory, Thoracic, and Mediastinal Disorders: wheezing, pneumonia aspiration, sinus congestion, dysphonia, productive cough, pulmonary congestion, respiratory tract congestion, rales, respiratory disorder, hyperventilation, nasal edema

 Skin and Subcutaneous Tissue Disorders: erythema, skin discoloration, skin lesion, pruritus, skin disorder, rash erythematous, rash papular, rash generalized, rash maculopapular, acne, hyperkeratosis, seborrheic dermatitis

 Vascular Disorders: hypotension, flushing

     Additional Adverse Reactions Reported with RISPERDAL CONSTA  (r)    

 The following is a list of additional adverse reactions that have been reported during the premarketing evaluation of RISPERDAL CONSTA  (r)  , regardless of frequency of occurrence:

 Cardiac Disorders: bradycardia

 Ear and Labyrinth Disorders: vertigo

 Eye Disorders: blepharospasm

 Gastrointestinal Disorders: toothache, tongue spasm

 General Disorders and Administration Site Conditions: pain

 Infections and Infestations: lower respiratory tract infection, infection, gastroenteritis, subcutaneous abscess

 Injury and Poisoning: fall

 Investigations: weight decreased, gamma-glutamyltransferase increased, hepatic enzyme increased

 Musculoskeletal, Connective Tissue, and Bone Disorders: buttock pain

 Nervous System Disorders: convulsion, paresthesia

 Psychiatric Disorders: depression

 Skin and Subcutaneous Tissue Disorders: eczema

 Vascular Disorders: hypertension

     Discontinuations Due to Adverse Reactions  

     Schizophrenia - Adults  

 Approximately 7% (39/564) of RISPERDAL  (r)  -treated patients in double-blind, placebo-controlled trials discontinued treatment due to an adverse reaction, compared with 4% (10/225) who were receiving placebo. The adverse reactions associated with discontinuation in 2 or more RISPERDAL  (r)  -treated patients were:

 Table 14. Adverse Reactions Associated With Discontinuation in 2 or More RISPERDAL(r)-Treated Adult Patients in Schizophrenia Trials 
                                RISPERDAL  (r)                                     
 Adverse Reaction               2-8 mg/day(N=366)         &gt;8-16 mg/day(N=198)          Placebo(N=225)         
  
 Dizziness                            1.4%                       1.0%                        0%               
 Nausea                               1.4%                        0%                         0%               
 Vomiting                             0.8%                        0%                         0%               
 Parkinsonism                         0.8%                        0%                         0%               
 Somnolence                           0.8%                        0%                         0%               
 Dystonia                             0.5%                        0%                         0%               
 Agitation                            0.5%                        0%                         0%               
 Abdominal pain                       0.5%                        0%                         0%               
 Orthostatic hypotension              0.3%                       0.5%                        0%               
 Akathisia                            0.3%                       2.0%                        0%               
          Discontinuation for extrapyramidal symptoms (including Parkinsonism, akathisia, dystonia, and tardive dyskinesia) was 1% in placebo-treated patients, and 3.4% in active control-treated patients in a double-blind, placebo- and active-controlled trial.
 

     Schizophrenia - Pediatrics  

 Approximately 7% (7/106), of RISPERDAL  (r)  -treated patients discontinued treatment due to an adverse reaction in a double-blind, placebo-controlled trial, compared with 4% (2/54) placebo-treated patients. The adverse reactions associated with discontinuation for at least one RISPERDAL  (r)  -treated patient were dizziness (2%), somnolence (1%), sedation (1%), lethargy (1%), anxiety (1%), balance disorder (1%), hypotension (1%), and palpitation (1%).

     Bipolar Mania - Adults  

 In double-blind, placebo-controlled trials with RISPERDAL  (r)  as monotherapy, approximately 6% (25/448) of RISPERDAL  (r)  -treated patients discontinued treatment due to an adverse event, compared with approximately 5% (19/424) of placebo-treated patients. The adverse reactions associated with discontinuation in RISPERDAL  (r)  -treated patients were:

 Table 15. Adverse Reactions Associated With Discontinuation in 2 or More RISPERDAL(r)-Treated Adult Patients in Bipolar Mania Clinical Trials 
 Adverse Reaction                                    RISPERDAL  (r)  1-6 mg/day(N=448)       Placebo(N=424)         
  
 Parkinsonism                                                  0.4%                        0%               
 Lethargy                                                      0.2%                        0%               
 Dizziness                                                     0.2%                        0%               
 Alanine aminotransferase increased                            0.2%                       0.2%              
 Aspartate aminotransferase increased                          0.2%                       0.2%              
             Bipolar Mania - Pediatrics  
 

 In a double-blind, placebo-controlled trial 12% (13/111) of RISPERDAL  (r)  -treated patients discontinued due to an adverse reaction, compared with 7% (4/58) of placebo-treated patients. The adverse reactions associated with discontinuation in more than one RISPERDAL  (r)  -treated pediatric patient were nausea (3%), somnolence (2%), sedation (2%), and vomiting (2%).

     Autistic Disorder - Pediatrics  

 In the two 8-week, placebo-controlled trials in pediatric patients treated for irritability associated with autistic disorder (n=156), one RISPERDAL  (r)  -treated patient discontinued due to an adverse reaction (Parkinsonism), and one placebo-treated patient discontinued due to an adverse event.

     Dose Dependency of Adverse Reactions in Clinical Trials  

     Extrapyramidal Symptoms  

 Data from two fixed-dose trials in adults with schizophrenia provided evidence of dose-relatedness for extrapyramidal symptoms associated with RISPERDAL  (r)  treatment.

 Two methods were used to measure extrapyramidal symptoms (EPS) in an 8-week trial comparing 4 fixed doses of RISPERDAL  (r)  (2, 6, 10, and 16 mg/day), including (1) a Parkinsonism score (mean change from baseline) from the Extrapyramidal Symptom Rating Scale, and (2) incidence of spontaneous complaints of EPS:

 Table 16. 
 Dose Groups             Placebo       RISPERDAL  (r)  2 mg  RISPERDAL  (r)  6 mg  RISPERDAL  (r)  10 mg  RISPERDAL  (r)  16 mg   
  
 Parkinsonism              1.2                0.9                1.8               2.4               2.6          
 EPS Incidence             13%                17%                21%               21%               35%          
            Similar methods were used to measure extrapyramidal symptoms (EPS) in an 8-week trial comparing 5 fixed doses of RISPERDAL  (r)  (1, 4, 8, 12, and 16 mg/day):
 

 Table 17. 
 Dose Groups        RISPERDAL  (r)  1 mg  RISPERDAL  (r)  4 mg  RISPERDAL  (r)  8 mg  RISPERDAL  (r)  12 mg  RISPERDAL  (r)  16 mg   
  
 Parkinsonism              0.6                1.7                2.4               2.9               4.1          
 EPS Incidence             7%                 12%                17%               18%               20%          
                Dystonia  
 

     Class Effect:  Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.

     Other Adverse Reactions  

 Adverse event data elicited by a checklist for side effects from a large study comparing 5 fixed doses of RISPERDAL  (r)  (1, 4, 8, 12, and 16 mg/day) were explored for dose-relatedness of adverse events. A Cochran-Armitage Test for trend in these data revealed a positive trend (p&lt;0.05) for the following adverse reactions: somnolence, vision abnormal, dizziness, palpitations, weight increase, erectile dysfunction, ejaculation disorder, sexual function abnormal, fatigue, and skin discoloration.

     Changes in Body Weight  

 Weight gain was observed in short-term, controlled trials and longer-term uncontrolled studies in adult and pediatric patients  [see  Warnings and Precautions (5.5)  ,  Adverse Reactions (6)  , and  Use in Specific Populations (8.4)  ].  

     Changes in ECG Parameters  

 Between-group comparisons for pooled placebo-controlled trials in adults revealed no statistically significant differences between risperidone and placebo in mean changes from baseline in ECG parameters, including QT, QTc, and PR intervals, and heart rate. When all RISPERDAL  (r)  doses were pooled from randomized controlled trials in several indications, there was a mean increase in heart rate of 1 beat per minute compared to no change for placebo patients. In short-term schizophrenia trials, higher doses of risperidone (8-16 mg/day) were associated with a higher mean increase in heart rate compared to placebo (4-6 beats per minute). In pooled placebo-controlled acute mania trials in adults, there were small decreases in mean heart rate, similar among all treatment groups.

 In the two placebo-controlled trials in children and adolescents with autistic disorder (aged 5 - 16 years) mean changes in heart rate were an increase of 8.4 beats per minute in the RISPERDAL  (r)  groups and 6.5 beats per minute in the placebo group. There were no other notable ECG changes.

 In a placebo-controlled acute mania trial in children and adolescents (aged 10 - 17 years), there were no significant changes in ECG parameters, other than the effect of RISPERDAL  (r)  to transiently increase pulse rate (&lt; 6 beats per minute). In two controlled schizophrenia trials in adolescents (aged 13 - 17 years), there were no clinically meaningful changes in ECG parameters including corrected QT intervals between treatment groups or within treatment groups over time.

   6.2 Postmarketing Experience

  The following adverse reactions have been identified during postapproval use of risperidone. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These adverse reactions include: alopecia, anaphylactic reaction, angioedema, atrial fibrillation, cardiopulmonary arrest, diabetic ketoacidosis in patients with impaired glucose metabolism, dysgeusia, hypoglycemia, hypothermia, ileus, inappropriate antidiuretic hormone secretion, intestinal obstruction, jaundice, mania, pancreatitis, pituitary adenoma, precocious puberty, pulmonary embolism, QT prolongation, sleep apnea syndrome, sudden death, thrombocytopenia, thrombotic thrombocytopenic purpura, urinary retention, and water intoxication.

</Section>
    <Section id="S2" name="boxed warnings">

    BOXED WARNING: WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

    WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS  

    Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. RISPERDAL  (r)   (risperidone) is not approved for the treatment of patients with dementia-related psychosis.   [See   Warnings and Precautions (5.1)  ]    

   EXCERPT:   WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

   See full prescribing information for complete boxed warning.  

 *  Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. 
 *  RISPERDAL(r) is not approved for use in patients with dementia-related psychosis. (5.1) 
    

</Section>
    <Section id="S3" name="warnings and precautions">   5 WARNINGS AND PRECAUTIONS

   EXCERPT:    *  Cerebrovascular events, including stroke, in elderly patients with dementia-related psychosis: RISPERDAL  (r)  is not approved for use in patients with dementia-related psychosis. (  5.2  ) 
 *  Neuroleptic Malignant Syndrome: Manage with immediate discontinuation of RISPERDAL  (r)  and close monitoring. (  5.3  ) 
 *  Tardive dyskinesia: Consider discontinuing RISPERDAL  (r)  if clinically indicated. (  5.4  ) 
 *  *   Hyperglycemia and Diabetes Mellitus: Monitor patients for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Monitor glucose regularly in patients with diabetes or at risk for diabetes. (  5.5  ) 
 *   Dyslipidemia: Undesirable alterations have been observed in patients treated with atypical antipsychotics. (  5.5  ) 
 *   Weight Gain: Significant weight gain has been reported. Monitor weight gain. (  5.5  ) 
   Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/ cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain. (  5.5  ) 
 *  Hyperprolactinemia: Prolactin elevations occur and persist during chronic administration. (  5.6  ) 
 *  Orthostatic hypotension: For patients at risk, consider a lower starting dose and slower titration. (  5.7  ) 
 *  Leukopenia, Neutropenia, and Agranulocytosis: Perform complete blood counts in patients with a history of clinically significant low white blood cell count (WBC). Consider discontinuing RISPERDAL  (r)  if a clinically significant decline in WBC occurs in the absence of other causative factors. (  5.9  ) 
 *  Potential for cognitive and motor impairment: Use caution when operating machinery. (  5.10  ) 
 *  Seizures: Use cautiously in patients with a history of seizures or with conditions that lower the seizure threshold. (  5.11  ) 
    
 

   5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis

  Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear.

 In two of four placebo-controlled trials in elderly patients with dementia-related psychosis, a higher incidence of mortality was observed in patients treated with furosemide plus RISPERDAL  (r)  when compared to patients treated with RISPERDAL  (r)  alone or with placebo plus furosemide. No pathological mechanism has been identified to explain this finding, and no consistent pattern for cause of death was observed.

 RISPERDAL  (r)  (risperidone) is not approved for the treatment of dementia-related psychosis [see  Boxed Warning  ]  .

    5.2 Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis

  Cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack), including fatalities, were reported in patients (mean age 85 years; range 73-97) in trials of risperidone in elderly patients with dementia-related psychosis. In placebo-controlled trials, there was a significantly higher incidence of cerebrovascular adverse events in patients treated with risperidone compared to patients treated with placebo. RISPERDAL  (r)  is not approved for the treatment of patients with dementia-related psychosis. [see     Boxed Warning     and     Warnings and Precautions (5.1)  ]  

    5.3 Neuroleptic Malignant Syndrome

  Antipsychotic drugs including RISPERDAL  (r)  can cause a potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS). Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status, and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase (CPK), myoglobinuria, rhabdomyolysis, and acute renal failure.

 The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases in which the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology.

 The management of NMS should include: (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS.

 If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported.

    5.4 Tardive Dyskinesia

  A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. The risk of developing tardive dyskinesia and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses.

 There is no known treatment for established cases of tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.

 Given these considerations, prescribe RISPERDAL  (r)  in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that: (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.

 If signs and symptoms of tardive dyskinesia appear in a patient treated with RISPERDAL  (r)  , consider drug discontinuation. However, some patients may require treatment with RISPERDAL  (r)  despite the presence of the syndrome.

    5.5 Metabolic Changes

  Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain. While all of the drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile.

    Hyperglycemia and Diabetes Mellitus  

 Hyperglycemia and diabetes mellitus, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, have been reported in patients treated with atypical antipsychotics including RISPERDAL  (r)  . Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse events is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotics. Precise risk estimates for hyperglycemia-related adverse events in patients treated with atypical antipsychotics are not available.

 Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics, including RISPERDAL  (r)  , should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics, including RISPERDAL  (r)  , should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics, including RISPERDAL  (r)  , should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics, including RISPERDAL  (r)  , should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic, including RISPERDAL  (r)  , was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of RISPERDAL  (r)  .

 Pooled data from three double-blind, placebo-controlled schizophrenia studies and four double-blind, placebo-controlled bipolar monotherapy studies are presented in Table 2.

 Table 2. Change in Random Glucose from Seven Placebo-Controlled, 3- to 8-Week, Fixed- or Flexible-Dose Studies in Adult Subjects with Schizophrenia or Bipolar Mania 
                                                                RISPERDAL  (r)               
                                          Placebo                  1-8 mg/day                &gt;8-16 mg/day     
  
                                       Mean change from baseline (mg/dL)     
                                          n=555                      n=748                      n=164         
 Serum Glucose                             -1.4                        0.8                        0.6         
                                       Proportion of patients with shifts     
 Serum Glucose(&lt;140 mg/dL to &gt;=200 mg/dL)    0.6%(3/525)                0.4%(3/702)                 0%(0/158)      
          In longer-term, controlled and uncontrolled studies, RISPERDAL  (r)  was associated with a mean change in glucose of +2.8 mg/dL at Week 24 (n=151) and +4.1 mg/dL at Week 48 (n=50).
 

 Data from the placebo-controlled 3- to 6-week study in children and adolescents with schizophrenia (13-17 years of age), bipolar mania (10-17 years of age), or autistic disorder (5 to 17 years of age) are presented in Table 3.

 Table 3. Change in Fasting Glucose from Three Placebo-Controlled, 3- to 6-Week, Fixed-Dose Studies in Children and Adolescents with Schizophrenia (13-17 years of age), Bipolar Mania (10-17 years of age), or Autistic Disorder (5 to 17 years of age) 
                                                                                RISPERDAL  (r)              
                                                 Placebo                          0.5-6 mg/day              
  
                                     Mean change from baseline (mg/dL)     
                                                  n=76                               n=135                  
 Serum Glucose                                     -1.3                                2.6                  
                                     Proportion of patients with shifts     
 Serum Glucose(&lt;100 mg/dL to &gt;=126 mg/dL)               0%(0/64)                          0.8%(1/120)              
         In longer-term, uncontrolled, open-label extension pediatric studies, RISPERDAL  (r)  was associated with a mean change in fasting glucose of +5.2 mg/dL at Week 24 (n=119).
 

    Dyslipidemia  

 Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.

 Pooled data from 7 placebo-controlled, 3- to 8- week, fixed- or flexible-dose studies in adult subjects with schizophrenia or bipolar mania are presented in Table 4.

 Table 4. Change in Random Lipids from Seven Placebo-Controlled, 3- to 8-Week, Fixed- or Flexible-Dose Studies in Adult Subjects with Schizophrenia or Bipolar Mania 
                                                                RISPERDAL  (r)               
                                          Placebo                  1-8 mg/day                &gt;8-16 mg/day     
  
                                       Mean change from baseline (mg/dL)     
  Cholesterol                             n=559                      n=742                      n=156         
 Change from baseline                       0.6                        6.9                        1.8         
                                                                                                              
  Triglycerides                           n=183                      n=307                      n=123         
 Change from baseline                      -17.4                      -4.9                       -8.3         
                                                                                                              
                                       Proportion of patients With Shifts     
  Cholesterol  (&lt;200 mg/dL to &gt;=240 mg/dL)       2.7%                       4.3%                       6.3%         
                                         (10/368)                   (22/516)                    (6/96)        
  Triglycerides  (&lt;500 mg/dL to &gt;=500 mg/dL)    1.1%(2/180)                2.7%(8/301)                2.5%(3/121)     
          In longer-term, controlled and uncontrolled studies, RISPERDAL  (r)  was associated with a mean change in (a) non-fasting cholesterol of +4.4 mg/dL at Week 24 (n=231) and +5.5 mg/dL at Week 48 (n=86); and (b) non-fasting triglycerides of +19.9 mg/dL at Week 24 (n=52).
 

 Pooled data from 3 placebo-controlled, 3- to 6-week, fixed-dose studies in children and adolescents with schizophrenia (13-17 years of age), bipolar mania (10-17 years of age), or autistic disorder (5-17 years of age) are presented in Table 5.

 Table 5. Change in Fasting Lipids from Three Placebo-Controlled, 3- to 6-Week, Fixed-Dose Studies in Children and Adolescents with Schizophrenia (13-17 Years of Age), Bipolar Mania (10-17 Years of Age), or Autistic Disorder (5 to 17 Years of Age) 
                                                                                RISPERDAL  (r)              
                                                 Placebo                          0.5-6 mg/day              
  
                                     Mean change from baseline (mg/dL)     
  Cholesterol                                     n=74                               n=133                  
 Change from baseline                              0.3                                -0.3                  
                                                                                                            
  LDL                                             n=22                                n=22                  
 Change from baseline                              3.7                                 0.5                  
                                                                                                            
  HDL                                             n=22                                n=22                  
 Change from baseline                              1.6                                -1.9                  
                                                                                                            
  Triglycerides                                   n=77                               n=138                  
 Change from baseline                              -9.0                               -2.6                  
                                                                                                            
                                     Proportion of patients with shifts     
  Cholesterol  (&lt;170 mg/dL to &gt;=200 mg/dL)              2.4%(1/42)                         3.8%(3/80)               
  LDL  (&lt;110 mg/dL to &gt;=130 mg/dL)               0%(0/16)                           0%(0/16)                
  HDL  (&gt;=40 mg/dL to &lt;40 mg/dL)                 0%(0/19)                           10%(2/20)               
  Triglycerides  (&lt;150 mg/dL to &gt;=200 mg/dL)              1.5%(1/65)                         7.1%(8/113)              
         In longer-term, uncontrolled, open-label extension pediatric studies, RISPERDAL  (r)  was associated with a mean change in (a) fasting cholesterol of +2.1 mg/dL at Week 24 (n=114); (b) fasting LDL of -0.2 mg/dL at Week 24 (n=103); (c) fasting HDL of +0.4 mg/dL at Week 24 (n=103); and (d) fasting triglycerides of +6.8 mg/dL at Week 24 (n=120).
 

    Weight Gain  

 Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.

 Data on mean changes in body weight and the proportion of subjects meeting a weight gain criterion of 7% or greater of body weight from 7 placebo-controlled, 3- to 8- week, fixed- or flexible-dose studies in adult subjects with schizophrenia or bipolar mania are presented in Table 6.

 Table 6. Mean Change in Body Weight (kg) and the Proportion of Subjects with &gt;=7% Gain in Body Weight From Seven Placebo-Controlled, 3- to 8-Week, Fixed- or Flexible-Dose Studies in Adult Subjects With Schizophrenia or Bipolar Mania 
                                                           RISPERDAL  (r)          
                                 Placebo(n=597)            1-8 mg/day(n=769)         &gt;8-16 mg/day(n=158)      
  
  Weight (kg)                                                                                                 
 Change from baseline                 -0.3                        0.7                        2.2              
  Weight Gain                                                                                                 
 &gt;=7% increase from baseline            2.9%                       8.7%                       20.9%             
          In longer-term, controlled and uncontrolled studies, RISPERDAL  (r)  was associated with a mean change in weight of +4.3 kg at Week 24 (n=395) and +5.3 kg at Week 48 (n=203).
 

 Data on mean changes in body weight and the proportion of subjects meeting the criterion of &gt;=7% gain in body weight from nine placebo-controlled, 3- to 8-week, fixed-dose studies in children and adolescents with schizophrenia (13-17 years of age), bipolar mania (10-17 years of age), autistic disorder (5-17 years of age), or other psychiatric disorders (5-17 years of age) are presented in Table 7.

 Table 7. Mean Change in Body Weight (kg) and the Proportion of Subjects With &gt;=7% Gain in Body Weight From Nine Placebo-Controlled, 3- to 8-Week, Fixed-Dose Studies in Children and Adolescents With Schizophrenia (13-17 Years of Age), Bipolar Mania (10-17 Years of Age), Autistic Disorder (5 to 17 Years of Age) or Other Psychiatric Disorders (5-17 Years of Age) 
                                                   Placebo(n=375)          RISPERDAL  (r)  0.5-6 mg/day(n=448)   
  
  Weight (kg)                                                                                               
 Change from baseline                                   0.6                             2.0                 
  Weight Gain                                                                                               
 &gt;=7% increase from baseline                            6.9%                           32.6%                
         In longer-term, uncontrolled, open-label extension pediatric studies, RISPERDAL  (r)  was associated with a mean change in weight of +5.5 kg at Week 24 (n=748) and +8.0 kg at Week 48 (n=242).
 

 In a long-term, open-label extension study in adolescent patients with schizophrenia, weight increase was reported as a treatment-emergent adverse event in 14% of patients. In 103 adolescent patients with schizophrenia, a mean increase of 9.0 kg was observed after 8 months of RISPERDAL  (r)  treatment. The majority of that increase was observed within the first 6 months. The average percentiles at baseline and 8 months, respectively, were 56 and 72 for weight, 55 and 58 for height, and 51 and 71 for body mass index.

 In long-term, open-label trials (studies in patients with autistic disorder or other psychiatric disorders), a mean increase of 7.5 kg after 12 months of RISPERDAL  (r)  treatment was observed, which was higher than the expected normal weight gain (approximately 3 to 3.5 kg per year adjusted for age, based on Centers for Disease Control and Prevention normative data). The majority of that increase occurred within the first 6 months of exposure to RISPERDAL  (r)  . The average percentiles at baseline and 12 months, respectively, were 49 and 60 for weight, 48 and 53 for height, and 50 and 62 for body mass index.

 In one 3-week, placebo-controlled trial in children and adolescent patients with acute manic or mixed episodes of bipolar I disorder, increases in body weight were higher in the RISPERDAL  (r)  groups than the placebo group, but not dose related (1.90 kg in the RISPERDAL  (r)  0.5-2.5 mg group, 1.44 kg in the RISPERDAL  (r)  3-6 mg group, and 0.65 kg in the placebo group). A similar trend was observed in the mean change from baseline in body mass index.

 When treating pediatric patients with RISPERDAL  (r)  for any indication, weight gain should be assessed against that expected with normal growth.

    5.6 Hyperprolactinemia

  As with other drugs that antagonize dopamine D2receptors, RISPERDAL  (r)  elevates prolactin levels and the elevation persists during chronic administration. RISPERDAL  (r)  is associated with higher levels of prolactin elevation than other antipsychotic agents.

 Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds. Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male subjects.

 Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent in vitro  , a factor of potential importance if the prescription of these drugs is contemplated in a patient with previously detected breast cancer. An increase in pituitary gland, mammary gland, and pancreatic islet cell neoplasia (mammary adenocarcinomas, pituitary and pancreatic adenomas) was observed in the risperidone carcinogenicity studies conducted in mice and rats [see     Nonclinical Toxicology (13.1)  ]  . Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans; the available evidence is considered too limited to be conclusive at this time.

    5.7 Orthostatic Hypotension

  RISPERDAL  (r)  may induce orthostatic hypotension associated with dizziness, tachycardia, and in some patients, syncope, especially during the initial dose-titration period, probably reflecting its alpha-adrenergic antagonistic properties. Syncope was reported in 0.2% (6/2607) of RISPERDAL  (r)  -treated patients in Phase 2 and 3 studies in adults with schizophrenia. The risk of orthostatic hypotension and syncope may be minimized by limiting the initial dose to 2 mg total (either once daily or 1 mg twice daily) in normal adults and 0.5 mg twice daily in the elderly and patients with renal or hepatic impairment [see     Dosage and Administration (2.1    ,   2.4)  ]  . Monitoring of orthostatic vital signs should be considered in patients for whom this is of concern. A dose reduction should be considered if hypotension occurs. RISPERDAL  (r)  should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension, e.g., dehydration and hypovolemia. Clinically significant hypotension has been observed with concomitant use of RISPERDAL  (r)  and antihypertensive medication.

    5.8 Falls

   Somnolence, postural hypotension, motor and sensory instability have been reported with the use of antipsychotics, including RISPERDAL  (r)  , which may lead to falls and, consequently, fractures or other fall-related injuries. For patients, particularly the elderly, with diseases, conditions, or medications that could exacerbate these effects, assess the risk of falls when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy.  

    5.9 Leukopenia, Neutropenia, and Agranulocytosis

   Class Effect:  In clinical trial and/or postmarketing experience, events of leukopenia/neutropenia have been reported temporally related to antipsychotic agents, including RISPERDAL  (r)  . Agranulocytosis has also been reported.

 Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC) and history of drug-induced leukopenia/neutropenia. Patients with a history of a clinically significant low WBC or a drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of RISPERDAL  (r)  should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors.

 Patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count &lt;1000/mm  3  ) should discontinue RISPERDAL  (r)  and have their WBC followed until recovery.

    5.10 Potential for Cognitive and Motor Impairment

  Somnolence was a commonly reported adverse reaction associated with RISPERDAL  (r)  treatment, especially when ascertained by direct questioning of patients. This adverse reaction is dose-related, and in a study utilizing a checklist to detect adverse events, 41% of the high-dose patients (RISPERDAL  (r)  16 mg/day) reported somnolence compared to 16% of placebo patients. Direct questioning is more sensitive for detecting adverse events than spontaneous reporting, by which 8% of RISPERDAL  (r)  16 mg/day patients and 1% of placebo patients reported somnolence as an adverse reaction. Since RISPERDAL  (r)  has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that RISPERDAL  (r)  therapy does not affect them adversely.

    5.11 Seizures

  During premarketing testing in adult patients with schizophrenia, seizures occurred in 0.3% (9/2607) of RISPERDAL  (r)  -treated patients, two in association with hyponatremia. RISPERDAL  (r)  should be used cautiously in patients with a history of seizures.

    5.12 Dysphagia

  Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in patients with advanced Alzheimer's dementia. RISPERDAL  (r)  and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia. [see     Boxed Warning  and  Warnings and Precautions (5.1)  ]  

    5.13 Priapism

  Priapism has been reported during postmarketing surveillance. Severe priapism may require surgical intervention.

    5.14 Body Temperature Regulation

  Disruption of body temperature regulation has been attributed to antipsychotic agents. Both hyperthermia and hypothermia have been reported in association with oral RISPERDAL  (r)  use. Caution is advised when prescribing for patients who will be exposed to temperature extremes.

    5.15 Patients with Phenylketonuria

  Inform patients that RISPERDAL  (r)  M-TAB  (r)  Orally Disintegrating Tablets contain phenylalanine .  Phenylalanine is a component of aspartame. Each 4 mg RISPERDAL  (r)  M-TAB  (r)  Orally Disintegrating Tablet contains 0.84 mg phenylalanine; each 3 mg RISPERDAL  (r)  M-TAB  (r)  Orally Disintegrating Tablet contains 0.63 mg phenylalanine; each 2 mg RISPERDAL  (r)  M-TAB  (r)  Orally Disintegrating Tablet contains 0.42 mg phenylalanine; each 1 mg RISPERDAL  (r)  M-TAB  (r)  Orally Disintegrating Tablet contains 0.28 mg phenylalanine; and each 0.5 mg RISPERDAL  (r)  M-TAB  (r)  Orally Disintegrating Tablet contains 0.14 mg phenylalanine.

</Section>
  </Text>
  <IgnoredRegions>
    <IgnoredRegion len="19" name="heading" section="S1" start="2" />
    <IgnoredRegion len="26" name="heading" section="S3" start="3" />
    <IgnoredRegion len="1893" name="excerpt" section="S3" start="33" />
    <IgnoredRegion len="84" name="heading" section="S2" start="105" />
    <IgnoredRegion len="380" name="excerpt" section="S2" start="472" />
    <IgnoredRegion len="75" name="heading" section="S3" start="1933" />
    <IgnoredRegion len="648" name="excerpt" section="S1" start="3124" />
    <IgnoredRegion len="108" name="heading" section="S3" start="3618" />
    <IgnoredRegion len="30" name="heading" section="S1" start="3776" />
    <IgnoredRegion len="34" name="heading" section="S3" start="4324" />
    <IgnoredRegion len="22" name="heading" section="S3" start="6009" />
    <IgnoredRegion len="21" name="heading" section="S3" start="7861" />
    <IgnoredRegion len="22" name="heading" section="S3" start="22795" />
    <IgnoredRegion len="27" name="heading" section="S3" start="24373" />
    <IgnoredRegion len="9" name="heading" section="S3" start="25690" />
    <IgnoredRegion len="48" name="heading" section="S3" start="26188" />
    <IgnoredRegion len="49" name="heading" section="S3" start="27342" />
    <IgnoredRegion len="13" name="heading" section="S3" start="28261" />
    <IgnoredRegion len="14" name="heading" section="S3" start="28542" />
    <IgnoredRegion len="13" name="heading" section="S3" start="28950" />
    <IgnoredRegion len="32" name="heading" section="S3" start="29085" />
    <IgnoredRegion len="34" name="heading" section="S3" start="29406" />
    <IgnoredRegion len="28" name="heading" section="S1" start="41027" />
  </IgnoredRegions>
  <Mentions>
    <Mention id="M1" len="26" reason="preexisting_condition_or_risk_factor" section="S1" start="153" type="Not_AE_Candidate">
      <Normalization meddra_llt="Dementia" meddra_llt_id="10012267" meddra_pt="Dementia" meddra_pt_id="10012267" />
    </Mention>
    <Mention id="M30" len="30" reason="AE_from_off_label" section="S1" start="252" type="NonOSE_AE">
      <Normalization meddra_llt="Cerebrovascular disorder" meddra_llt_id="10008196" meddra_pt="Cerebrovascular disorder" meddra_pt_id="10008196" />
    </Mention>
    <Mention id="M31" len="6" reason="AE_from_off_label" section="S1" start="294" type="NonOSE_AE">
      <Normalization meddra_llt="Stroke" meddra_llt_id="10042244" meddra_pt="Cerebrovascular accident" meddra_pt_id="10008190" />
    </Mention>
    <Mention id="M2" len="26" reason="preexisting_condition_or_risk_factor" section="S1" start="327" type="Not_AE_Candidate">
      <Normalization meddra_llt="Senile psychosis" meddra_llt_id="10039987" meddra_pt="Senile psychosis" meddra_pt_id="10039987" />
    </Mention>
    <Mention id="M129" len="30" reason="from_drug_use" section="S1" start="402" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neuroleptic malignant syndrome" meddra_llt_id="10029282" meddra_pt="Neuroleptic malignant syndrome" meddra_pt_id="10029282" />
    </Mention>
    <Mention id="M615" len="18" reason="class_effect" section="S1" start="481" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyskinesia tardive" meddra_llt_id="10013928" meddra_pt="Tardive dyskinesia" meddra_pt_id="10043118" />
    </Mention>
    <Mention id="M616" len="17" reason="class_effect" section="S1" start="548" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Metabolic disorder" meddra_llt_id="10058097" meddra_pt="Metabolic disorder" meddra_pt_id="10058097" />
    </Mention>
    <Mention id="M130" len="13" reason="from_drug_use" section="S1" start="567" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperglycemia" meddra_llt_id="10020639" meddra_pt="Hyperglycaemia" meddra_pt_id="10020635" />
    </Mention>
    <Mention id="M131" len="17" reason="from_drug_use" section="S1" start="585" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diabetes mellitus" meddra_llt_id="10012601" meddra_pt="Diabetes mellitus" meddra_pt_id="10012601" />
    </Mention>
    <Mention id="M617" len="12" reason="from_drug_use" section="S1" start="604" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyslipidemia" meddra_llt_id="10058110" meddra_pt="Dyslipidaemia" meddra_pt_id="10058108" />
    </Mention>
    <Mention id="M132" len="11" reason="from_drug_use" section="S1" start="622" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight gain" meddra_llt_id="10047896" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M133" len="18" reason="from_drug_use" section="S1" start="683" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperprolactinemia" meddra_llt_id="10020739" meddra_pt="Hyperprolactinaemia" meddra_pt_id="10020737" />
      <Normalization meddra_pt="Blood prolactin increased" meddra_pt_id="10005780" />
    </Mention>
    <Mention id="M134" len="23" reason="from_drug_use" section="S1" start="750" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Orthostatic hypotension" meddra_llt_id="10031127" meddra_pt="Orthostatic hypotension" meddra_pt_id="10031127" />
    </Mention>
    <Mention id="M126" len="5" reason="manifestation_or_complication" section="S1" start="822" type="NonOSE_AE">
      <Normalization meddra_llt="Fall" meddra_llt_id="10016173" meddra_pt="Fall" meddra_pt_id="10016173" />
    </Mention>
    <Mention id="M135" len="10" reason="from_drug_use" section="S1" start="874" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Leukopenia" meddra_llt_id="10024384" meddra_pt="Leukopenia" meddra_pt_id="10024384" />
    </Mention>
    <Mention id="M136" len="11" reason="from_drug_use" section="S1" start="886" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M137" len="15" reason="from_drug_use" section="S1" start="903" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Agranulocytosis" meddra_llt_id="10001507" meddra_pt="Agranulocytosis" meddra_pt_id="10001507" />
    </Mention>
    <Mention id="M618" len="9,10" reason="from_drug_use" section="S1" start="979,999" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cognitive impairment" meddra_llt_id="10009846" meddra_pt="Cognitive disorder" meddra_pt_id="10057668" />
    </Mention>
    <Mention id="M138" len="16" reason="from_drug_use" section="S1" start="993" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Motor deficit" meddra_llt_id="10079471" meddra_pt="Motor dysfunction" meddra_pt_id="10061296" />
    </Mention>
    <Mention id="M620" len="8" reason="from_drug_use" section="S1" start="1057" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Seizures" meddra_llt_id="10039910" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M619" len="9" reason="class_effect" section="S1" start="1115" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dysphagia" meddra_llt_id="10013950" meddra_pt="Dysphagia" meddra_pt_id="10013950" />
    </Mention>
    <Mention id="M139" len="8" reason="from_drug_use" section="S1" start="1174" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Priapism" meddra_llt_id="10036661" meddra_pt="Priapism" meddra_pt_id="10036661" />
    </Mention>
    <Mention id="M140" len="41" reason="from_drug_use" section="S1" start="1232" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Temperature regulation disorder" meddra_llt_id="10061376" meddra_pt="Temperature regulation disorder" meddra_pt_id="10061376" />
    </Mention>
    <Mention id="M3" len="15" reason="preexisting_condition_or_risk_factor" section="S1" start="1337" type="Not_AE_Candidate">
      <Normalization meddra_llt="Phenylketonuria" meddra_llt_id="10034872" meddra_pt="Phenylketonuria" meddra_pt_id="10034872" />
    </Mention>
    <Mention id="M141" len="12" reason="from_drug_use" section="S1" start="1485" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Parkinsonism" meddra_llt_id="10034010" meddra_pt="Parkinsonism" meddra_pt_id="10034010" />
    </Mention>
    <Mention id="M142" len="9" reason="from_drug_use" section="S1" start="1499" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Akathisia" meddra_llt_id="10001540" meddra_pt="Akathisia" meddra_pt_id="10001540" />
    </Mention>
    <Mention id="M143" len="8" reason="from_drug_use" section="S1" start="1510" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dystonia" meddra_llt_id="10013983" meddra_pt="Dystonia" meddra_pt_id="10013983" />
    </Mention>
    <Mention id="M144" len="6" reason="from_drug_use" section="S1" start="1520" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tremor" meddra_llt_id="10044565" meddra_pt="Tremor" meddra_pt_id="10044565" />
    </Mention>
    <Mention id="M145" len="8" reason="from_drug_use" section="S1" start="1528" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sedation" meddra_llt_id="10039897" meddra_pt="Sedation" meddra_pt_id="10039897" />
    </Mention>
    <Mention id="M146" len="9" reason="from_drug_use" section="S1" start="1538" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M147" len="7" reason="from_drug_use" section="S1" start="1549" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety" meddra_llt_id="10002855" meddra_pt="Anxiety" meddra_pt_id="10002855" />
    </Mention>
    <Mention id="M148" len="14" reason="from_drug_use" section="S1" start="1558" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vision blurred" meddra_llt_id="10047513" meddra_pt="Vision blurred" meddra_pt_id="10047513" />
    </Mention>
    <Mention id="M149" len="6" reason="from_drug_use" section="S1" start="1574" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M150" len="8" reason="from_drug_use" section="S1" start="1582" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vomiting" meddra_llt_id="10047700" meddra_pt="Vomiting" meddra_pt_id="10047700" />
    </Mention>
    <Mention id="M151" len="20" reason="from_drug_use" section="S1" start="1592" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Upper abdominal pain" meddra_llt_id="10046272" meddra_pt="Abdominal pain upper" meddra_pt_id="10000087" />
    </Mention>
    <Mention id="M152" len="18" reason="from_drug_use" section="S1" start="1614" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Stomach discomfort" meddra_llt_id="10042101" meddra_pt="Abdominal discomfort" meddra_pt_id="10000059" />
    </Mention>
    <Mention id="M153" len="9" reason="from_drug_use" section="S1" start="1634" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspepsia-aggravated" meddra_llt_id="10048482" meddra_pt="Dyspepsia" meddra_pt_id="10013946" />
    </Mention>
    <Mention id="M154" len="8" reason="from_drug_use" section="S1" start="1645" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M155" len="23" reason="from_drug_use" section="S1" start="1655" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Salivary hypersecretion" meddra_llt_id="10039424" meddra_pt="Salivary hypersecretion" meddra_pt_id="10039424" />
    </Mention>
    <Mention id="M156" len="12" reason="from_drug_use" section="S1" start="1680" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Constipation" meddra_llt_id="10010774" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M157" len="9" reason="from_drug_use" section="S1" start="1694" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry mouth" meddra_llt_id="10013781" meddra_pt="Dry mouth" meddra_pt_id="10013781" />
    </Mention>
    <Mention id="M158" len="18" reason="from_drug_use" section="S1" start="1705" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Increased appetite" meddra_llt_id="10021654" meddra_pt="Increased appetite" meddra_pt_id="10021654" />
    </Mention>
    <Mention id="M159" len="16" reason="from_drug_use" section="S1" start="1725" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight increased" meddra_llt_id="10047899" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M160" len="7" reason="from_drug_use" section="S1" start="1743" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fatigue" meddra_llt_id="10016256" meddra_pt="Fatigue" meddra_pt_id="10016256" />
    </Mention>
    <Mention id="M161" len="4" reason="from_drug_use" section="S1" start="1752" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rash" meddra_llt_id="10037844" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Mention>
    <Mention id="M621" len="16" reason="from_drug_use" section="S1" start="1758" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Congestion nasal" meddra_llt_id="10010676" meddra_pt="Nasal congestion" meddra_pt_id="10028735" />
    </Mention>
    <Mention id="M162" len="33" reason="from_drug_use" section="S1" start="1776" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Upper respiratory tract infection" meddra_llt_id="10046306" meddra_pt="Upper respiratory tract infection" meddra_pt_id="10046306" />
    </Mention>
    <Mention id="M163" len="15" reason="from_drug_use" section="S1" start="1811" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nasopharyngitis" meddra_llt_id="10028810" meddra_pt="Nasopharyngitis" meddra_pt_id="10028810" />
    </Mention>
    <Mention id="M164" len="22" reason="from_drug_use" section="S1" start="1832" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pharyngolaryngeal pain" meddra_llt_id="10034844" meddra_pt="Laryngeal pain" meddra_pt_id="10023848" />
    </Mention>
    <Mention id="M165" len="6" reason="from_drug_use" section="S1" start="2030" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M166" len="10" reason="from_drug_use" section="S1" start="2038" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Somnolence" meddra_llt_id="10041349" meddra_pt="Somnolence" meddra_pt_id="10041349" />
    </Mention>
    <Mention id="M167" len="8" reason="from_drug_use" section="S1" start="2050" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sedation" meddra_llt_id="10039897" meddra_pt="Sedation" meddra_pt_id="10039897" />
    </Mention>
    <Mention id="M168" len="8" reason="from_drug_use" section="S1" start="2060" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vomiting" meddra_llt_id="10047700" meddra_pt="Vomiting" meddra_pt_id="10047700" />
    </Mention>
    <Mention id="M169" len="9" reason="from_drug_use" section="S1" start="2070" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M170" len="9" reason="from_drug_use" section="S1" start="2085" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Akathisia" meddra_llt_id="10001540" meddra_pt="Akathisia" meddra_pt_id="10001540" />
    </Mention>
    <Mention id="M4" len="13" reason="indication" section="S1" start="2376" type="Not_AE_Candidate">
      <Normalization meddra_llt="Schizophrenia" meddra_llt_id="10039626" meddra_pt="Schizophrenia" meddra_pt_id="10039626" />
    </Mention>
    <Mention id="M5" len="13" reason="indication" section="S1" start="2391" type="Not_AE_Candidate">
      <Normalization meddra_llt="Mania" meddra_llt_id="10026749" meddra_pt="Mania" meddra_pt_id="10026749" />
    </Mention>
    <Mention id="M18" len="17" reason="indication" section="S1" start="2406" type="Not_AE_Candidate">
      <Normalization meddra_llt="Autistic disorder" meddra_llt_id="10003808" meddra_pt="Autism spectrum disorder" meddra_pt_id="10063844" />
    </Mention>
    <Mention id="M19" len="21" reason="preexisting_condition_or_risk_factor" section="S1" start="2435" type="Not_AE_Candidate">
      <Normalization meddra_llt="Psychiatric disorder NOS" meddra_llt_id="10037174" meddra_pt="Mental disorder" meddra_pt_id="10061284" />
      <Normalization meddra_pt="Psychiatric symptom" meddra_pt_id="10061472" />
    </Mention>
    <Mention id="M25" len="7,8" reason="preexisting_condition_or_risk_factor" section="S1" start="2475,2497" type="Not_AE_Candidate">
      <Normalization meddra_llt="Senile dementia" meddra_llt_id="10039966" meddra_pt="Senile dementia" meddra_pt_id="10039966" />
    </Mention>
    <Mention id="M6" len="8" reason="preexisting_condition_or_risk_factor" section="S1" start="2497" type="Not_AE_Candidate">
      <Normalization meddra_llt="Dementia" meddra_llt_id="10012267" meddra_pt="Dementia" meddra_pt_id="10012267" />
    </Mention>
    <Mention id="M7" len="13" reason="indication" section="S1" start="4346" type="Not_AE_Candidate">
      <Normalization meddra_llt="Schizophrenia" meddra_llt_id="10039626" meddra_pt="Schizophrenia" meddra_pt_id="10039626" />
    </Mention>
    <Mention id="M32" len="17" reason="general_term" section="S1" start="4888" type="NonOSE_AE">
      <Normalization meddra_llt="Cardiac disorder" meddra_llt_id="10061024" meddra_pt="Cardiac disorder" meddra_pt_id="10061024" />
    </Mention>
    <Mention id="M171" len="11" reason="from_drug_use" section="S1" start="4999" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tachycardia" meddra_llt_id="10043071" meddra_pt="Tachycardia" meddra_pt_id="10043071" />
    </Mention>
    <Mention id="M33" len="13" reason="general_term" section="S1" start="5110" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder eye" meddra_llt_id="10013221" meddra_pt="Eye disorder" meddra_pt_id="10015916" />
      <Normalization meddra_pt="Ocular toxicity" meddra_pt_id="10061137" />
    </Mention>
    <Mention id="M172" len="14" reason="from_drug_use" section="S1" start="5221" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vision blurred" meddra_llt_id="10047513" meddra_pt="Vision blurred" meddra_pt_id="10047513" />
    </Mention>
    <Mention id="M34" len="26" reason="general_term" section="S1" start="5332" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M173" len="6" reason="from_drug_use" section="S1" start="5443" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M174" len="12" reason="from_drug_use" section="S1" start="5554" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Constipation" meddra_llt_id="10010774" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M175" len="9" reason="from_drug_use" section="S1" start="5665" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspepsia-aggravated" meddra_llt_id="10048482" meddra_pt="Dyspepsia" meddra_pt_id="10013946" />
    </Mention>
    <Mention id="M176" len="9" reason="from_drug_use" section="S1" start="5776" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry mouth" meddra_llt_id="10013781" meddra_pt="Dry mouth" meddra_pt_id="10013781" />
    </Mention>
    <Mention id="M177" len="20" reason="from_drug_use" section="S1" start="5887" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Discomfort abdominal" meddra_llt_id="10013084" meddra_pt="Abdominal discomfort" meddra_pt_id="10000059" />
    </Mention>
    <Mention id="M178" len="23" reason="from_drug_use" section="S1" start="5998" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Salivary hypersecretion" meddra_llt_id="10039424" meddra_pt="Salivary hypersecretion" meddra_pt_id="10039424" />
    </Mention>
    <Mention id="M179" len="8" reason="from_drug_use" section="S1" start="6109" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M35" len="17" reason="general_term" section="S1" start="6220" type="NonOSE_AE">
      <Normalization meddra_llt="General symptom" meddra_llt_id="10060891" meddra_pt="General symptom" meddra_pt_id="10060891" />
    </Mention>
    <Mention id="M180" len="7" reason="from_drug_use" section="S1" start="6331" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fatigue" meddra_llt_id="10016256" meddra_pt="Fatigue" meddra_pt_id="10016256" />
    </Mention>
    <Mention id="M181" len="10" reason="from_drug_use" section="S1" start="6442" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain chest" meddra_llt_id="10033387" meddra_pt="Chest pain" meddra_pt_id="10008479" />
    </Mention>
    <Mention id="M182" len="8" reason="from_drug_use" section="S1" start="6553" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Asthenia" meddra_llt_id="10003549" meddra_pt="Asthenia" meddra_pt_id="10003549" />
    </Mention>
    <Mention id="M36" len="27" reason="general_term" section="S1" start="6664" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M183" len="15" reason="from_drug_use" section="S1" start="6775" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nasopharyngitis" meddra_llt_id="10028810" meddra_pt="Nasopharyngitis" meddra_pt_id="10028810" />
    </Mention>
    <Mention id="M184" len="33" reason="from_drug_use" section="S1" start="6886" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Upper respiratory tract infection" meddra_llt_id="10046306" meddra_pt="Upper respiratory tract infection" meddra_pt_id="10046306" />
    </Mention>
    <Mention id="M185" len="9" reason="from_drug_use" section="S1" start="6997" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sinusitis" meddra_llt_id="10040753" meddra_pt="Sinusitis" meddra_pt_id="10040753" />
    </Mention>
    <Mention id="M186" len="23" reason="from_drug_use" section="S1" start="7108" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Infection urinary tract" meddra_llt_id="10021872" meddra_pt="Urinary tract infection" meddra_pt_id="10046571" />
    </Mention>
    <Mention id="M37" len="14" reason="general_term" section="S1" start="7219" type="NonOSE_AE">
      <Normalization meddra_llt="Investigation" meddra_llt_id="10062026" meddra_pt="Investigation" meddra_pt_id="10062026" />
    </Mention>
    <Mention id="M187" len="38" reason="from_drug_use" section="S1" start="7330" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Blood creatine phosphokinase increased" meddra_llt_id="10005470" meddra_pt="Blood creatine phosphokinase increased" meddra_pt_id="10005470" />
    </Mention>
    <Mention id="M188" len="20" reason="from_drug_use" section="S1" start="7441" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Heart rate increased" meddra_llt_id="10019303" meddra_pt="Heart rate increased" meddra_pt_id="10019303" />
    </Mention>
    <Mention id="M38" len="47" reason="general_term" section="S1" start="7552" type="NonOSE_AE">
      <Normalization meddra_llt="Musculoskeletal disorder" meddra_llt_id="10048592" meddra_pt="Musculoskeletal disorder" meddra_pt_id="10048592" />
    </Mention>
    <Mention id="M189" len="9" reason="from_drug_use" section="S1" start="7674" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain back" meddra_llt_id="10033380" meddra_pt="Back pain" meddra_pt_id="10003988" />
    </Mention>
    <Mention id="M190" len="10" reason="from_drug_use" section="S1" start="7785" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Arthralgia" meddra_llt_id="10003239" meddra_pt="Arthralgia" meddra_pt_id="10003239" />
    </Mention>
    <Mention id="M191" len="17" reason="from_drug_use" section="S1" start="7896" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain in extremity" meddra_llt_id="10033425" meddra_pt="Pain in extremity" meddra_pt_id="10033425" />
    </Mention>
    <Mention id="M39" len="24" reason="general_term" section="S1" start="8007" type="NonOSE_AE">
      <Normalization meddra_llt="Nervous system disorder" meddra_llt_id="10029202" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M192" len="12" reason="from_drug_use" section="S1" start="8116" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Parkinsonism" meddra_llt_id="10034010" meddra_pt="Parkinsonism" meddra_pt_id="10034010" />
    </Mention>
    <Mention id="M193" len="12" reason="from_drug_use" section="S1" start="8136" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Parkinsonism" meddra_llt_id="10034010" meddra_pt="Parkinsonism" meddra_pt_id="10034010" />
    </Mention>
    <Mention id="M194" len="23" reason="from_drug_use" section="S1" start="8158" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Extrapyramidal disorder" meddra_llt_id="10015832" meddra_pt="Extrapyramidal disorder" meddra_pt_id="10015832" />
    </Mention>
    <Mention id="M195" len="25" reason="from_drug_use" section="S1" start="8183" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Musculoskeletal stiffness" meddra_llt_id="10052904" meddra_pt="Musculoskeletal stiffness" meddra_pt_id="10052904" />
    </Mention>
    <Mention id="M196" len="12" reason="from_drug_use" section="S1" start="8210" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Parkinsonism" meddra_llt_id="10034010" meddra_pt="Parkinsonism" meddra_pt_id="10034010" />
    </Mention>
    <Mention id="M197" len="17" reason="from_drug_use" section="S1" start="8224" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rigidity cogwheel" meddra_llt_id="10039170" meddra_pt="Cogwheel rigidity" meddra_pt_id="10009848" />
    </Mention>
    <Mention id="M198" len="8" reason="from_drug_use" section="S1" start="8243" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Akinesia" meddra_llt_id="10001541" meddra_pt="Akinesia" meddra_pt_id="10001541" />
    </Mention>
    <Mention id="M199" len="12" reason="from_drug_use" section="S1" start="8253" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bradykinesia" meddra_llt_id="10006100" meddra_pt="Bradykinesia" meddra_pt_id="10006100" />
    </Mention>
    <Mention id="M200" len="11" reason="from_drug_use" section="S1" start="8267" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypokinesia" meddra_llt_id="10021021" meddra_pt="Hypokinesia" meddra_pt_id="10021021" />
    </Mention>
    <Mention id="M201" len="13" reason="from_drug_use" section="S1" start="8280" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Facies masked" meddra_llt_id="10016066" meddra_pt="Reduced facial expression" meddra_pt_id="10078576" />
    </Mention>
    <Mention id="M202" len="15" reason="from_drug_use" section="S1" start="8295" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Muscle rigidity" meddra_llt_id="10028330" meddra_pt="Muscle rigidity" meddra_pt_id="10028330" />
    </Mention>
    <Mention id="M203" len="19" reason="from_drug_use" section="S1" start="8316" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Parkinson's disease" meddra_llt_id="10061536" meddra_pt="Parkinson's disease" meddra_pt_id="10061536" />
    </Mention>
    <Mention id="M204" len="9" reason="from_drug_use" section="S1" start="8337" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Akathisia" meddra_llt_id="10001540" meddra_pt="Akathisia" meddra_pt_id="10001540" />
    </Mention>
    <Mention id="M205" len="9" reason="from_drug_use" section="S1" start="8356" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Akathisia" meddra_llt_id="10001540" meddra_pt="Akathisia" meddra_pt_id="10001540" />
    </Mention>
    <Mention id="M206" len="12" reason="from_drug_use" section="S1" start="8370" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Restlessness" meddra_llt_id="10038743" meddra_pt="Restlessness" meddra_pt_id="10038743" />
    </Mention>
    <Mention id="M207" len="8" reason="from_drug_use" section="S1" start="8384" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dystonia" meddra_llt_id="10013983" meddra_pt="Dystonia" meddra_pt_id="10013983" />
    </Mention>
    <Mention id="M208" len="8" reason="from_drug_use" section="S1" start="8402" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dystonia" meddra_llt_id="10013983" meddra_pt="Dystonia" meddra_pt_id="10013983" />
    </Mention>
    <Mention id="M209" len="13" reason="from_drug_use" section="S1" start="8412" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Muscle spasms" meddra_llt_id="10028334" meddra_pt="Muscle spasms" meddra_pt_id="10028334" />
    </Mention>
    <Mention id="M210" len="31" reason="from_drug_use" section="S1" start="8427" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Muscle contractions involuntary" meddra_llt_id="10028293" meddra_pt="Muscle contractions involuntary" meddra_pt_id="10028293" />
    </Mention>
    <Mention id="M211" len="18" reason="from_drug_use" section="S1" start="8460" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Muscle contracture" meddra_llt_id="10062575" meddra_pt="Muscle contracture" meddra_pt_id="10062575" />
    </Mention>
    <Mention id="M212" len="13" reason="from_drug_use" section="S1" start="8480" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Oculogyration" meddra_llt_id="10061552" meddra_pt="Oculogyric crisis" meddra_pt_id="10030071" />
    </Mention>
    <Mention id="M213" len="16" reason="from_drug_use" section="S1" start="8495" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tongue paralysis" meddra_llt_id="10043972" meddra_pt="Tongue paralysis" meddra_pt_id="10043972" />
    </Mention>
    <Mention id="M214" len="6" reason="from_drug_use" section="S1" start="8513" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tremor" meddra_llt_id="10044565" meddra_pt="Tremor" meddra_pt_id="10044565" />
    </Mention>
    <Mention id="M215" len="6" reason="from_drug_use" section="S1" start="8529" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tremor" meddra_llt_id="10044565" meddra_pt="Tremor" meddra_pt_id="10044565" />
    </Mention>
    <Mention id="M216" len="24" reason="from_drug_use" section="S1" start="8540" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Parkinsonian rest tremor" meddra_llt_id="10056437" meddra_pt="Parkinsonian rest tremor" meddra_pt_id="10056437" />
    </Mention>
    <Mention id="M217" len="9" reason="from_drug_use" section="S1" start="8640" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Akathisia" meddra_llt_id="10001540" meddra_pt="Akathisia" meddra_pt_id="10001540" />
    </Mention>
    <Mention id="M218" len="8" reason="from_drug_use" section="S1" start="8751" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sedation" meddra_llt_id="10039897" meddra_pt="Sedation" meddra_pt_id="10039897" />
    </Mention>
    <Mention id="M219" len="9" reason="from_drug_use" section="S1" start="8862" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M220" len="8" reason="from_drug_use" section="S1" start="8973" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dystonia" meddra_llt_id="10013983" meddra_pt="Dystonia" meddra_pt_id="10013983" />
    </Mention>
    <Mention id="M221" len="6" reason="from_drug_use" section="S1" start="9084" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tremor" meddra_llt_id="10044565" meddra_pt="Tremor" meddra_pt_id="10044565" />
    </Mention>
    <Mention id="M222" len="18" reason="from_drug_use" section="S1" start="9195" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness postural" meddra_llt_id="10013578" meddra_pt="Dizziness postural" meddra_pt_id="10013578" />
    </Mention>
    <Mention id="M119" len="21" reason="general_term" section="S1" start="9306" type="NonOSE_AE">
      <Normalization meddra_llt="Psychiatric disorder NOS" meddra_llt_id="10037174" meddra_pt="Mental disorder" meddra_pt_id="10061284" />
      <Normalization meddra_pt="Psychiatric symptom" meddra_pt_id="10061472" />
    </Mention>
    <Mention id="M223" len="8" reason="from_drug_use" section="S1" start="9417" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Insomnia" meddra_llt_id="10022437" meddra_pt="Insomnia" meddra_pt_id="10022437" />
    </Mention>
    <Mention id="M224" len="7" reason="from_drug_use" section="S1" start="9528" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety" meddra_llt_id="10002855" meddra_pt="Anxiety" meddra_pt_id="10002855" />
    </Mention>
    <Mention id="M40" len="47" reason="general_term" section="S1" start="9639" type="NonOSE_AE">
      <Normalization meddra_llt="Respiratory disorder" meddra_llt_id="10038683" meddra_pt="Respiratory disorder" meddra_pt_id="10038683" />
    </Mention>
    <Mention id="M225" len="16" reason="from_drug_use" section="S1" start="9761" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Congestion nasal" meddra_llt_id="10010676" meddra_pt="Nasal congestion" meddra_pt_id="10028735" />
    </Mention>
    <Mention id="M226" len="7" reason="from_drug_use" section="S1" start="9872" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspnea" meddra_llt_id="10013963" meddra_pt="Dyspnoea" meddra_pt_id="10013968" />
    </Mention>
    <Mention id="M227" len="9" reason="from_drug_use" section="S1" start="9983" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Epistaxis" meddra_llt_id="10015090" meddra_pt="Epistaxis" meddra_pt_id="10015090" />
    </Mention>
    <Mention id="M41" len="38" reason="general_term" section="S1" start="10094" type="NonOSE_AE">
      <Normalization meddra_llt="Other disorders of skin and subcutaneous tissue" meddra_llt_id="10032001" meddra_pt="Skin disorder" meddra_pt_id="10040831" />
    </Mention>
    <Mention id="M228" len="4" reason="from_drug_use" section="S1" start="10207" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rash" meddra_llt_id="10037844" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Mention>
    <Mention id="M229" len="8" reason="from_drug_use" section="S1" start="10318" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry skin" meddra_llt_id="10013786" meddra_pt="Dry skin" meddra_pt_id="10013786" />
    </Mention>
    <Mention id="M42" len="18" reason="general_term" section="S1" start="10429" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder vascular" meddra_llt_id="10013282" meddra_pt="Angiopathy" meddra_pt_id="10059245" />
    </Mention>
    <Mention id="M230" len="23" reason="from_drug_use" section="S1" start="10540" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Orthostatic hypotension" meddra_llt_id="10031127" meddra_pt="Orthostatic hypotension" meddra_pt_id="10031127" />
    </Mention>
    <Mention id="M8" len="13" reason="indication" section="S1" start="10817" type="Not_AE_Candidate">
      <Normalization meddra_llt="Schizophrenia" meddra_llt_id="10039626" meddra_pt="Schizophrenia" meddra_pt_id="10039626" />
    </Mention>
    <Mention id="M43" len="26" reason="general_term" section="S1" start="11328" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M231" len="23" reason="from_drug_use" section="S1" start="11439" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Salivary hypersecretion" meddra_llt_id="10039424" meddra_pt="Salivary hypersecretion" meddra_pt_id="10039424" />
    </Mention>
    <Mention id="M44" len="24" reason="general_term" section="S1" start="11550" type="NonOSE_AE">
      <Normalization meddra_llt="Nervous system disorder" meddra_llt_id="10029202" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M232" len="8" reason="from_drug_use" section="S1" start="11661" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sedation" meddra_llt_id="10039897" meddra_pt="Sedation" meddra_pt_id="10039897" />
    </Mention>
    <Mention id="M233" len="12" reason="from_drug_use" section="S1" start="11770" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Parkinsonism" meddra_llt_id="10034010" meddra_pt="Parkinsonism" meddra_pt_id="10034010" />
    </Mention>
    <Mention id="M234" len="12" reason="from_drug_use" section="S1" start="11790" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Parkinsonism" meddra_llt_id="10034010" meddra_pt="Parkinsonism" meddra_pt_id="10034010" />
    </Mention>
    <Mention id="M235" len="23" reason="from_drug_use" section="S1" start="11812" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Extrapyramidal disorder" meddra_llt_id="10015832" meddra_pt="Extrapyramidal disorder" meddra_pt_id="10015832" />
    </Mention>
    <Mention id="M236" len="15" reason="from_drug_use" section="S1" start="11837" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Muscle rigidity" meddra_llt_id="10028330" meddra_pt="Muscle rigidity" meddra_pt_id="10028330" />
    </Mention>
    <Mention id="M237" len="25" reason="from_drug_use" section="S1" start="11854" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Musculoskeletal stiffness" meddra_llt_id="10052904" meddra_pt="Musculoskeletal stiffness" meddra_pt_id="10052904" />
    </Mention>
    <Mention id="M238" len="11" reason="from_drug_use" section="S1" start="11885" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypokinesia" meddra_llt_id="10021021" meddra_pt="Hypokinesia" meddra_pt_id="10021021" />
    </Mention>
    <Mention id="M239" len="9" reason="from_drug_use" section="S1" start="11898" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Akathisia" meddra_llt_id="10001540" meddra_pt="Akathisia" meddra_pt_id="10001540" />
    </Mention>
    <Mention id="M240" len="9" reason="from_drug_use" section="S1" start="11917" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Akathisia" meddra_llt_id="10001540" meddra_pt="Akathisia" meddra_pt_id="10001540" />
    </Mention>
    <Mention id="M241" len="12" reason="from_drug_use" section="S1" start="11931" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Restlessness" meddra_llt_id="10038743" meddra_pt="Restlessness" meddra_pt_id="10038743" />
    </Mention>
    <Mention id="M242" len="8" reason="from_drug_use" section="S1" start="11945" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dystonia" meddra_llt_id="10013983" meddra_pt="Dystonia" meddra_pt_id="10013983" />
    </Mention>
    <Mention id="M243" len="8" reason="from_drug_use" section="S1" start="11963" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dystonia" meddra_llt_id="10013983" meddra_pt="Dystonia" meddra_pt_id="10013983" />
    </Mention>
    <Mention id="M244" len="13" reason="from_drug_use" section="S1" start="11976" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Oculogyration" meddra_llt_id="10061552" meddra_pt="Oculogyric crisis" meddra_pt_id="10030071" />
    </Mention>
    <Mention id="M245" len="6" reason="from_drug_use" section="S1" start="12065" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tremor" meddra_llt_id="10044565" meddra_pt="Tremor" meddra_pt_id="10044565" />
    </Mention>
    <Mention id="M246" len="9" reason="from_drug_use" section="S1" start="12176" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Akathisia" meddra_llt_id="10001540" meddra_pt="Akathisia" meddra_pt_id="10001540" />
    </Mention>
    <Mention id="M247" len="9" reason="from_drug_use" section="S1" start="12287" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M248" len="8" reason="from_drug_use" section="S1" start="12398" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dystonia" meddra_llt_id="10013983" meddra_pt="Dystonia" meddra_pt_id="10013983" />
    </Mention>
    <Mention id="M45" len="21" reason="general_term" section="S1" start="12509" type="NonOSE_AE">
      <Normalization meddra_llt="Psychiatric disorder NOS" meddra_llt_id="10037174" meddra_pt="Mental disorder" meddra_pt_id="10061284" />
      <Normalization meddra_pt="Psychiatric symptom" meddra_pt_id="10061472" />
    </Mention>
    <Mention id="M249" len="7" reason="from_drug_use" section="S1" start="12620" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety" meddra_llt_id="10002855" meddra_pt="Anxiety" meddra_pt_id="10002855" />
    </Mention>
    <Mention id="M9" len="13" reason="indication" section="S1" start="12832" type="Not_AE_Candidate">
      <Normalization meddra_llt="Mania" meddra_llt_id="10026749" meddra_pt="Mania" meddra_pt_id="10026749" />
    </Mention>
    <Mention id="M10" len="13" reason="indication" section="S1" start="13002" type="Not_AE_Candidate">
      <Normalization meddra_llt="Mania" meddra_llt_id="10026749" meddra_pt="Mania" meddra_pt_id="10026749" />
    </Mention>
    <Mention id="M46" len="13" reason="general_term" section="S1" start="13489" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder eye" meddra_llt_id="10013221" meddra_pt="Eye disorder" meddra_pt_id="10015916" />
      <Normalization meddra_pt="Ocular toxicity" meddra_pt_id="10061137" />
    </Mention>
    <Mention id="M250" len="14" reason="from_drug_use" section="S1" start="13598" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vision blurred" meddra_llt_id="10047513" meddra_pt="Vision blurred" meddra_pt_id="10047513" />
    </Mention>
    <Mention id="M47" len="26" reason="general_term" section="S1" start="13707" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M251" len="6" reason="from_drug_use" section="S1" start="13816" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M252" len="8" reason="from_drug_use" section="S1" start="13925" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M253" len="23" reason="from_drug_use" section="S1" start="14034" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Salivary hypersecretion" meddra_llt_id="10039424" meddra_pt="Salivary hypersecretion" meddra_pt_id="10039424" />
    </Mention>
    <Mention id="M254" len="18" reason="from_drug_use" section="S1" start="14143" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Stomach discomfort" meddra_llt_id="10042101" meddra_pt="Abdominal discomfort" meddra_pt_id="10000059" />
    </Mention>
    <Mention id="M48" len="17" reason="general_term" section="S1" start="14252" type="NonOSE_AE">
      <Normalization meddra_llt="General symptom" meddra_llt_id="10060891" meddra_pt="General symptom" meddra_pt_id="10060891" />
    </Mention>
    <Mention id="M255" len="7" reason="from_drug_use" section="S1" start="14361" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fatigue" meddra_llt_id="10016256" meddra_pt="Fatigue" meddra_pt_id="10016256" />
    </Mention>
    <Mention id="M49" len="24" reason="general_term" section="S1" start="14470" type="NonOSE_AE">
      <Normalization meddra_llt="Nervous system disorder" meddra_llt_id="10029202" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M256" len="12" reason="from_drug_use" section="S1" start="14579" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Parkinsonism" meddra_llt_id="10034010" meddra_pt="Parkinsonism" meddra_pt_id="10034010" />
    </Mention>
    <Mention id="M257" len="12" reason="from_drug_use" section="S1" start="14599" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Parkinsonism" meddra_llt_id="10034010" meddra_pt="Parkinsonism" meddra_pt_id="10034010" />
    </Mention>
    <Mention id="M258" len="23" reason="from_drug_use" section="S1" start="14621" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Extrapyramidal disorder" meddra_llt_id="10015832" meddra_pt="Extrapyramidal disorder" meddra_pt_id="10015832" />
    </Mention>
    <Mention id="M259" len="12" reason="from_drug_use" section="S1" start="14646" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Parkinsonism" meddra_llt_id="10034010" meddra_pt="Parkinsonism" meddra_pt_id="10034010" />
    </Mention>
    <Mention id="M260" len="25" reason="from_drug_use" section="S1" start="14660" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Musculoskeletal stiffness" meddra_llt_id="10052904" meddra_pt="Musculoskeletal stiffness" meddra_pt_id="10052904" />
    </Mention>
    <Mention id="M261" len="11" reason="from_drug_use" section="S1" start="14687" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypokinesia" meddra_llt_id="10021021" meddra_pt="Hypokinesia" meddra_pt_id="10021021" />
    </Mention>
    <Mention id="M262" len="15" reason="from_drug_use" section="S1" start="14700" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Muscle rigidity" meddra_llt_id="10028330" meddra_pt="Muscle rigidity" meddra_pt_id="10028330" />
    </Mention>
    <Mention id="M263" len="16" reason="from_drug_use" section="S1" start="14717" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Muscle tightness" meddra_llt_id="10049816" meddra_pt="Muscle tightness" meddra_pt_id="10049816" />
    </Mention>
    <Mention id="M264" len="12" reason="from_drug_use" section="S1" start="14735" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bradykinesia" meddra_llt_id="10006100" meddra_pt="Bradykinesia" meddra_pt_id="10006100" />
    </Mention>
    <Mention id="M265" len="17" reason="from_drug_use" section="S1" start="14749" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rigidity cogwheel" meddra_llt_id="10039170" meddra_pt="Cogwheel rigidity" meddra_pt_id="10009848" />
    </Mention>
    <Mention id="M266" len="9" reason="from_drug_use" section="S1" start="14768" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Akathisia" meddra_llt_id="10001540" meddra_pt="Akathisia" meddra_pt_id="10001540" />
    </Mention>
    <Mention id="M267" len="9" reason="from_drug_use" section="S1" start="14787" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Akathisia" meddra_llt_id="10001540" meddra_pt="Akathisia" meddra_pt_id="10001540" />
    </Mention>
    <Mention id="M268" len="12" reason="from_drug_use" section="S1" start="14801" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Restlessness" meddra_llt_id="10038743" meddra_pt="Restlessness" meddra_pt_id="10038743" />
    </Mention>
    <Mention id="M269" len="6" reason="from_drug_use" section="S1" start="14815" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tremor" meddra_llt_id="10044565" meddra_pt="Tremor" meddra_pt_id="10044565" />
    </Mention>
    <Mention id="M270" len="6" reason="from_drug_use" section="S1" start="14831" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tremor" meddra_llt_id="10044565" meddra_pt="Tremor" meddra_pt_id="10044565" />
    </Mention>
    <Mention id="M271" len="24" reason="from_drug_use" section="S1" start="14842" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Parkinsonian rest tremor" meddra_llt_id="10056437" meddra_pt="Parkinsonian rest tremor" meddra_pt_id="10056437" />
    </Mention>
    <Mention id="M272" len="8" reason="from_drug_use" section="S1" start="14868" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dystonia" meddra_llt_id="10013983" meddra_pt="Dystonia" meddra_pt_id="10013983" />
    </Mention>
    <Mention id="M273" len="8" reason="from_drug_use" section="S1" start="14886" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dystonia" meddra_llt_id="10013983" meddra_pt="Dystonia" meddra_pt_id="10013983" />
    </Mention>
    <Mention id="M274" len="13" reason="from_drug_use" section="S1" start="14896" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Muscle spasms" meddra_llt_id="10028334" meddra_pt="Muscle spasms" meddra_pt_id="10028334" />
    </Mention>
    <Mention id="M275" len="13" reason="from_drug_use" section="S1" start="14911" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Oculogyration" meddra_llt_id="10061552" meddra_pt="Oculogyric crisis" meddra_pt_id="10030071" />
    </Mention>
    <Mention id="M276" len="11" reason="from_drug_use" section="S1" start="14926" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Torticollis" meddra_llt_id="10044074" meddra_pt="Torticollis" meddra_pt_id="10044074" />
    </Mention>
    <Mention id="M622" len="8" reason="from_drug_use" section="S1" start="15001" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sedation" meddra_llt_id="10039897" meddra_pt="Sedation" meddra_pt_id="10039897" />
    </Mention>
    <Mention id="M277" len="9" reason="from_drug_use" section="S1" start="15110" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Akathisia" meddra_llt_id="10001540" meddra_pt="Akathisia" meddra_pt_id="10001540" />
    </Mention>
    <Mention id="M278" len="6" reason="from_drug_use" section="S1" start="15219" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tremor" meddra_llt_id="10044565" meddra_pt="Tremor" meddra_pt_id="10044565" />
    </Mention>
    <Mention id="M279" len="9" reason="from_drug_use" section="S1" start="15328" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M280" len="8" reason="from_drug_use" section="S1" start="15437" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dystonia" meddra_llt_id="10013983" meddra_pt="Dystonia" meddra_pt_id="10013983" />
    </Mention>
    <Mention id="M281" len="8" reason="from_drug_use" section="S1" start="15546" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lethargy" meddra_llt_id="10024264" meddra_pt="Lethargy" meddra_pt_id="10024264" />
    </Mention>
    <Mention id="M11" len="13" reason="indication" section="S1" start="15769" type="Not_AE_Candidate">
      <Normalization meddra_llt="Mania" meddra_llt_id="10026749" meddra_pt="Mania" meddra_pt_id="10026749" />
    </Mention>
    <Mention id="M50" len="17" reason="general_term" section="S1" start="16356" type="NonOSE_AE">
      <Normalization meddra_llt="Cardiac disorder" meddra_llt_id="10061024" meddra_pt="Cardiac disorder" meddra_pt_id="10061024" />
    </Mention>
    <Mention id="M282" len="12" reason="from_drug_use" section="S1" start="16465" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Palpitation" meddra_llt_id="10033556" meddra_pt="Palpitations" meddra_pt_id="10033557" />
    </Mention>
    <Mention id="M51" len="26" reason="general_term" section="S1" start="16574" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M283" len="9" reason="from_drug_use" section="S1" start="16683" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspepsia-aggravated" meddra_llt_id="10048482" meddra_pt="Dyspepsia" meddra_pt_id="10013946" />
    </Mention>
    <Mention id="M284" len="6" reason="from_drug_use" section="S1" start="16792" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M285" len="8" reason="from_drug_use" section="S1" start="16901" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M286" len="23" reason="from_drug_use" section="S1" start="17010" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Salivary hypersecretion" meddra_llt_id="10039424" meddra_pt="Salivary hypersecretion" meddra_pt_id="10039424" />
    </Mention>
    <Mention id="M52" len="17" reason="general_term" section="S1" start="17119" type="NonOSE_AE">
      <Normalization meddra_llt="General symptom" meddra_llt_id="10060891" meddra_pt="General symptom" meddra_pt_id="10060891" />
    </Mention>
    <Mention id="M287" len="10" reason="from_drug_use" section="S1" start="17228" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain chest" meddra_llt_id="10033387" meddra_pt="Chest pain" meddra_pt_id="10008479" />
    </Mention>
    <Mention id="M53" len="27" reason="general_term" section="S1" start="17337" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M288" len="23" reason="from_drug_use" section="S1" start="17446" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Infection urinary tract" meddra_llt_id="10021872" meddra_pt="Urinary tract infection" meddra_pt_id="10046571" />
    </Mention>
    <Mention id="M54" len="24" reason="general_term" section="S1" start="17555" type="NonOSE_AE">
      <Normalization meddra_llt="Nervous system disorder" meddra_llt_id="10029202" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M289" len="12" reason="from_drug_use" section="S1" start="17664" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Parkinsonism" meddra_llt_id="10034010" meddra_pt="Parkinsonism" meddra_pt_id="10034010" />
    </Mention>
    <Mention id="M290" len="12" reason="from_drug_use" section="S1" start="17684" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Parkinsonism" meddra_llt_id="10034010" meddra_pt="Parkinsonism" meddra_pt_id="10034010" />
    </Mention>
    <Mention id="M291" len="23" reason="from_drug_use" section="S1" start="17706" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Extrapyramidal disorder" meddra_llt_id="10015832" meddra_pt="Extrapyramidal disorder" meddra_pt_id="10015832" />
    </Mention>
    <Mention id="M292" len="11" reason="from_drug_use" section="S1" start="17731" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypokinesia" meddra_llt_id="10021021" meddra_pt="Hypokinesia" meddra_pt_id="10021021" />
    </Mention>
    <Mention id="M293" len="12" reason="from_drug_use" section="S1" start="17747" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bradykinesia" meddra_llt_id="10006100" meddra_pt="Bradykinesia" meddra_pt_id="10006100" />
    </Mention>
    <Mention id="M294" len="9" reason="from_drug_use" section="S1" start="17761" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Akathisia" meddra_llt_id="10001540" meddra_pt="Akathisia" meddra_pt_id="10001540" />
    </Mention>
    <Mention id="M295" len="12" reason="from_drug_use" section="S1" start="17780" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperkinesia" meddra_llt_id="10020651" meddra_pt="Hyperkinesia" meddra_pt_id="10020651" />
    </Mention>
    <Mention id="M296" len="9" reason="from_drug_use" section="S1" start="17797" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Akathisia" meddra_llt_id="10001540" meddra_pt="Akathisia" meddra_pt_id="10001540" />
    </Mention>
    <Mention id="M297" len="8" reason="from_drug_use" section="S1" start="17878" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sedation" meddra_llt_id="10039897" meddra_pt="Sedation" meddra_pt_id="10039897" />
    </Mention>
    <Mention id="M298" len="9" reason="from_drug_use" section="S1" start="17989" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Akathisia" meddra_llt_id="10001540" meddra_pt="Akathisia" meddra_pt_id="10001540" />
    </Mention>
    <Mention id="M299" len="9" reason="from_drug_use" section="S1" start="18098" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M300" len="6" reason="from_drug_use" section="S1" start="18207" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tremor" meddra_llt_id="10044565" meddra_pt="Tremor" meddra_pt_id="10044565" />
    </Mention>
    <Mention id="M301" len="8" reason="from_drug_use" section="S1" start="18316" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lethargy" meddra_llt_id="10024264" meddra_pt="Lethargy" meddra_pt_id="10024264" />
    </Mention>
    <Mention id="M55" len="21" reason="general_term" section="S1" start="18425" type="NonOSE_AE">
      <Normalization meddra_llt="Psychiatric disorder NOS" meddra_llt_id="10037174" meddra_pt="Mental disorder" meddra_pt_id="10061284" />
      <Normalization meddra_pt="Psychiatric symptom" meddra_pt_id="10061472" />
    </Mention>
    <Mention id="M302" len="7" reason="from_drug_use" section="S1" start="18534" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety" meddra_llt_id="10002855" meddra_pt="Anxiety" meddra_pt_id="10002855" />
    </Mention>
    <Mention id="M56" len="47" reason="general_term" section="S1" start="18643" type="NonOSE_AE">
      <Normalization meddra_llt="Respiratory disorder" meddra_llt_id="10038683" meddra_pt="Respiratory disorder" meddra_pt_id="10038683" />
    </Mention>
    <Mention id="M303" len="22" reason="from_drug_use" section="S1" start="18763" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pharyngolaryngeal pain" meddra_llt_id="10034844" meddra_pt="Laryngeal pain" meddra_pt_id="10023848" />
    </Mention>
    <Mention id="M304" len="5" reason="from_drug_use" section="S1" start="18872" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cough" meddra_llt_id="10011224" meddra_pt="Cough" meddra_pt_id="10011224" />
    </Mention>
    <Mention id="M12" len="13" reason="indication" section="S1" start="19015" type="Not_AE_Candidate">
      <Normalization meddra_llt="Mania" meddra_llt_id="10026749" meddra_pt="Mania" meddra_pt_id="10026749" />
    </Mention>
    <Mention id="M13" len="13" reason="indication" section="S1" start="19147" type="Not_AE_Candidate">
      <Normalization meddra_llt="Mania" meddra_llt_id="10026749" meddra_pt="Mania" meddra_pt_id="10026749" />
    </Mention>
    <Mention id="M57" len="13" reason="general_term" section="S1" start="19682" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder eye" meddra_llt_id="10013221" meddra_pt="Eye disorder" meddra_pt_id="10015916" />
      <Normalization meddra_pt="Ocular toxicity" meddra_pt_id="10061137" />
    </Mention>
    <Mention id="M305" len="14" reason="from_drug_use" section="S1" start="19793" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vision blurred" meddra_llt_id="10047513" meddra_pt="Vision blurred" meddra_pt_id="10047513" />
    </Mention>
    <Mention id="M58" len="26" reason="general_term" section="S1" start="19904" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M306" len="20" reason="from_drug_use" section="S1" start="20015" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Upper abdominal pain" meddra_llt_id="10046272" meddra_pt="Abdominal pain upper" meddra_pt_id="10000087" />
    </Mention>
    <Mention id="M307" len="6" reason="from_drug_use" section="S1" start="20126" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M308" len="8" reason="from_drug_use" section="S1" start="20237" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vomiting" meddra_llt_id="10047700" meddra_pt="Vomiting" meddra_pt_id="10047700" />
    </Mention>
    <Mention id="M309" len="8" reason="from_drug_use" section="S1" start="20348" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diarrhea" meddra_llt_id="10012727" meddra_pt="Diarrhoea" meddra_pt_id="10012735" />
    </Mention>
    <Mention id="M310" len="9" reason="from_drug_use" section="S1" start="20459" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyspepsia-aggravated" meddra_llt_id="10048482" meddra_pt="Dyspepsia" meddra_pt_id="10013946" />
    </Mention>
    <Mention id="M311" len="18" reason="from_drug_use" section="S1" start="20570" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Stomach discomfort" meddra_llt_id="10042101" meddra_pt="Abdominal discomfort" meddra_pt_id="10000059" />
    </Mention>
    <Mention id="M60" len="17" reason="general_term" section="S1" start="20681" type="NonOSE_AE">
      <Normalization meddra_llt="General symptom" meddra_llt_id="10060891" meddra_pt="General symptom" meddra_pt_id="10060891" />
    </Mention>
    <Mention id="M312" len="7" reason="from_drug_use" section="S1" start="20792" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fatigue" meddra_llt_id="10016256" meddra_pt="Fatigue" meddra_pt_id="10016256" />
    </Mention>
    <Mention id="M59" len="34" reason="general_term" section="S1" start="20903" type="NonOSE_AE">
      <Normalization meddra_llt="Unspecified disorder of metabolism" meddra_llt_id="10045811" meddra_pt="Metabolic disorder" meddra_pt_id="10058097" />
    </Mention>
    <Mention id="M313" len="18" reason="from_drug_use" section="S1" start="21014" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Increased appetite" meddra_llt_id="10021654" meddra_pt="Increased appetite" meddra_pt_id="10021654" />
    </Mention>
    <Mention id="M61" len="24" reason="general_term" section="S1" start="21125" type="NonOSE_AE">
      <Normalization meddra_llt="Nervous system disorder" meddra_llt_id="10029202" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M314" len="8" reason="from_drug_use" section="S1" start="21236" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sedation" meddra_llt_id="10039897" meddra_pt="Sedation" meddra_pt_id="10039897" />
    </Mention>
    <Mention id="M315" len="9" reason="from_drug_use" section="S1" start="21347" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M316" len="12" reason="from_drug_use" section="S1" start="21456" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Parkinsonism" meddra_llt_id="10034010" meddra_pt="Parkinsonism" meddra_pt_id="10034010" />
    </Mention>
    <Mention id="M317" len="12" reason="from_drug_use" section="S1" start="21476" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Parkinsonism" meddra_llt_id="10034010" meddra_pt="Parkinsonism" meddra_pt_id="10034010" />
    </Mention>
    <Mention id="M318" len="25" reason="from_drug_use" section="S1" start="21498" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Musculoskeletal stiffness" meddra_llt_id="10052904" meddra_pt="Musculoskeletal stiffness" meddra_pt_id="10052904" />
    </Mention>
    <Mention id="M319" len="23" reason="from_drug_use" section="S1" start="21525" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Extrapyramidal disorder" meddra_llt_id="10015832" meddra_pt="Extrapyramidal disorder" meddra_pt_id="10015832" />
    </Mention>
    <Mention id="M320" len="12" reason="from_drug_use" section="S1" start="21550" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bradykinesia" meddra_llt_id="10006100" meddra_pt="Bradykinesia" meddra_pt_id="10006100" />
    </Mention>
    <Mention id="M321" len="15" reason="from_drug_use" section="S1" start="21568" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nuchal rigidity" meddra_llt_id="10058483" meddra_pt="Nuchal rigidity" meddra_pt_id="10058483" />
    </Mention>
    <Mention id="M322" len="8" reason="from_drug_use" section="S1" start="21585" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dystonia" meddra_llt_id="10013983" meddra_pt="Dystonia" meddra_pt_id="10013983" />
    </Mention>
    <Mention id="M323" len="8" reason="from_drug_use" section="S1" start="21603" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dystonia" meddra_llt_id="10013983" meddra_pt="Dystonia" meddra_pt_id="10013983" />
    </Mention>
    <Mention id="M324" len="12" reason="from_drug_use" section="S1" start="21613" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Laryngospasm" meddra_llt_id="10023891" meddra_pt="Laryngospasm" meddra_pt_id="10023891" />
    </Mention>
    <Mention id="M325" len="13" reason="from_drug_use" section="S1" start="21631" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Muscle spasms" meddra_llt_id="10028334" meddra_pt="Muscle spasms" meddra_pt_id="10028334" />
    </Mention>
    <Mention id="M326" len="9" reason="from_drug_use" section="S1" start="21646" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Akathisia" meddra_llt_id="10001540" meddra_pt="Akathisia" meddra_pt_id="10001540" />
    </Mention>
    <Mention id="M327" len="12" reason="from_drug_use" section="S1" start="21665" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Restlessness" meddra_llt_id="10038743" meddra_pt="Restlessness" meddra_pt_id="10038743" />
    </Mention>
    <Mention id="M328" len="9" reason="from_drug_use" section="S1" start="21682" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Akathisia" meddra_llt_id="10001540" meddra_pt="Akathisia" meddra_pt_id="10001540" />
    </Mention>
    <Mention id="M329" len="8" reason="from_drug_use" section="S1" start="21767" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dystonia" meddra_llt_id="10013983" meddra_pt="Dystonia" meddra_pt_id="10013983" />
    </Mention>
    <Mention id="M330" len="9" reason="from_drug_use" section="S1" start="21878" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Akathisia" meddra_llt_id="10001540" meddra_pt="Akathisia" meddra_pt_id="10001540" />
    </Mention>
    <Mention id="M62" len="21" reason="general_term" section="S1" start="21989" type="NonOSE_AE">
      <Normalization meddra_llt="Psychiatric disorder NOS" meddra_llt_id="10037174" meddra_pt="Mental disorder" meddra_pt_id="10061284" />
      <Normalization meddra_pt="Psychiatric symptom" meddra_pt_id="10061472" />
    </Mention>
    <Mention id="M331" len="7" reason="from_drug_use" section="S1" start="22100" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety" meddra_llt_id="10002855" meddra_pt="Anxiety" meddra_pt_id="10002855" />
    </Mention>
    <Mention id="M63" len="47" reason="general_term" section="S1" start="22211" type="NonOSE_AE">
      <Normalization meddra_llt="Respiratory disorder" meddra_llt_id="10038683" meddra_pt="Respiratory disorder" meddra_pt_id="10038683" />
    </Mention>
    <Mention id="M332" len="22" reason="from_drug_use" section="S1" start="22333" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pharyngolaryngeal pain" meddra_llt_id="10034844" meddra_pt="Laryngeal pain" meddra_pt_id="10023848" />
    </Mention>
    <Mention id="M64" len="38" reason="general_term" section="S1" start="22444" type="NonOSE_AE">
      <Normalization meddra_llt="Other disorders of skin and subcutaneous tissue" meddra_llt_id="10032001" meddra_pt="Skin disorder" meddra_pt_id="10040831" />
    </Mention>
    <Mention id="M333" len="4" reason="from_drug_use" section="S1" start="22557" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rash" meddra_llt_id="10037844" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Mention>
    <Mention id="M20" len="46" reason="indication" section="S1" start="22912" type="Not_AE_Candidate">
      <Normalization meddra_llt="Irritability" meddra_llt_id="10022998" meddra_pt="Irritability" meddra_pt_id="10022998" />
    </Mention>
    <Mention id="M26" len="17" reason="preexisting_condition_or_risk_factor" section="S1" start="22941" type="Not_AE_Candidate">
      <Normalization meddra_llt="Autistic disorder" meddra_llt_id="10003808" meddra_pt="Autism spectrum disorder" meddra_pt_id="10063844" />
    </Mention>
    <Mention id="M66" len="26" reason="general_term" section="S1" start="23612" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M334" len="8" reason="from_drug_use" section="S1" start="23721" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vomiting" meddra_llt_id="10047700" meddra_pt="Vomiting" meddra_pt_id="10047700" />
    </Mention>
    <Mention id="M335" len="12" reason="from_drug_use" section="S1" start="23830" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Constipation" meddra_llt_id="10010774" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M336" len="9" reason="from_drug_use" section="S1" start="23939" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry mouth" meddra_llt_id="10013781" meddra_pt="Dry mouth" meddra_pt_id="10013781" />
    </Mention>
    <Mention id="M337" len="6" reason="from_drug_use" section="S1" start="24048" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M338" len="23" reason="from_drug_use" section="S1" start="24157" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Salivary hypersecretion" meddra_llt_id="10039424" meddra_pt="Salivary hypersecretion" meddra_pt_id="10039424" />
    </Mention>
    <Mention id="M67" len="52" reason="general_term" section="S1" start="24266" type="NonOSE_AE">
      <Normalization meddra_llt="General symptom" meddra_llt_id="10060891" meddra_pt="General symptom" meddra_pt_id="10060891" />
    </Mention>
    <Mention id="M339" len="7" reason="from_drug_use" section="S1" start="24376" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fatigue" meddra_llt_id="10016256" meddra_pt="Fatigue" meddra_pt_id="10016256" />
    </Mention>
    <Mention id="M340" len="7" reason="from_drug_use" section="S1" start="24485" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pyrexia" meddra_llt_id="10037660" meddra_pt="Pyrexia" meddra_pt_id="10037660" />
    </Mention>
    <Mention id="M341" len="6" reason="from_drug_use" section="S1" start="24594" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thirst" meddra_llt_id="10043458" meddra_pt="Thirst" meddra_pt_id="10043458" />
    </Mention>
    <Mention id="M65" len="27" reason="general_term" section="S1" start="24703" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M342" len="15" reason="from_drug_use" section="S1" start="24812" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nasopharyngitis" meddra_llt_id="10028810" meddra_pt="Nasopharyngitis" meddra_pt_id="10028810" />
    </Mention>
    <Mention id="M343" len="8" reason="from_drug_use" section="S1" start="24921" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rhinitis" meddra_llt_id="10039083" meddra_pt="Rhinitis" meddra_pt_id="10039083" />
    </Mention>
    <Mention id="M344" len="33" reason="from_drug_use" section="S1" start="25030" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Upper respiratory tract infection" meddra_llt_id="10046306" meddra_pt="Upper respiratory tract infection" meddra_pt_id="10046306" />
    </Mention>
    <Mention id="M68" len="14" reason="general_term" section="S1" start="25139" type="NonOSE_AE">
      <Normalization meddra_llt="Investigation" meddra_llt_id="10062026" meddra_pt="Investigation" meddra_pt_id="10062026" />
    </Mention>
    <Mention id="M345" len="16" reason="from_drug_use" section="S1" start="25248" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight increased" meddra_llt_id="10047899" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M69" len="34" reason="general_term" section="S1" start="25357" type="NonOSE_AE">
      <Normalization meddra_llt="Unspecified disorder of metabolism" meddra_llt_id="10045811" meddra_pt="Metabolic disorder" meddra_pt_id="10058097" />
    </Mention>
    <Mention id="M346" len="18" reason="from_drug_use" section="S1" start="25466" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Increased appetite" meddra_llt_id="10021654" meddra_pt="Increased appetite" meddra_pt_id="10021654" />
    </Mention>
    <Mention id="M70" len="24" reason="general_term" section="S1" start="25575" type="NonOSE_AE">
      <Normalization meddra_llt="Nervous system disorder" meddra_llt_id="10029202" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M347" len="8" reason="from_drug_use" section="S1" start="25684" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sedation" meddra_llt_id="10039897" meddra_pt="Sedation" meddra_pt_id="10039897" />
    </Mention>
    <Mention id="M348" len="8" reason="from_drug_use" section="S1" start="25793" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Drooling" meddra_llt_id="10013642" meddra_pt="Drooling" meddra_pt_id="10013642" />
    </Mention>
    <Mention id="M349" len="8" reason="from_drug_use" section="S1" start="25902" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Headache" meddra_llt_id="10019211" meddra_pt="Headache" meddra_pt_id="10019211" />
    </Mention>
    <Mention id="M350" len="6" reason="from_drug_use" section="S1" start="26011" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tremor" meddra_llt_id="10044565" meddra_pt="Tremor" meddra_pt_id="10044565" />
    </Mention>
    <Mention id="M351" len="9" reason="from_drug_use" section="S1" start="26120" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M352" len="12" reason="from_drug_use" section="S1" start="26229" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Parkinsonism" meddra_llt_id="10034010" meddra_pt="Parkinsonism" meddra_pt_id="10034010" />
    </Mention>
    <Mention id="M353" len="12" reason="from_drug_use" section="S1" start="26249" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Parkinsonism" meddra_llt_id="10034010" meddra_pt="Parkinsonism" meddra_pt_id="10034010" />
    </Mention>
    <Mention id="M354" len="25" reason="from_drug_use" section="S1" start="26271" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Musculoskeletal stiffness" meddra_llt_id="10052904" meddra_pt="Musculoskeletal stiffness" meddra_pt_id="10052904" />
    </Mention>
    <Mention id="M355" len="23" reason="from_drug_use" section="S1" start="26298" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Extrapyramidal disorder" meddra_llt_id="10015832" meddra_pt="Extrapyramidal disorder" meddra_pt_id="10015832" />
    </Mention>
    <Mention id="M356" len="15" reason="from_drug_use" section="S1" start="26323" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Muscle rigidity" meddra_llt_id="10028330" meddra_pt="Muscle rigidity" meddra_pt_id="10028330" />
    </Mention>
    <Mention id="M357" len="17" reason="from_drug_use" section="S1" start="26340" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rigidity cogwheel" meddra_llt_id="10039170" meddra_pt="Cogwheel rigidity" meddra_pt_id="10009848" />
    </Mention>
    <Mention id="M358" len="16" reason="from_drug_use" section="S1" start="26363" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Muscle tightness" meddra_llt_id="10049816" meddra_pt="Muscle tightness" meddra_pt_id="10049816" />
    </Mention>
    <Mention id="M72" len="27" reason="general_term" section="S1" start="26438" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder renal" meddra_llt_id="10013263" meddra_pt="Renal disorder" meddra_pt_id="10038428" />
    </Mention>
    <Mention id="M359" len="8" reason="from_drug_use" section="S1" start="26547" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Enuresis" meddra_llt_id="10014928" meddra_pt="Enuresis" meddra_pt_id="10014928" />
    </Mention>
    <Mention id="M71" len="47" reason="general_term" section="S1" start="26656" type="NonOSE_AE">
      <Normalization meddra_llt="Respiratory disorder" meddra_llt_id="10038683" meddra_pt="Respiratory disorder" meddra_pt_id="10038683" />
    </Mention>
    <Mention id="M360" len="5" reason="from_drug_use" section="S1" start="26765" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cough" meddra_llt_id="10011224" meddra_pt="Cough" meddra_pt_id="10011224" />
    </Mention>
    <Mention id="M361" len="10" reason="from_drug_use" section="S1" start="26874" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rhinorrhea" meddra_llt_id="10039100" meddra_pt="Rhinorrhoea" meddra_pt_id="10039101" />
    </Mention>
    <Mention id="M362" len="16" reason="from_drug_use" section="S1" start="26983" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Congestion nasal" meddra_llt_id="10010676" meddra_pt="Nasal congestion" meddra_pt_id="10028735" />
    </Mention>
    <Mention id="M73" len="38" reason="general_term" section="S1" start="27092" type="NonOSE_AE">
      <Normalization meddra_llt="Other disorders of skin and subcutaneous tissue" meddra_llt_id="10032001" meddra_pt="Skin disorder" meddra_pt_id="10040831" />
    </Mention>
    <Mention id="M363" len="4" reason="from_drug_use" section="S1" start="27201" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rash" meddra_llt_id="10037844" meddra_pt="Rash" meddra_pt_id="10037844" />
    </Mention>
    <Mention id="M74" len="36" reason="general_term" section="S1" start="27591" type="NonOSE_AE">
      <Normalization meddra_llt="Blood disorder" meddra_llt_id="10061590" meddra_pt="Blood disorder" meddra_pt_id="10061590" />
      <Normalization meddra_pt="Haematology test abnormal" meddra_pt_id="10057755" />
    </Mention>
    <Mention id="M364" len="6" reason="from_drug_use" section="S1" start="27629" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anemia" meddra_llt_id="10002272" meddra_pt="Anaemia" meddra_pt_id="10002034" />
    </Mention>
    <Mention id="M365" len="16" reason="from_drug_use" section="S1" start="27637" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Granulocytopenia" meddra_llt_id="10018687" meddra_pt="Granulocytopenia" meddra_pt_id="10018687" />
    </Mention>
    <Mention id="M366" len="11" reason="from_drug_use" section="S1" start="27655" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M75" len="17" reason="general_term" section="S1" start="27669" type="NonOSE_AE">
      <Normalization meddra_llt="Cardiac disorder" meddra_llt_id="10061024" meddra_pt="Cardiac disorder" meddra_pt_id="10061024" />
    </Mention>
    <Mention id="M367" len="17" reason="from_drug_use" section="S1" start="27688" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bradycardia sinus" meddra_llt_id="10006098" meddra_pt="Sinus bradycardia" meddra_pt_id="10040741" />
    </Mention>
    <Mention id="M368" len="17" reason="from_drug_use" section="S1" start="27707" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tachycardia sinus" meddra_llt_id="10043083" meddra_pt="Sinus tachycardia" meddra_pt_id="10040752" />
    </Mention>
    <Mention id="M369" len="35" reason="from_drug_use" section="S1" start="27726" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Atrioventricular block first degree" meddra_llt_id="10003674" meddra_pt="Atrioventricular block first degree" meddra_pt_id="10003674" />
    </Mention>
    <Mention id="M370" len="24" reason="from_drug_use" section="S1" start="27763" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bundle branch block left" meddra_llt_id="10006580" meddra_pt="Bundle branch block left" meddra_pt_id="10006580" />
    </Mention>
    <Mention id="M371" len="25" reason="from_drug_use" section="S1" start="27789" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bundle branch block right" meddra_llt_id="10006582" meddra_pt="Bundle branch block right" meddra_pt_id="10006582" />
    </Mention>
    <Mention id="M372" len="22" reason="from_drug_use" section="S1" start="27816" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Atrioventricular block" meddra_llt_id="10003671" meddra_pt="Atrioventricular block" meddra_pt_id="10003671" />
    </Mention>
    <Mention id="M76" len="27" reason="general_term" section="S1" start="27841" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder ear" meddra_llt_id="10013214" meddra_pt="Ear disorder" meddra_pt_id="10014004" />
    </Mention>
    <Mention id="M373" len="8" reason="from_drug_use" section="S1" start="27870" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain ear" meddra_llt_id="10033393" meddra_pt="Ear pain" meddra_pt_id="10014020" />
    </Mention>
    <Mention id="M374" len="8" reason="from_drug_use" section="S1" start="27880" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tinnitus" meddra_llt_id="10043882" meddra_pt="Tinnitus" meddra_pt_id="10043882" />
    </Mention>
    <Mention id="M77" len="19" reason="general_term" section="S1" start="27891" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder endocrine" meddra_llt_id="10013217" meddra_pt="Endocrine disorder" meddra_pt_id="10014695" />
    </Mention>
    <Mention id="M375" len="18" reason="from_drug_use" section="S1" start="27912" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperprolactinemia" meddra_llt_id="10020739" meddra_pt="Hyperprolactinaemia" meddra_pt_id="10020737" />
      <Normalization meddra_pt="Blood prolactin increased" meddra_pt_id="10005780" />
    </Mention>
    <Mention id="M79" len="13" reason="general_term" section="S1" start="27933" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder eye" meddra_llt_id="10013221" meddra_pt="Eye disorder" meddra_pt_id="10015916" />
      <Normalization meddra_pt="Ocular toxicity" meddra_pt_id="10061137" />
    </Mention>
    <Mention id="M376" len="16" reason="from_drug_use" section="S1" start="27948" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ocular hyperemia" meddra_llt_id="10030042" meddra_pt="Ocular hyperaemia" meddra_pt_id="10030041" />
    </Mention>
    <Mention id="M377" len="13" reason="from_drug_use" section="S1" start="27966" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Discharge eye" meddra_llt_id="10013067" meddra_pt="Eye discharge" meddra_pt_id="10015915" />
    </Mention>
    <Mention id="M378" len="14" reason="from_drug_use" section="S1" start="27981" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Conjunctivitis" meddra_llt_id="10010741" meddra_pt="Conjunctivitis" meddra_pt_id="10010741" />
    </Mention>
    <Mention id="M379" len="11" reason="from_drug_use" section="S1" start="27997" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Eye rolling" meddra_llt_id="10015964" meddra_pt="Eye movement disorder" meddra_pt_id="10061129" />
    </Mention>
    <Mention id="M380" len="12" reason="from_drug_use" section="S1" start="28010" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Eyelid edema" meddra_llt_id="10015985" meddra_pt="Eyelid oedema" meddra_pt_id="10015993" />
    </Mention>
    <Mention id="M381" len="12" reason="from_drug_use" section="S1" start="28024" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Eye swelling" meddra_llt_id="10015967" meddra_pt="Eye swelling" meddra_pt_id="10015967" />
    </Mention>
    <Mention id="M382" len="22" reason="from_drug_use" section="S1" start="28038" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Eyelid margin crusting" meddra_llt_id="10052132" meddra_pt="Eyelid margin crusting" meddra_pt_id="10052132" />
    </Mention>
    <Mention id="M383" len="7" reason="from_drug_use" section="S1" start="28062" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry eye" meddra_llt_id="10013774" meddra_pt="Dry eye" meddra_pt_id="10013774" />
    </Mention>
    <Mention id="M384" len="21" reason="from_drug_use" section="S1" start="28071" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lacrimation increased" meddra_llt_id="10023644" meddra_pt="Lacrimation increased" meddra_pt_id="10023644" />
    </Mention>
    <Mention id="M385" len="11" reason="from_drug_use" section="S1" start="28094" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Photophobia" meddra_llt_id="10034960" meddra_pt="Photophobia" meddra_pt_id="10034960" />
    </Mention>
    <Mention id="M386" len="8" reason="from_drug_use" section="S1" start="28107" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Glaucoma" meddra_llt_id="10018304" meddra_pt="Glaucoma" meddra_pt_id="10018304" />
    </Mention>
    <Mention id="M387" len="21" reason="from_drug_use" section="S1" start="28117" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Visual acuity reduced" meddra_llt_id="10047531" meddra_pt="Visual acuity reduced" meddra_pt_id="10047531" />
    </Mention>
    <Mention id="M78" len="26" reason="general_term" section="S1" start="28141" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M388" len="9" reason="from_drug_use" section="S1" start="28169" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dysphagia" meddra_llt_id="10013950" meddra_pt="Dysphagia" meddra_pt_id="10013950" />
    </Mention>
    <Mention id="M389" len="8" reason="from_drug_use" section="S1" start="28180" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fecaloma" meddra_llt_id="10056329" meddra_pt="Faecaloma" meddra_pt_id="10056325" />
    </Mention>
    <Mention id="M390" len="18" reason="from_drug_use" section="S1" start="28190" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Incontinence fecal" meddra_llt_id="10021640" meddra_pt="Anal incontinence" meddra_pt_id="10077605" />
    </Mention>
    <Mention id="M391" len="9" reason="from_drug_use" section="S1" start="28210" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gastritis" meddra_llt_id="10017853" meddra_pt="Gastritis" meddra_pt_id="10017853" />
    </Mention>
    <Mention id="M392" len="12" reason="from_drug_use" section="S1" start="28221" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lip swelling" meddra_llt_id="10024570" meddra_pt="Lip swelling" meddra_pt_id="10024570" />
    </Mention>
    <Mention id="M393" len="9" reason="from_drug_use" section="S1" start="28235" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cheilitis" meddra_llt_id="10008417" meddra_pt="Cheilitis" meddra_pt_id="10008417" />
    </Mention>
    <Mention id="M394" len="9" reason="from_drug_use" section="S1" start="28246" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Aptyalism" meddra_llt_id="10003068" meddra_pt="Aptyalism" meddra_pt_id="10003068" />
    </Mention>
    <Mention id="M80" len="17" reason="general_term" section="S1" start="28258" type="NonOSE_AE">
      <Normalization meddra_llt="General symptom" meddra_llt_id="10060891" meddra_pt="General symptom" meddra_pt_id="10060891" />
    </Mention>
    <Mention id="M395" len="16" reason="from_drug_use" section="S1" start="28277" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Peripheral edema" meddra_llt_id="10034570" meddra_pt="Oedema peripheral" meddra_pt_id="10030124" />
    </Mention>
    <Mention id="M396" len="6" reason="from_drug_use" section="S1" start="28295" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thirst" meddra_llt_id="10043458" meddra_pt="Thirst" meddra_pt_id="10043458" />
    </Mention>
    <Mention id="M397" len="16" reason="from_drug_use" section="S1" start="28303" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gait disturbance" meddra_llt_id="10017577" meddra_pt="Gait disturbance" meddra_pt_id="10017577" />
    </Mention>
    <Mention id="M398" len="22" reason="from_drug_use" section="S1" start="28321" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Influenza like illness" meddra_llt_id="10022004" meddra_pt="Influenza like illness" meddra_pt_id="10022004" />
    </Mention>
    <Mention id="M399" len="13" reason="from_drug_use" section="S1" start="28345" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pitting edema" meddra_llt_id="10054547" meddra_pt="Oedema" meddra_pt_id="10030095" />
    </Mention>
    <Mention id="M400" len="5" reason="from_drug_use" section="S1" start="28360" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Edema" meddra_llt_id="10014210" meddra_pt="Oedema" meddra_pt_id="10030095" />
    </Mention>
    <Mention id="M401" len="6" reason="from_drug_use" section="S1" start="28367" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Chills" meddra_llt_id="10008531" meddra_pt="Chills" meddra_pt_id="10008531" />
    </Mention>
    <Mention id="M402" len="12" reason="from_drug_use" section="S1" start="28375" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sluggishness" meddra_llt_id="10041052" meddra_pt="Sluggishness" meddra_pt_id="10041052" />
    </Mention>
    <Mention id="M403" len="7" reason="from_drug_use" section="S1" start="28389" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Malaise" meddra_llt_id="10025482" meddra_pt="Malaise" meddra_pt_id="10025482" />
    </Mention>
    <Mention id="M404" len="16" reason="from_drug_use" section="S1" start="28398" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Chest discomfort" meddra_llt_id="10008469" meddra_pt="Chest discomfort" meddra_pt_id="10008469" />
    </Mention>
    <Mention id="M405" len="10" reason="from_drug_use" section="S1" start="28416" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Face edema" meddra_llt_id="10016025" meddra_pt="Face oedema" meddra_pt_id="10016029" />
    </Mention>
    <Mention id="M406" len="10" reason="from_drug_use" section="S1" start="28428" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Discomfort" meddra_llt_id="10013082" meddra_pt="Discomfort" meddra_pt_id="10013082" />
    </Mention>
    <Mention id="M407" len="17" reason="from_drug_use" section="S1" start="28440" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Generalized edema" meddra_llt_id="10018112" meddra_pt="Generalised oedema" meddra_pt_id="10018092" />
    </Mention>
    <Mention id="M408" len="24" reason="from_drug_use" section="S1" start="28459" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Drug withdrawal syndrome" meddra_llt_id="10013754" meddra_pt="Drug withdrawal syndrome" meddra_pt_id="10013754" />
      <Normalization meddra_pt="Withdrawal syndrome" meddra_pt_id="10048010" />
    </Mention>
    <Mention id="M409" len="19" reason="from_drug_use" section="S1" start="28485" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Peripheral coldness" meddra_llt_id="10034568" meddra_pt="Peripheral coldness" meddra_pt_id="10034568" />
    </Mention>
    <Mention id="M410" len="16" reason="from_drug_use" section="S1" start="28506" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Feeling abnormal" meddra_llt_id="10016322" meddra_pt="Feeling abnormal" meddra_pt_id="10016322" />
    </Mention>
    <Mention id="M81" len="23" reason="general_term" section="S1" start="28525" type="NonOSE_AE">
      <Normalization meddra_llt="Immune system disorder" meddra_llt_id="10021425" meddra_pt="Immune system disorder" meddra_pt_id="10021425" />
    </Mention>
    <Mention id="M411" len="21" reason="from_drug_use" section="S1" start="28550" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Drug hypersensitivity" meddra_llt_id="10013700" meddra_pt="Drug hypersensitivity" meddra_pt_id="10013700" />
      <Normalization meddra_pt="Hypersensitivity" meddra_pt_id="10020751" />
    </Mention>
    <Mention id="M82" len="27" reason="general_term" section="S1" start="28574" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M412" len="9" reason="from_drug_use" section="S1" start="28603" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pneumonia" meddra_llt_id="10035664" meddra_pt="Pneumonia" meddra_pt_id="10035664" />
    </Mention>
    <Mention id="M413" len="9" reason="from_drug_use" section="S1" start="28614" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Influenza" meddra_llt_id="10022000" meddra_pt="Influenza" meddra_pt_id="10022000" />
    </Mention>
    <Mention id="M414" len="13" reason="from_drug_use" section="S1" start="28625" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ear infection" meddra_llt_id="10014011" meddra_pt="Ear infection" meddra_pt_id="10014011" />
    </Mention>
    <Mention id="M415" len="15" reason="from_drug_use" section="S1" start="28640" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Infection viral" meddra_llt_id="10021876" meddra_pt="Viral infection" meddra_pt_id="10047461" />
      <Normalization meddra_pt="Infection reactivation" meddra_pt_id="10070891" />
    </Mention>
    <Mention id="M416" len="11" reason="from_drug_use" section="S1" start="28657" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pharyngitis" meddra_llt_id="10034835" meddra_pt="Pharyngitis" meddra_pt_id="10034835" />
    </Mention>
    <Mention id="M417" len="11" reason="from_drug_use" section="S1" start="28670" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tonsillitis" meddra_llt_id="10044008" meddra_pt="Tonsillitis" meddra_pt_id="10044008" />
    </Mention>
    <Mention id="M418" len="10" reason="from_drug_use" section="S1" start="28683" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bronchitis" meddra_llt_id="10006451" meddra_pt="Bronchitis" meddra_pt_id="10006451" />
    </Mention>
    <Mention id="M419" len="13" reason="from_drug_use" section="S1" start="28695" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Eye infection" meddra_llt_id="10015929" meddra_pt="Eye infection" meddra_pt_id="10015929" />
    </Mention>
    <Mention id="M420" len="19" reason="from_drug_use" section="S1" start="28710" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Localized infection" meddra_llt_id="10062469" meddra_pt="Localised infection" meddra_pt_id="10024774" />
    </Mention>
    <Mention id="M421" len="8" reason="from_drug_use" section="S1" start="28731" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cystitis" meddra_llt_id="10011781" meddra_pt="Cystitis" meddra_pt_id="10011781" />
    </Mention>
    <Mention id="M422" len="10" reason="from_drug_use" section="S1" start="28741" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cellulitis" meddra_llt_id="10007882" meddra_pt="Cellulitis" meddra_pt_id="10007882" />
    </Mention>
    <Mention id="M423" len="12" reason="from_drug_use" section="S1" start="28753" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Otitis media" meddra_llt_id="10033078" meddra_pt="Otitis media" meddra_pt_id="10033078" />
    </Mention>
    <Mention id="M424" len="13" reason="from_drug_use" section="S1" start="28767" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Onychomycosis" meddra_llt_id="10030338" meddra_pt="Onychomycosis" meddra_pt_id="10030338" />
    </Mention>
    <Mention id="M425" len="15" reason="from_drug_use" section="S1" start="28782" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Acarodermatitis" meddra_llt_id="10063409" meddra_pt="Acarodermatitis" meddra_pt_id="10063409" />
    </Mention>
    <Mention id="M426" len="16" reason="from_drug_use" section="S1" start="28799" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bronchopneumonia" meddra_llt_id="10006469" meddra_pt="Pneumonia" meddra_pt_id="10035664" />
    </Mention>
    <Mention id="M427" len="27" reason="from_drug_use" section="S1" start="28817" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Respiratory tract infection" meddra_llt_id="10062352" meddra_pt="Respiratory tract infection" meddra_pt_id="10062352" />
    </Mention>
    <Mention id="M428" len="17" reason="from_drug_use" section="S1" start="28846" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tracheobronchitis" meddra_llt_id="10044314" meddra_pt="Tracheobronchitis" meddra_pt_id="10044314" />
    </Mention>
    <Mention id="M429" len="20" reason="from_drug_use" section="S1" start="28865" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Otitis media chronic" meddra_llt_id="10033081" meddra_pt="Otitis media chronic" meddra_pt_id="10033081" />
    </Mention>
    <Mention id="M83" len="14" reason="general_term" section="S1" start="28888" type="NonOSE_AE">
      <Normalization meddra_llt="Investigation" meddra_llt_id="10062026" meddra_pt="Investigation" meddra_pt_id="10062026" />
    </Mention>
    <Mention id="M430" len="26" reason="from_drug_use" section="S1" start="28904" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Body temperature increased" meddra_llt_id="10005911" meddra_pt="Body temperature increased" meddra_pt_id="10005911" />
    </Mention>
    <Mention id="M431" len="25" reason="from_drug_use" section="S1" start="28932" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Blood prolactin increased" meddra_llt_id="10005780" meddra_pt="Blood prolactin increased" meddra_pt_id="10005780" />
      <Normalization meddra_pt="Hyperprolactinaemia" meddra_pt_id="10020737" />
    </Mention>
    <Mention id="M432" len="34" reason="from_drug_use" section="S1" start="28959" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Alanine aminotransferase increased" meddra_llt_id="10001551" meddra_pt="Alanine aminotransferase increased" meddra_pt_id="10001551" />
    </Mention>
    <Mention id="M433" len="26" reason="from_drug_use" section="S1" start="28995" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Electrocardiogram abnormal" meddra_llt_id="10014363" meddra_pt="Electrocardiogram abnormal" meddra_pt_id="10014363" />
    </Mention>
    <Mention id="M434" len="26" reason="from_drug_use" section="S1" start="29023" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Eosinophil count increased" meddra_llt_id="10014945" meddra_pt="Eosinophil count increased" meddra_pt_id="10014945" />
    </Mention>
    <Mention id="M435" len="32" reason="from_drug_use" section="S1" start="29051" type="OSE_Labeled_AE">
      <Normalization meddra_llt="White blood cell count decreased" meddra_llt_id="10047942" meddra_pt="White blood cell count decreased" meddra_pt_id="10047942" />
    </Mention>
    <Mention id="M436" len="23" reason="from_drug_use" section="S1" start="29085" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Blood glucose increased" meddra_llt_id="10005557" meddra_pt="Blood glucose increased" meddra_pt_id="10005557" />
      <Normalization meddra_pt="Impaired fasting glucose" meddra_pt_id="10056997" />
    </Mention>
    <Mention id="M437" len="20" reason="from_drug_use" section="S1" start="29110" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hemoglobin decreased" meddra_llt_id="10019483" meddra_pt="Haemoglobin decreased" meddra_pt_id="10018884" />
    </Mention>
    <Mention id="M438" len="20" reason="from_drug_use" section="S1" start="29132" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hematocrit decreased" meddra_llt_id="10019423" meddra_pt="Haematocrit decreased" meddra_pt_id="10018838" />
    </Mention>
    <Mention id="M439" len="26" reason="from_drug_use" section="S1" start="29154" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Body temperature decreased" meddra_llt_id="10005910" meddra_pt="Body temperature decreased" meddra_pt_id="10005910" />
    </Mention>
    <Mention id="M440" len="24" reason="from_drug_use" section="S1" start="29182" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Blood pressure decreased" meddra_llt_id="10005734" meddra_pt="Blood pressure decreased" meddra_pt_id="10005734" />
    </Mention>
    <Mention id="M441" len="23" reason="from_drug_use" section="S1" start="29208" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Transaminases increased" meddra_llt_id="10054889" meddra_pt="Transaminases increased" meddra_pt_id="10054889" />
    </Mention>
    <Mention id="M84" len="34" reason="general_term" section="S1" start="29234" type="NonOSE_AE">
      <Normalization meddra_llt="Unspecified disorder of metabolism" meddra_llt_id="10045811" meddra_pt="Metabolic disorder" meddra_pt_id="10058097" />
    </Mention>
    <Mention id="M442" len="18" reason="from_drug_use" section="S1" start="29270" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Decreased appetite" meddra_llt_id="10061428" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M443" len="10" reason="from_drug_use" section="S1" start="29290" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Polydipsia" meddra_llt_id="10036067" meddra_pt="Polydipsia" meddra_pt_id="10036067" />
    </Mention>
    <Mention id="M444" len="8" reason="from_drug_use" section="S1" start="29302" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anorexia" meddra_llt_id="10002646" meddra_pt="Decreased appetite" meddra_pt_id="10061428" />
    </Mention>
    <Mention id="M85" len="47" reason="general_term" section="S1" start="29313" type="NonOSE_AE">
      <Normalization meddra_llt="Musculoskeletal disorder" meddra_llt_id="10048592" meddra_pt="Musculoskeletal disorder" meddra_pt_id="10048592" />
    </Mention>
    <Mention id="M445" len="15" reason="from_drug_use" section="S1" start="29362" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Joint stiffness" meddra_llt_id="10023230" meddra_pt="Joint stiffness" meddra_pt_id="10023230" />
    </Mention>
    <Mention id="M446" len="14" reason="from_drug_use" section="S1" start="29379" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Joint swelling" meddra_llt_id="10023232" meddra_pt="Joint swelling" meddra_pt_id="10023232" />
    </Mention>
    <Mention id="M447" len="26" reason="from_drug_use" section="S1" start="29395" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Musculoskeletal chest pain" meddra_llt_id="10050819" meddra_pt="Musculoskeletal chest pain" meddra_pt_id="10050819" />
    </Mention>
    <Mention id="M448" len="16" reason="from_drug_use" section="S1" start="29423" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Posture abnormal" meddra_llt_id="10036436" meddra_pt="Posture abnormal" meddra_pt_id="10036436" />
    </Mention>
    <Mention id="M449" len="7" reason="from_drug_use" section="S1" start="29441" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Myalgia" meddra_llt_id="10028411" meddra_pt="Myalgia" meddra_pt_id="10028411" />
    </Mention>
    <Mention id="M450" len="9" reason="from_drug_use" section="S1" start="29450" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain neck" meddra_llt_id="10033467" meddra_pt="Neck pain" meddra_pt_id="10028836" />
    </Mention>
    <Mention id="M451" len="17" reason="from_drug_use" section="S1" start="29461" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Muscular weakness" meddra_llt_id="10028372" meddra_pt="Muscular weakness" meddra_pt_id="10028372" />
    </Mention>
    <Mention id="M452" len="14" reason="from_drug_use" section="S1" start="29480" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rhabdomyolysis" meddra_llt_id="10039020" meddra_pt="Rhabdomyolysis" meddra_pt_id="10039020" />
    </Mention>
    <Mention id="M86" len="24" reason="general_term" section="S1" start="29497" type="NonOSE_AE">
      <Normalization meddra_llt="Nervous system disorder" meddra_llt_id="10029202" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M453" len="16" reason="from_drug_use" section="S1" start="29523" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Balance disorder" meddra_llt_id="10049848" meddra_pt="Balance disorder" meddra_pt_id="10049848" />
    </Mention>
    <Mention id="M454" len="24" reason="from_drug_use" section="S1" start="29541" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disturbance in attention" meddra_llt_id="10013496" meddra_pt="Disturbance in attention" meddra_pt_id="10013496" />
    </Mention>
    <Mention id="M455" len="10" reason="from_drug_use" section="S1" start="29567" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dysarthria" meddra_llt_id="10013887" meddra_pt="Dysarthria" meddra_pt_id="10013887" />
    </Mention>
    <Mention id="M456" len="23" reason="from_drug_use" section="S1" start="29579" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Unresponsive to stimuli" meddra_llt_id="10045555" meddra_pt="Unresponsive to stimuli" meddra_pt_id="10045555" />
    </Mention>
    <Mention id="M457" len="32" reason="from_drug_use" section="S1" start="29604" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Depressed level of consciousness" meddra_llt_id="10012373" meddra_pt="Depressed level of consciousness" meddra_pt_id="10012373" />
    </Mention>
    <Mention id="M458" len="17" reason="from_drug_use" section="S1" start="29638" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Movement disorder" meddra_llt_id="10028035" meddra_pt="Movement disorder" meddra_pt_id="10028035" />
    </Mention>
    <Mention id="M459" len="25" reason="from_drug_use" section="S1" start="29657" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Transient ischemic attack" meddra_llt_id="10072760" meddra_pt="Transient ischaemic attack" meddra_pt_id="10044390" />
    </Mention>
    <Mention id="M460" len="21" reason="from_drug_use" section="S1" start="29684" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Coordination abnormal" meddra_llt_id="10010947" meddra_pt="Coordination abnormal" meddra_pt_id="10010947" />
    </Mention>
    <Mention id="M461" len="24" reason="from_drug_use" section="S1" start="29707" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Accident cerebrovascular" meddra_llt_id="10000374" meddra_pt="Cerebrovascular accident" meddra_pt_id="10008190" />
    </Mention>
    <Mention id="M462" len="15" reason="from_drug_use" section="S1" start="29733" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder speech" meddra_llt_id="10013269" meddra_pt="Speech disorder" meddra_pt_id="10041466" />
    </Mention>
    <Mention id="M463" len="7" reason="from_drug_use" section="S1" start="29750" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Syncope" meddra_llt_id="10042772" meddra_pt="Syncope" meddra_pt_id="10042772" />
    </Mention>
    <Mention id="M464" len="21" reason="from_drug_use" section="S1" start="29759" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Consciousness loss of" meddra_llt_id="10010772" meddra_pt="Loss of consciousness" meddra_pt_id="10024855" />
    </Mention>
    <Mention id="M465" len="12" reason="from_drug_use" section="S1" start="29782" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypoesthesia" meddra_llt_id="10020976" meddra_pt="Hypoaesthesia" meddra_pt_id="10020937" />
    </Mention>
    <Mention id="M466" len="18" reason="from_drug_use" section="S1" start="29796" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyskinesia tardive" meddra_llt_id="10013928" meddra_pt="Tardive dyskinesia" meddra_pt_id="10043118" />
    </Mention>
    <Mention id="M467" len="10" reason="from_drug_use" section="S1" start="29816" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyskinesia" meddra_llt_id="10013916" meddra_pt="Dyskinesia" meddra_pt_id="10013916" />
    </Mention>
    <Mention id="M468" len="17" reason="from_drug_use" section="S1" start="29828" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ischemia cerebral" meddra_llt_id="10023029" meddra_pt="Cerebral ischaemia" meddra_pt_id="10008120" />
    </Mention>
    <Mention id="M623" len="24" reason="from_drug_use" section="S1" start="29847" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder cerebrovascular" meddra_llt_id="10013203" meddra_pt="Cerebrovascular disorder" meddra_pt_id="10008196" />
    </Mention>
    <Mention id="M469" len="30" reason="from_drug_use" section="S1" start="29873" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neuroleptic malignant syndrome" meddra_llt_id="10029282" meddra_pt="Neuroleptic malignant syndrome" meddra_pt_id="10029282" />
    </Mention>
    <Mention id="M470" len="13" reason="from_drug_use" section="S1" start="29905" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Coma diabetic" meddra_llt_id="10010074" meddra_pt="Diabetic coma" meddra_pt_id="10012650" />
    </Mention>
    <Mention id="M471" len="15" reason="from_drug_use" section="S1" start="29920" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Head titubation" meddra_llt_id="10064950" meddra_pt="Head titubation" meddra_pt_id="10064950" />
    </Mention>
    <Mention id="M87" len="21" reason="general_term" section="S1" start="29938" type="NonOSE_AE">
      <Normalization meddra_llt="Psychiatric disorder NOS" meddra_llt_id="10037174" meddra_pt="Mental disorder" meddra_pt_id="10061284" />
      <Normalization meddra_pt="Psychiatric symptom" meddra_pt_id="10061472" />
    </Mention>
    <Mention id="M472" len="9" reason="from_drug_use" section="S1" start="29961" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Agitation" meddra_llt_id="10001497" meddra_pt="Agitation" meddra_pt_id="10001497" />
    </Mention>
    <Mention id="M473" len="14" reason="from_drug_use" section="S1" start="29972" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Blunted affect" meddra_llt_id="10005885" meddra_pt="Blunted affect" meddra_pt_id="10005885" />
    </Mention>
    <Mention id="M474" len="17" reason="from_drug_use" section="S1" start="29988" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Confusional state" meddra_llt_id="10010305" meddra_pt="Confusional state" meddra_pt_id="10010305" />
    </Mention>
    <Mention id="M475" len="15" reason="from_drug_use" section="S1" start="30007" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Middle insomnia" meddra_llt_id="10027590" meddra_pt="Middle insomnia" meddra_pt_id="10027590" />
    </Mention>
    <Mention id="M476" len="11" reason="from_drug_use" section="S1" start="30024" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nervousness" meddra_llt_id="10029216" meddra_pt="Nervousness" meddra_pt_id="10029216" />
    </Mention>
    <Mention id="M477" len="14" reason="from_drug_use" section="S1" start="30037" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder sleep" meddra_llt_id="10013268" meddra_pt="Sleep disorder" meddra_pt_id="10040984" />
    </Mention>
    <Mention id="M478" len="12" reason="from_drug_use" section="S1" start="30053" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Listlessness" meddra_llt_id="10024643" meddra_pt="Listless" meddra_pt_id="10024642" />
    </Mention>
    <Mention id="M479" len="16" reason="from_drug_use" section="S1" start="30067" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Libido decreased" meddra_llt_id="10024419" meddra_pt="Libido decreased" meddra_pt_id="10024419" />
    </Mention>
    <Mention id="M480" len="10" reason="from_drug_use" section="S1" start="30089" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anorgasmia" meddra_llt_id="10002652" meddra_pt="Anorgasmia" meddra_pt_id="10002652" />
    </Mention>
    <Mention id="M88" len="27" reason="general_term" section="S1" start="30102" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder renal" meddra_llt_id="10013263" meddra_pt="Renal disorder" meddra_pt_id="10038428" />
    </Mention>
    <Mention id="M481" len="8" reason="from_drug_use" section="S1" start="30131" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Enuresis" meddra_llt_id="10014928" meddra_pt="Enuresis" meddra_pt_id="10014928" />
    </Mention>
    <Mention id="M482" len="7" reason="from_drug_use" section="S1" start="30141" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dysuria" meddra_llt_id="10013990" meddra_pt="Dysuria" meddra_pt_id="10013990" />
    </Mention>
    <Mention id="M483" len="11" reason="from_drug_use" section="S1" start="30150" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pollakiuria" meddra_llt_id="10036018" meddra_pt="Pollakiuria" meddra_pt_id="10036018" />
    </Mention>
    <Mention id="M484" len="20" reason="from_drug_use" section="S1" start="30163" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Incontinence urinary" meddra_llt_id="10021643" meddra_pt="Urinary incontinence" meddra_pt_id="10046543" />
    </Mention>
    <Mention id="M89" len="40" reason="general_term" section="S1" start="30186" type="NonOSE_AE">
      <Normalization meddra_llt="Reproductive tract disorder" meddra_llt_id="10061483" meddra_pt="Reproductive tract disorder" meddra_pt_id="10061483" />
      <Normalization meddra_pt="Reproductive toxicity" meddra_pt_id="10074268" />
    </Mention>
    <Mention id="M485" len="22" reason="from_drug_use" section="S1" start="30228" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Menstruation irregular" meddra_llt_id="10027339" meddra_pt="Menstruation irregular" meddra_pt_id="10027339" />
    </Mention>
    <Mention id="M486" len="10" reason="from_drug_use" section="S1" start="30252" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Amenorrhea" meddra_llt_id="10001927" meddra_pt="Amenorrhoea" meddra_pt_id="10001928" />
    </Mention>
    <Mention id="M487" len="12" reason="from_drug_use" section="S1" start="30264" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gynecomastia" meddra_llt_id="10018801" meddra_pt="Gynaecomastia" meddra_pt_id="10018800" />
    </Mention>
    <Mention id="M488" len="12" reason="from_drug_use" section="S1" start="30278" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Galactorrhea" meddra_llt_id="10017592" meddra_pt="Galactorrhoea" meddra_pt_id="10017600" />
    </Mention>
    <Mention id="M489" len="17" reason="from_drug_use" section="S1" start="30292" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Discharge vaginal" meddra_llt_id="10013069" meddra_pt="Vaginal discharge" meddra_pt_id="10046901" />
    </Mention>
    <Mention id="M490" len="18" reason="from_drug_use" section="S1" start="30311" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Menstrual disorder" meddra_llt_id="10027327" meddra_pt="Menstrual disorder" meddra_pt_id="10027327" />
    </Mention>
    <Mention id="M491" len="20" reason="from_drug_use" section="S1" start="30331" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Erectile dysfunction" meddra_llt_id="10061461" meddra_pt="Erectile dysfunction" meddra_pt_id="10061461" />
    </Mention>
    <Mention id="M492" len="22" reason="from_drug_use" section="S1" start="30353" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Retrograde ejaculation" meddra_llt_id="10038967" meddra_pt="Retrograde ejaculation" meddra_pt_id="10038967" />
    </Mention>
    <Mention id="M493" len="20" reason="from_drug_use" section="S1" start="30377" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ejaculation disorder" meddra_llt_id="10014326" meddra_pt="Ejaculation disorder" meddra_pt_id="10014326" />
    </Mention>
    <Mention id="M494" len="18" reason="from_drug_use" section="S1" start="30399" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sexual dysfunction" meddra_llt_id="10040477" meddra_pt="Sexual dysfunction" meddra_pt_id="10040477" />
    </Mention>
    <Mention id="M495" len="18" reason="from_drug_use" section="S1" start="30419" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Breast enlargement" meddra_llt_id="10006242" meddra_pt="Breast enlargement" meddra_pt_id="10006242" />
    </Mention>
    <Mention id="M90" len="48" reason="general_term" section="S1" start="30440" type="NonOSE_AE">
      <Normalization meddra_llt="Respiratory disorder" meddra_llt_id="10038683" meddra_pt="Respiratory disorder" meddra_pt_id="10038683" />
    </Mention>
    <Mention id="M496" len="8" reason="from_drug_use" section="S1" start="30490" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Wheezing" meddra_llt_id="10047924" meddra_pt="Wheezing" meddra_pt_id="10047924" />
    </Mention>
    <Mention id="M497" len="20" reason="from_drug_use" section="S1" start="30500" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Aspiration pneumonia" meddra_llt_id="10003525" meddra_pt="Pneumonia aspiration" meddra_pt_id="10035669" />
    </Mention>
    <Mention id="M498" len="16" reason="from_drug_use" section="S1" start="30522" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sinus congestion" meddra_llt_id="10040742" meddra_pt="Sinus congestion" meddra_pt_id="10040742" />
    </Mention>
    <Mention id="M499" len="9" reason="from_drug_use" section="S1" start="30540" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dysphonia" meddra_llt_id="10013952" meddra_pt="Dysphonia" meddra_pt_id="10013952" />
    </Mention>
    <Mention id="M500" len="16" reason="from_drug_use" section="S1" start="30551" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Productive cough" meddra_llt_id="10036790" meddra_pt="Productive cough" meddra_pt_id="10036790" />
    </Mention>
    <Mention id="M501" len="20" reason="from_drug_use" section="S1" start="30569" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Congestion pulmonary" meddra_llt_id="10010680" meddra_pt="Pulmonary congestion" meddra_pt_id="10037368" />
    </Mention>
    <Mention id="M502" len="28" reason="from_drug_use" section="S1" start="30591" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Respiratory tract congestion" meddra_llt_id="10052251" meddra_pt="Respiratory tract congestion" meddra_pt_id="10052251" />
    </Mention>
    <Mention id="M503" len="5" reason="from_drug_use" section="S1" start="30621" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rales" meddra_llt_id="10037833" meddra_pt="Rales" meddra_pt_id="10037833" />
    </Mention>
    <Mention id="M504" len="20" reason="from_drug_use" section="S1" start="30628" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Respiratory disorder" meddra_llt_id="10038683" meddra_pt="Respiratory disorder" meddra_pt_id="10038683" />
    </Mention>
    <Mention id="M505" len="16" reason="from_drug_use" section="S1" start="30650" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperventilation" meddra_llt_id="10020910" meddra_pt="Hyperventilation" meddra_pt_id="10020910" />
    </Mention>
    <Mention id="M506" len="11" reason="from_drug_use" section="S1" start="30668" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nasal edema" meddra_llt_id="10054480" meddra_pt="Nasal oedema" meddra_pt_id="10028750" />
    </Mention>
    <Mention id="M91" len="38" reason="general_term" section="S1" start="30682" type="NonOSE_AE">
      <Normalization meddra_llt="Other disorders of skin and subcutaneous tissue" meddra_llt_id="10032001" meddra_pt="Skin disorder" meddra_pt_id="10040831" />
    </Mention>
    <Mention id="M507" len="8" reason="from_drug_use" section="S1" start="30722" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Erythema" meddra_llt_id="10015150" meddra_pt="Erythema" meddra_pt_id="10015150" />
    </Mention>
    <Mention id="M508" len="18" reason="from_drug_use" section="S1" start="30732" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Discoloration skin" meddra_llt_id="10013076" meddra_pt="Skin discolouration" meddra_pt_id="10040829" />
    </Mention>
    <Mention id="M509" len="11" reason="from_drug_use" section="S1" start="30752" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Skin lesion" meddra_llt_id="10040882" meddra_pt="Skin lesion" meddra_pt_id="10040882" />
    </Mention>
    <Mention id="M510" len="8" reason="from_drug_use" section="S1" start="30765" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pruritus" meddra_llt_id="10037087" meddra_pt="Pruritus" meddra_pt_id="10037087" />
    </Mention>
    <Mention id="M511" len="13" reason="from_drug_use" section="S1" start="30775" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Skin disorder" meddra_llt_id="10040831" meddra_pt="Skin disorder" meddra_pt_id="10040831" />
    </Mention>
    <Mention id="M512" len="17" reason="from_drug_use" section="S1" start="30790" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Erythematous rash" meddra_llt_id="10015243" meddra_pt="Rash erythematous" meddra_pt_id="10037855" />
    </Mention>
    <Mention id="M513" len="12" reason="from_drug_use" section="S1" start="30809" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Papular rash" meddra_llt_id="10033726" meddra_pt="Rash papular" meddra_pt_id="10037876" />
    </Mention>
    <Mention id="M514" len="16" reason="from_drug_use" section="S1" start="30823" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Generalized rash" meddra_llt_id="10049201" meddra_pt="Rash generalised" meddra_pt_id="10037858" />
    </Mention>
    <Mention id="M515" len="18" reason="from_drug_use" section="S1" start="30841" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Maculopapular rash" meddra_llt_id="10025424" meddra_pt="Rash maculo-papular" meddra_pt_id="10037868" />
    </Mention>
    <Mention id="M516" len="4" reason="from_drug_use" section="S1" start="30861" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Acne" meddra_llt_id="10000496" meddra_pt="Acne" meddra_pt_id="10000496" />
    </Mention>
    <Mention id="M517" len="14" reason="from_drug_use" section="S1" start="30867" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperkeratosis" meddra_llt_id="10020649" meddra_pt="Hyperkeratosis" meddra_pt_id="10020649" />
    </Mention>
    <Mention id="M518" len="21" reason="from_drug_use" section="S1" start="30883" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dermatitis seborrheic" meddra_llt_id="10012488" meddra_pt="Seborrhoeic dermatitis" meddra_pt_id="10039793" />
    </Mention>
    <Mention id="M92" len="18" reason="general_term" section="S1" start="30907" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder vascular" meddra_llt_id="10013282" meddra_pt="Angiopathy" meddra_pt_id="10059245" />
    </Mention>
    <Mention id="M519" len="11" reason="from_drug_use" section="S1" start="30927" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypotension" meddra_llt_id="10021097" meddra_pt="Hypotension" meddra_pt_id="10021097" />
    </Mention>
    <Mention id="M520" len="8" reason="from_drug_use" section="S1" start="30940" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Flushing" meddra_llt_id="10016825" meddra_pt="Flushing" meddra_pt_id="10016825" />
    </Mention>
    <Mention id="M93" len="17" reason="general_term" section="S1" start="31210" type="NonOSE_AE">
      <Normalization meddra_llt="Cardiac disorder" meddra_llt_id="10061024" meddra_pt="Cardiac disorder" meddra_pt_id="10061024" />
    </Mention>
    <Mention id="M521" len="11" reason="from_drug_use" section="S1" start="31229" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Bradycardia" meddra_llt_id="10006093" meddra_pt="Bradycardia" meddra_pt_id="10006093" />
    </Mention>
    <Mention id="M94" len="27" reason="general_term" section="S1" start="31243" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder ear" meddra_llt_id="10013214" meddra_pt="Ear disorder" meddra_pt_id="10014004" />
    </Mention>
    <Mention id="M522" len="7" reason="from_drug_use" section="S1" start="31272" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vertigo" meddra_llt_id="10047340" meddra_pt="Vertigo" meddra_pt_id="10047340" />
    </Mention>
    <Mention id="M95" len="13" reason="general_term" section="S1" start="31282" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder eye" meddra_llt_id="10013221" meddra_pt="Eye disorder" meddra_pt_id="10015916" />
      <Normalization meddra_pt="Ocular toxicity" meddra_pt_id="10061137" />
    </Mention>
    <Mention id="M523" len="13" reason="from_drug_use" section="S1" start="31297" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Blepharospasm" meddra_llt_id="10005159" meddra_pt="Blepharospasm" meddra_pt_id="10005159" />
    </Mention>
    <Mention id="M96" len="26" reason="general_term" section="S1" start="31313" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M524" len="9" reason="from_drug_use" section="S1" start="31341" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Toothache" meddra_llt_id="10044055" meddra_pt="Toothache" meddra_pt_id="10044055" />
    </Mention>
    <Mention id="M525" len="12" reason="from_drug_use" section="S1" start="31352" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Spasm tongue" meddra_llt_id="10041403" meddra_pt="Tongue spasm" meddra_pt_id="10043981" />
    </Mention>
    <Mention id="M98" len="52" reason="general_term" section="S1" start="31367" type="NonOSE_AE">
      <Normalization meddra_llt="General symptom" meddra_llt_id="10060891" meddra_pt="General symptom" meddra_pt_id="10060891" />
    </Mention>
    <Mention id="M526" len="4" reason="from_drug_use" section="S1" start="31421" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain" meddra_llt_id="10033371" meddra_pt="Pain" meddra_pt_id="10033371" />
    </Mention>
    <Mention id="M97" len="27" reason="general_term" section="S1" start="31428" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M527" len="33" reason="from_drug_use" section="S1" start="31457" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lower respiratory tract infection" meddra_llt_id="10024968" meddra_pt="Lower respiratory tract infection" meddra_pt_id="10024968" />
    </Mention>
    <Mention id="M528" len="9" reason="from_drug_use" section="S1" start="31492" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M529" len="15" reason="from_drug_use" section="S1" start="31503" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gastroenteritis" meddra_llt_id="10017888" meddra_pt="Gastroenteritis" meddra_pt_id="10017888" />
    </Mention>
    <Mention id="M530" len="20" reason="from_drug_use" section="S1" start="31520" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Subcutaneous abscess" meddra_llt_id="10042343" meddra_pt="Subcutaneous abscess" meddra_pt_id="10042343" />
    </Mention>
    <Mention id="M127" len="20" reason="general_term" section="S1" start="31543" type="NonOSE_AE">
      <Normalization meddra_llt="Injury" meddra_llt_id="10022116" meddra_pt="Injury" meddra_pt_id="10022116" />
    </Mention>
    <Mention id="M531" len="4" reason="from_drug_use" section="S1" start="31565" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fall" meddra_llt_id="10016173" meddra_pt="Fall" meddra_pt_id="10016173" />
    </Mention>
    <Mention id="M99" len="14" reason="general_term" section="S1" start="31572" type="NonOSE_AE">
      <Normalization meddra_llt="Investigation" meddra_llt_id="10062026" meddra_pt="Investigation" meddra_pt_id="10062026" />
    </Mention>
    <Mention id="M532" len="16" reason="from_drug_use" section="S1" start="31588" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight decreased" meddra_llt_id="10047895" meddra_pt="Weight decreased" meddra_pt_id="10047895" />
    </Mention>
    <Mention id="M533" len="35" reason="from_drug_use" section="S1" start="31606" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gamma-glutamyltransferase increased" meddra_llt_id="10017693" meddra_pt="Gamma-glutamyltransferase increased" meddra_pt_id="10017693" />
    </Mention>
    <Mention id="M534" len="24" reason="from_drug_use" section="S1" start="31643" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hepatic enzyme increased" meddra_llt_id="10060795" meddra_pt="Hepatic enzyme increased" meddra_pt_id="10060795" />
    </Mention>
    <Mention id="M100" len="54" reason="general_term" section="S1" start="31670" type="NonOSE_AE">
      <Normalization meddra_llt="Musculoskeletal disorder" meddra_llt_id="10048592" meddra_pt="Musculoskeletal disorder" meddra_pt_id="10048592" />
    </Mention>
    <Mention id="M624" len="12" reason="from_drug_use" section="S1" start="31726" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Buttock pain" meddra_llt_id="10048677" meddra_pt="Musculoskeletal pain" meddra_pt_id="10028391" />
    </Mention>
    <Mention id="M101" len="24" reason="general_term" section="S1" start="31741" type="NonOSE_AE">
      <Normalization meddra_llt="Nervous system disorder" meddra_llt_id="10029202" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M535" len="10" reason="from_drug_use" section="S1" start="31767" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Convulsion" meddra_llt_id="10010904" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M536" len="11" reason="from_drug_use" section="S1" start="31779" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Paresthesia" meddra_llt_id="10033987" meddra_pt="Paraesthesia" meddra_pt_id="10033775" />
    </Mention>
    <Mention id="M102" len="21" reason="general_term" section="S1" start="31793" type="NonOSE_AE">
      <Normalization meddra_llt="Psychiatric disorder NOS" meddra_llt_id="10037174" meddra_pt="Mental disorder" meddra_pt_id="10061284" />
      <Normalization meddra_pt="Psychiatric symptom" meddra_pt_id="10061472" />
    </Mention>
    <Mention id="M537" len="10" reason="from_drug_use" section="S1" start="31816" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety/depression" meddra_llt_id="10002872" meddra_pt="Depression" meddra_pt_id="10012378" />
    </Mention>
    <Mention id="M103" len="38" reason="general_term" section="S1" start="31829" type="NonOSE_AE">
      <Normalization meddra_llt="Other disorders of skin and subcutaneous tissue" meddra_llt_id="10032001" meddra_pt="Skin disorder" meddra_pt_id="10040831" />
    </Mention>
    <Mention id="M538" len="6" reason="from_drug_use" section="S1" start="31869" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Eczema" meddra_llt_id="10014184" meddra_pt="Eczema" meddra_pt_id="10014184" />
    </Mention>
    <Mention id="M104" len="18" reason="general_term" section="S1" start="31878" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder vascular" meddra_llt_id="10013282" meddra_pt="Angiopathy" meddra_pt_id="10059245" />
    </Mention>
    <Mention id="M539" len="12" reason="from_drug_use" section="S1" start="31898" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypertension" meddra_llt_id="10020772" meddra_pt="Hypertension" meddra_pt_id="10020772" />
    </Mention>
    <Mention id="M14" len="13" reason="indication" section="S1" start="31967" type="Not_AE_Candidate">
      <Normalization meddra_llt="Schizophrenia" meddra_llt_id="10039626" meddra_pt="Schizophrenia" meddra_pt_id="10039626" />
    </Mention>
    <Mention id="M540" len="9" reason="from_drug_use" section="S1" start="32647" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M541" len="6" reason="from_drug_use" section="S1" start="32758" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M542" len="8" reason="from_drug_use" section="S1" start="32869" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vomiting" meddra_llt_id="10047700" meddra_pt="Vomiting" meddra_pt_id="10047700" />
    </Mention>
    <Mention id="M543" len="12" reason="from_drug_use" section="S1" start="32980" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Parkinsonism" meddra_llt_id="10034010" meddra_pt="Parkinsonism" meddra_pt_id="10034010" />
    </Mention>
    <Mention id="M544" len="10" reason="from_drug_use" section="S1" start="33091" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Somnolence" meddra_llt_id="10041349" meddra_pt="Somnolence" meddra_pt_id="10041349" />
    </Mention>
    <Mention id="M545" len="8" reason="from_drug_use" section="S1" start="33202" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dystonia" meddra_llt_id="10013983" meddra_pt="Dystonia" meddra_pt_id="10013983" />
    </Mention>
    <Mention id="M546" len="9" reason="from_drug_use" section="S1" start="33313" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Agitation" meddra_llt_id="10001497" meddra_pt="Agitation" meddra_pt_id="10001497" />
    </Mention>
    <Mention id="M547" len="14" reason="from_drug_use" section="S1" start="33424" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pain abdominal" meddra_llt_id="10033374" meddra_pt="Abdominal pain" meddra_pt_id="10000081" />
    </Mention>
    <Mention id="M548" len="23" reason="from_drug_use" section="S1" start="33535" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Orthostatic hypotension" meddra_llt_id="10031127" meddra_pt="Orthostatic hypotension" meddra_pt_id="10031127" />
    </Mention>
    <Mention id="M549" len="9" reason="from_drug_use" section="S1" start="33646" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Akathisia" meddra_llt_id="10001540" meddra_pt="Akathisia" meddra_pt_id="10001540" />
    </Mention>
    <Mention id="M550" len="23" reason="from_drug_use" section="S1" start="33786" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Extrapyramidal symptoms" meddra_llt_id="10015835" meddra_pt="Extrapyramidal disorder" meddra_pt_id="10015832" />
    </Mention>
    <Mention id="M551" len="12" reason="from_drug_use" section="S1" start="33821" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Parkinsonism" meddra_llt_id="10034010" meddra_pt="Parkinsonism" meddra_pt_id="10034010" />
    </Mention>
    <Mention id="M552" len="9" reason="from_drug_use" section="S1" start="33835" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Akathisia" meddra_llt_id="10001540" meddra_pt="Akathisia" meddra_pt_id="10001540" />
    </Mention>
    <Mention id="M553" len="8" reason="from_drug_use" section="S1" start="33846" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dystonia" meddra_llt_id="10013983" meddra_pt="Dystonia" meddra_pt_id="10013983" />
    </Mention>
    <Mention id="M554" len="18" reason="from_drug_use" section="S1" start="33860" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyskinesia tardive" meddra_llt_id="10013928" meddra_pt="Tardive dyskinesia" meddra_pt_id="10043118" />
    </Mention>
    <Mention id="M555" len="9" reason="from_drug_use" section="S1" start="34373" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M556" len="10" reason="from_drug_use" section="S1" start="34389" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Somnolence" meddra_llt_id="10041349" meddra_pt="Somnolence" meddra_pt_id="10041349" />
    </Mention>
    <Mention id="M557" len="8" reason="from_drug_use" section="S1" start="34406" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sedation" meddra_llt_id="10039897" meddra_pt="Sedation" meddra_pt_id="10039897" />
    </Mention>
    <Mention id="M558" len="8" reason="from_drug_use" section="S1" start="34421" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lethargy" meddra_llt_id="10024264" meddra_pt="Lethargy" meddra_pt_id="10024264" />
    </Mention>
    <Mention id="M559" len="7" reason="from_drug_use" section="S1" start="34436" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety" meddra_llt_id="10002855" meddra_pt="Anxiety" meddra_pt_id="10002855" />
    </Mention>
    <Mention id="M560" len="16" reason="from_drug_use" section="S1" start="34450" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Balance disorder" meddra_llt_id="10049848" meddra_pt="Balance disorder" meddra_pt_id="10049848" />
    </Mention>
    <Mention id="M561" len="11" reason="from_drug_use" section="S1" start="34473" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypotension" meddra_llt_id="10021097" meddra_pt="Hypotension" meddra_pt_id="10021097" />
    </Mention>
    <Mention id="M562" len="11" reason="from_drug_use" section="S1" start="34495" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Palpitation" meddra_llt_id="10033556" meddra_pt="Palpitations" meddra_pt_id="10033557" />
    </Mention>
    <Mention id="M563" len="12" reason="from_drug_use" section="S1" start="35169" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Parkinsonism" meddra_llt_id="10034010" meddra_pt="Parkinsonism" meddra_pt_id="10034010" />
    </Mention>
    <Mention id="M564" len="8" reason="from_drug_use" section="S1" start="35278" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lethargy" meddra_llt_id="10024264" meddra_pt="Lethargy" meddra_pt_id="10024264" />
    </Mention>
    <Mention id="M565" len="9" reason="from_drug_use" section="S1" start="35387" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M566" len="34" reason="from_drug_use" section="S1" start="35496" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Alanine aminotransferase increased" meddra_llt_id="10001551" meddra_pt="Alanine aminotransferase increased" meddra_pt_id="10001551" />
    </Mention>
    <Mention id="M567" len="36" reason="from_drug_use" section="S1" start="35605" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Aspartate aminotransferase increased" meddra_llt_id="10003481" meddra_pt="Aspartate aminotransferase increased" meddra_pt_id="10003481" />
    </Mention>
    <Mention id="M568" len="6" reason="from_drug_use" section="S1" start="36066" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M569" len="10" reason="from_drug_use" section="S1" start="36079" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Somnolence" meddra_llt_id="10041349" meddra_pt="Somnolence" meddra_pt_id="10041349" />
    </Mention>
    <Mention id="M570" len="8" reason="from_drug_use" section="S1" start="36096" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sedation" meddra_llt_id="10039897" meddra_pt="Sedation" meddra_pt_id="10039897" />
    </Mention>
    <Mention id="M571" len="8" reason="from_drug_use" section="S1" start="36115" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vomiting" meddra_llt_id="10047700" meddra_pt="Vomiting" meddra_pt_id="10047700" />
    </Mention>
    <Mention id="M21" len="46" reason="indication" section="S1" start="36250" type="Not_AE_Candidate">
      <Normalization meddra_llt="Irritability" meddra_llt_id="10022998" meddra_pt="Irritability" meddra_pt_id="10022998" />
    </Mention>
    <Mention id="M27" len="17" reason="preexisting_condition_or_risk_factor" section="S1" start="36279" type="Not_AE_Candidate">
      <Normalization meddra_llt="Autistic disorder" meddra_llt_id="10003808" meddra_pt="Autism spectrum disorder" meddra_pt_id="10063844" />
    </Mention>
    <Mention id="M572" len="12" reason="from_drug_use" section="S1" start="36384" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Parkinsonism" meddra_llt_id="10034010" meddra_pt="Parkinsonism" meddra_pt_id="10034010" />
    </Mention>
    <Mention id="M15" len="13" reason="indication" section="S1" start="36614" type="Not_AE_Candidate">
      <Normalization meddra_llt="Schizophrenia" meddra_llt_id="10039626" meddra_pt="Schizophrenia" meddra_pt_id="10039626" />
    </Mention>
    <Mention id="M573" len="23" reason="from_drug_use" section="S1" start="36670" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Extrapyramidal symptoms" meddra_llt_id="10015835" meddra_pt="Extrapyramidal disorder" meddra_pt_id="10015832" />
    </Mention>
    <Mention id="M105" len="28" reason="AE_only_as_instruction" section="S1" start="36772" type="NonOSE_AE">
      <Normalization meddra_llt="Extrapyramidal symptoms" meddra_llt_id="10015835" meddra_pt="Extrapyramidal disorder" meddra_pt_id="10015832" />
    </Mention>
    <Mention id="M106" len="12" reason="AE_only_as_instruction" section="S1" start="36907" type="NonOSE_AE">
      <Normalization meddra_llt="Parkinsonism" meddra_llt_id="10034010" meddra_pt="Parkinsonism" meddra_pt_id="10034010" />
    </Mention>
    <Mention id="M107" len="22" reason="AE_only_as_instruction" section="S1" start="36963" type="NonOSE_AE">
      <Normalization meddra_llt="Syndrome extrapyramidal" meddra_llt_id="10042804" meddra_pt="Extrapyramidal disorder" meddra_pt_id="10015832" />
    </Mention>
    <Mention id="M108" len="3" reason="AE_only_as_instruction" section="S1" start="37047" type="NonOSE_AE">
      <Normalization meddra_llt="Extrapyramidal disorder" meddra_llt_id="10015832" meddra_pt="Extrapyramidal disorder" meddra_pt_id="10015832" />
    </Mention>
    <Mention id="M574" len="12" reason="from_drug_use" section="S1" start="37200" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Parkinsonism" meddra_llt_id="10034010" meddra_pt="Parkinsonism" meddra_pt_id="10034010" />
    </Mention>
    <Mention id="M625" len="3" reason="from_drug_use" section="S1" start="37315" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Extrapyramidal disorder" meddra_llt_id="10015832" meddra_pt="Extrapyramidal disorder" meddra_pt_id="10015832" />
    </Mention>
    <Mention id="M109" len="23" reason="AE_only_as_instruction" section="S1" start="37478" type="NonOSE_AE">
      <Normalization meddra_llt="Extrapyramidal symptoms" meddra_llt_id="10015835" meddra_pt="Extrapyramidal disorder" meddra_pt_id="10015832" />
    </Mention>
    <Mention id="M575" len="12" reason="from_drug_use" section="S1" start="37753" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Parkinsonism" meddra_llt_id="10034010" meddra_pt="Parkinsonism" meddra_pt_id="10034010" />
    </Mention>
    <Mention id="M576" len="3" reason="from_drug_use" section="S1" start="37868" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Extrapyramidal disorder" meddra_llt_id="10015832" meddra_pt="Extrapyramidal disorder" meddra_pt_id="10015832" />
    </Mention>
    <Mention id="M626" len="8" reason="class_effect" section="S1" start="38044" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dystonia" meddra_llt_id="10013983" meddra_pt="Dystonia" meddra_pt_id="10013983" />
    </Mention>
    <Mention id="M627" len="48" reason="class_effect" section="S1" start="38054" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Muscle contractions involuntary" meddra_llt_id="10028293" meddra_pt="Muscle contractions involuntary" meddra_pt_id="10028293" />
    </Mention>
    <Mention id="M110" len="17" reason="AE_only_as_instruction" section="S1" start="38181" type="NonOSE_AE">
      <Normalization meddra_llt="Dystonic reaction" meddra_llt_id="10013986" meddra_pt="Dystonia" meddra_pt_id="10013983" />
    </Mention>
    <Mention id="M115" len="25" reason="manifestation_or_complication" section="S1" start="38208" type="NonOSE_AE">
      <Normalization meddra_llt="Spasm of muscle" meddra_llt_id="10041396" meddra_pt="Muscle spasms" meddra_pt_id="10028334" />
    </Mention>
    <Mention id="M111" len="23" reason="manifestation_or_complication" section="S1" start="38260" type="NonOSE_AE">
      <Normalization meddra_llt="Throat tightness" meddra_llt_id="10043528" meddra_pt="Throat tightness" meddra_pt_id="10043528" />
    </Mention>
    <Mention id="M112" len="21" reason="manifestation_or_complication" section="S1" start="38285" type="NonOSE_AE">
      <Normalization meddra_llt="Swallowing difficult" meddra_llt_id="10042645" meddra_pt="Dysphagia" meddra_pt_id="10013950" />
    </Mention>
    <Mention id="M114" len="20" reason="manifestation_or_complication" section="S1" start="38308" type="NonOSE_AE">
      <Normalization meddra_llt="Difficulty breathing" meddra_llt_id="10012791" meddra_pt="Dyspnoea" meddra_pt_id="10013968" />
    </Mention>
    <Mention id="M113" len="24" reason="manifestation_or_complication" section="S1" start="38337" type="NonOSE_AE">
      <Normalization meddra_llt="Protrusion tongue" meddra_llt_id="10037076" meddra_pt="Protrusion tongue" meddra_pt_id="10037076" />
    </Mention>
    <Mention id="M128" len="14" reason="AE_only_as_instruction" section="S1" start="38560" type="NonOSE_AE">
      <Normalization meddra_llt="Acute dystonia" meddra_llt_id="10066608" meddra_pt="Dystonia" meddra_pt_id="10013983" />
    </Mention>
    <Mention id="M577" len="10" reason="from_drug_use" section="S1" start="38979" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Somnolence" meddra_llt_id="10041349" meddra_pt="Somnolence" meddra_pt_id="10041349" />
    </Mention>
    <Mention id="M578" len="15" reason="from_drug_use" section="S1" start="38991" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vision abnormal" meddra_llt_id="10047508" meddra_pt="Visual impairment" meddra_pt_id="10047571" />
    </Mention>
    <Mention id="M579" len="9" reason="from_drug_use" section="S1" start="39008" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M580" len="12" reason="from_drug_use" section="S1" start="39019" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Palpitation" meddra_llt_id="10033556" meddra_pt="Palpitations" meddra_pt_id="10033557" />
    </Mention>
    <Mention id="M581" len="15" reason="from_drug_use" section="S1" start="39033" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight increase" meddra_llt_id="10047898" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M582" len="20" reason="from_drug_use" section="S1" start="39050" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Erectile dysfunction" meddra_llt_id="10061461" meddra_pt="Erectile dysfunction" meddra_pt_id="10061461" />
    </Mention>
    <Mention id="M583" len="20" reason="from_drug_use" section="S1" start="39072" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ejaculation disorder" meddra_llt_id="10014326" meddra_pt="Ejaculation disorder" meddra_pt_id="10014326" />
    </Mention>
    <Mention id="M584" len="24" reason="from_drug_use" section="S1" start="39094" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sexual function abnormal" meddra_llt_id="10040482" meddra_pt="Sexual dysfunction" meddra_pt_id="10040477" />
    </Mention>
    <Mention id="M585" len="7" reason="from_drug_use" section="S1" start="39120" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fatigue" meddra_llt_id="10016256" meddra_pt="Fatigue" meddra_pt_id="10016256" />
    </Mention>
    <Mention id="M586" len="18" reason="from_drug_use" section="S1" start="39133" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Discoloration skin" meddra_llt_id="10013076" meddra_pt="Skin discolouration" meddra_pt_id="10040829" />
    </Mention>
    <Mention id="M628" len="22" reason="from_drug_use" section="S1" start="39159" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight fluctuation" meddra_llt_id="10049040" meddra_pt="Weight fluctuation" meddra_pt_id="10049040" />
    </Mention>
    <Mention id="M587" len="11" reason="from_drug_use" section="S1" start="39186" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight gain" meddra_llt_id="10047896" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M121" len="39" reason="AE_rate_lteq_placebo" section="S1" start="39624" type="NonOSE_AE">
      <Normalization meddra_llt="Change in ECG" meddra_llt_id="10008396" meddra_pt="Electrocardiogram change" meddra_pt_id="10061116" />
    </Mention>
    <Mention id="M122" len="7,2,10" reason="AE_rate_lteq_placebo" section="S1" start="39624,39642,39706" type="NonOSE_AE">
      <Normalization meddra_llt="Heart rate abnormal" meddra_llt_id="10019300" meddra_pt="Heart rate abnormal" meddra_pt_id="10019300" />
    </Mention>
    <Mention id="M123" len="7,2,12" reason="AE_rate_lteq_placebo" section="S1" start="39624,39642,39688" type="NonOSE_AE">
      <Normalization meddra_llt="Electrocardiogram change" meddra_llt_id="10061116" meddra_pt="Electrocardiogram change" meddra_pt_id="10061116" />
    </Mention>
    <Mention id="M124" len="7,2,3" reason="AE_rate_lteq_placebo" section="S1" start="39624,39642,39679" type="NonOSE_AE">
      <Normalization meddra_llt="Electrocardiogram QT interval abnormal" meddra_llt_id="10063748" meddra_pt="Electrocardiogram QT interval abnormal" meddra_pt_id="10063748" />
    </Mention>
    <Mention id="M125" len="7,2,2" reason="AE_rate_lteq_placebo" section="S1" start="39624,39642,39675" type="NonOSE_AE">
      <Normalization meddra_llt="Electrocardiogram QT interval abnormal" meddra_llt_id="10063748" meddra_pt="Electrocardiogram QT interval abnormal" meddra_pt_id="10063748" />
    </Mention>
    <Mention id="M629" len="22" reason="from_drug_use" section="S1" start="39836" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Heart rate high" meddra_llt_id="10019302" meddra_pt="Heart rate increased" meddra_pt_id="10019303" />
    </Mention>
    <Mention id="M16" len="13" reason="indication" section="S1" start="39938" type="Not_AE_Candidate">
      <Normalization meddra_llt="Schizophrenia" meddra_llt_id="10039626" meddra_pt="Schizophrenia" meddra_pt_id="10039626" />
    </Mention>
    <Mention id="M588" len="22" reason="from_drug_use" section="S1" start="40037" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Heart rate high" meddra_llt_id="10019302" meddra_pt="Heart rate increased" meddra_pt_id="10019303" />
    </Mention>
    <Mention id="M22" len="11" reason="indication" section="S1" start="40133" type="Not_AE_Candidate">
      <Normalization meddra_llt="Acute mania" meddra_llt_id="10000852" meddra_pt="Mania" meddra_pt_id="10026749" />
    </Mention>
    <Mention id="M120" len="28" reason="AE_rate_lteq_placebo" section="S1" start="40180" type="NonOSE_AE">
      <Normalization meddra_llt="Heart rate decreased" meddra_llt_id="10019301" meddra_pt="Heart rate decreased" meddra_pt_id="10019301" />
    </Mention>
    <Mention id="M23" len="17" reason="indication" section="S1" start="40318" type="Not_AE_Candidate">
      <Normalization meddra_llt="Autistic disorder" meddra_llt_id="10003808" meddra_pt="Autism spectrum disorder" meddra_pt_id="10063844" />
    </Mention>
    <Mention id="M630" len="10,8" reason="from_drug_use" section="S1" start="40372,40391" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Heart rate high" meddra_llt_id="10019302" meddra_pt="Heart rate increased" meddra_pt_id="10019303" />
    </Mention>
    <Mention id="M29" len="11" reason="negation" section="S1" start="40529" type="NonOSE_AE">
      <Normalization meddra_llt="Change in ECG" meddra_llt_id="10008396" meddra_pt="Electrocardiogram change" meddra_pt_id="10061116" />
    </Mention>
    <Mention id="M28" len="11" reason="indication" section="S1" start="40568" type="Not_AE_Candidate">
      <Normalization meddra_llt="Acute mania" meddra_llt_id="10000852" meddra_pt="Mania" meddra_pt_id="10026749" />
    </Mention>
    <Mention id="M116" len="25" reason="negation" section="S1" start="40662" type="NonOSE_AE">
      <Normalization meddra_llt="Change in ECG" meddra_llt_id="10008396" meddra_pt="Electrocardiogram change" meddra_pt_id="10061116" />
    </Mention>
    <Mention id="M589" len="19" reason="from_drug_use" section="S1" start="40745" type="OSE_Labeled_AE">
      <Normalization meddra_llt="High pulse rate" meddra_llt_id="10020081" meddra_pt="Heart rate increased" meddra_pt_id="10019303" />
    </Mention>
    <Mention id="M17" len="13" reason="indication" section="S1" start="40807" type="Not_AE_Candidate">
      <Normalization meddra_llt="Schizophrenia" meddra_llt_id="10039626" meddra_pt="Schizophrenia" meddra_pt_id="10039626" />
    </Mention>
    <Mention id="M117" len="25" reason="negation" section="S1" start="40901" type="NonOSE_AE">
      <Normalization meddra_llt="Change in ECG" meddra_llt_id="10008396" meddra_pt="Electrocardiogram change" meddra_pt_id="10061116" />
    </Mention>
    <Mention id="M118" len="10,22" reason="negation" section="S1" start="40901,40937" type="NonOSE_AE">
      <Normalization meddra_llt="Electrocardiogram QT interval abnormal" meddra_llt_id="10063748" meddra_pt="Electrocardiogram QT interval abnormal" meddra_pt_id="10063748" />
    </Mention>
    <Mention id="M590" len="8" reason="from_drug_use" section="S1" start="41387" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Alopecia" meddra_llt_id="10001760" meddra_pt="Alopecia" meddra_pt_id="10001760" />
    </Mention>
    <Mention id="M591" len="21" reason="from_drug_use" section="S1" start="41397" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anaphylactic reaction" meddra_llt_id="10002198" meddra_pt="Anaphylactic reaction" meddra_pt_id="10002198" />
    </Mention>
    <Mention id="M592" len="10" reason="from_drug_use" section="S1" start="41420" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Angioedema" meddra_llt_id="10002424" meddra_pt="Angioedema" meddra_pt_id="10002424" />
    </Mention>
    <Mention id="M593" len="19" reason="from_drug_use" section="S1" start="41432" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Atrial fibrillation" meddra_llt_id="10003658" meddra_pt="Atrial fibrillation" meddra_pt_id="10003658" />
    </Mention>
    <Mention id="M594" len="22" reason="from_drug_use" section="S1" start="41453" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cardiopulmonary arrest" meddra_llt_id="10007644" meddra_pt="Cardio-respiratory arrest" meddra_pt_id="10007617" />
    </Mention>
    <Mention id="M595" len="21" reason="from_drug_use" section="S1" start="41477" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ketoacidosis (diabetic)" meddra_llt_id="10023380" meddra_pt="Diabetic ketoacidosis" meddra_pt_id="10012671" />
    </Mention>
    <Mention id="M24" len="27" reason="preexisting_condition_or_risk_factor" section="S1" start="41516" type="Not_AE_Candidate">
      <Normalization meddra_llt="Glucose tolerance impaired" meddra_llt_id="10018429" meddra_pt="Glucose tolerance impaired" meddra_pt_id="10018429" />
    </Mention>
    <Mention id="M596" len="9" reason="from_drug_use" section="S1" start="41545" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dysgeusia" meddra_llt_id="10013911" meddra_pt="Dysgeusia" meddra_pt_id="10013911" />
    </Mention>
    <Mention id="M597" len="12" reason="from_drug_use" section="S1" start="41556" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypoglycemia" meddra_llt_id="10021005" meddra_pt="Hypoglycaemia" meddra_pt_id="10020993" />
    </Mention>
    <Mention id="M598" len="11" reason="from_drug_use" section="S1" start="41570" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypothermia" meddra_llt_id="10021113" meddra_pt="Hypothermia" meddra_pt_id="10021113" />
    </Mention>
    <Mention id="M599" len="5" reason="from_drug_use" section="S1" start="41583" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ileus" meddra_llt_id="10021328" meddra_pt="Ileus" meddra_pt_id="10021328" />
    </Mention>
    <Mention id="M600" len="44" reason="from_drug_use" section="S1" start="41590" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Inappropriate antidiuretic hormone secretion" meddra_llt_id="10053198" meddra_pt="Inappropriate antidiuretic hormone secretion" meddra_pt_id="10053198" />
    </Mention>
    <Mention id="M601" len="22" reason="from_drug_use" section="S1" start="41636" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Obstruction intestinal" meddra_llt_id="10029958" meddra_pt="Intestinal obstruction" meddra_pt_id="10022687" />
    </Mention>
    <Mention id="M602" len="8" reason="from_drug_use" section="S1" start="41660" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Jaundice" meddra_llt_id="10023126" meddra_pt="Jaundice" meddra_pt_id="10023126" />
    </Mention>
    <Mention id="M603" len="5" reason="from_drug_use" section="S1" start="41670" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Mania" meddra_llt_id="10026749" meddra_pt="Mania" meddra_pt_id="10026749" />
    </Mention>
    <Mention id="M604" len="12" reason="from_drug_use" section="S1" start="41677" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pancreatitis" meddra_llt_id="10033645" meddra_pt="Pancreatitis" meddra_pt_id="10033645" />
    </Mention>
    <Mention id="M605" len="17" reason="from_drug_use" section="S1" start="41691" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pituitary adenoma" meddra_llt_id="10035079" meddra_pt="Pituitary tumour benign" meddra_pt_id="10061538" />
    </Mention>
    <Mention id="M606" len="18" reason="from_drug_use" section="S1" start="41710" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Puberty precocious" meddra_llt_id="10037282" meddra_pt="Precocious puberty" meddra_pt_id="10058084" />
    </Mention>
    <Mention id="M607" len="18" reason="from_drug_use" section="S1" start="41730" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Pulmonary embolism" meddra_llt_id="10037377" meddra_pt="Pulmonary embolism" meddra_pt_id="10037377" />
    </Mention>
    <Mention id="M608" len="15" reason="from_drug_use" section="S1" start="41750" type="OSE_Labeled_AE">
      <Normalization meddra_llt="QT increased" meddra_llt_id="10037700" meddra_pt="Electrocardiogram QT prolonged" meddra_pt_id="10014387" />
    </Mention>
    <Mention id="M609" len="20" reason="from_drug_use" section="S1" start="41767" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sleep apnea syndrome" meddra_llt_id="10040976" meddra_pt="Sleep apnoea syndrome" meddra_pt_id="10040979" />
    </Mention>
    <Mention id="M610" len="12" reason="from_drug_use" section="S1" start="41789" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sudden death" meddra_llt_id="10042434" meddra_pt="Sudden death" meddra_pt_id="10042434" />
    </Mention>
    <Mention id="M611" len="16" reason="from_drug_use" section="S1" start="41803" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thrombocytopenia" meddra_llt_id="10043554" meddra_pt="Thrombocytopenia" meddra_pt_id="10043554" />
    </Mention>
    <Mention id="M612" len="35" reason="from_drug_use" section="S1" start="41821" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Thrombotic thrombocytopenic purpura" meddra_llt_id="10043648" meddra_pt="Thrombotic thrombocytopenic purpura" meddra_pt_id="10043648" />
    </Mention>
    <Mention id="M613" len="17" reason="from_drug_use" section="S1" start="41858" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Urinary retention" meddra_llt_id="10046555" meddra_pt="Urinary retention" meddra_pt_id="10046555" />
    </Mention>
    <Mention id="M614" len="18" reason="from_drug_use" section="S1" start="41881" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Water intoxication" meddra_llt_id="10047837" meddra_pt="Water intoxication" meddra_pt_id="10047837" />
    </Mention>
    <Mention id="M632" len="26" reason="preexisting_condition_or_risk_factor" section="S2" start="217" type="Not_AE_Candidate">
      <Normalization meddra_llt="Senile psychosis" meddra_llt_id="10039987" meddra_pt="Senile psychosis" meddra_pt_id="10039987" />
    </Mention>
    <Mention id="M633" len="5" reason="general_term" section="S2" start="305" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M631" len="26" reason="preexisting_condition_or_risk_factor" section="S2" start="394" type="Not_AE_Candidate">
      <Normalization meddra_llt="Dementia" meddra_llt_id="10012267" meddra_pt="Dementia" meddra_pt_id="10012267" />
    </Mention>
    <Mention id="M684" len="26" reason="preexisting_condition_or_risk_factor" section="S3" start="2034" type="Not_AE_Candidate">
      <Normalization meddra_llt="Senile psychosis" meddra_llt_id="10039987" meddra_pt="Senile psychosis" meddra_pt_id="10039987" />
    </Mention>
    <Mention id="M777" len="5" reason="general_term" section="S3" start="2122" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M778" len="5" reason="general_term" section="S3" start="2276" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M779" len="5" reason="general_term" section="S3" start="2347" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M780" len="5" reason="general_term" section="S3" start="2449" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M781" len="5" reason="general_term" section="S3" start="2574" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M774" len="6,14" reason="AE_from_off_label" section="S3" start="2605,2634" type="NonOSE_AE">
      <Normalization meddra_llt="Cardiac death" meddra_llt_id="10049993" meddra_pt="Cardiac death" meddra_pt_id="10049993" />
    </Mention>
    <Mention id="M783" len="6" reason="general_term" section="S3" start="2605" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M704" len="13" reason="AE_from_off_label" section="S3" start="2656" type="NonOSE_AE">
      <Normalization meddra_llt="Heart failure" meddra_llt_id="10019279" meddra_pt="Cardiac failure" meddra_pt_id="10007554" />
    </Mention>
    <Mention id="M705" len="12" reason="AE_from_off_label" section="S3" start="2671" type="NonOSE_AE">
      <Normalization meddra_llt="Sudden death" meddra_llt_id="10042434" meddra_pt="Sudden death" meddra_pt_id="10042434" />
    </Mention>
    <Mention id="M706" len="10" reason="AE_from_off_label" section="S3" start="2688" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M707" len="9" reason="AE_from_off_label" section="S3" start="2706" type="NonOSE_AE">
      <Normalization meddra_llt="Pneumonia" meddra_llt_id="10035664" meddra_pt="Pneumonia" meddra_pt_id="10035664" />
    </Mention>
    <Mention id="M784" len="9" reason="general_term" section="S3" start="2866" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M659" len="7,26" reason="preexisting_condition_or_risk_factor" section="S3" start="3115,3137" type="Not_AE_Candidate">
      <Normalization meddra_llt="Senile psychosis" meddra_llt_id="10039987" meddra_pt="Senile psychosis" meddra_pt_id="10039987" />
      <Normalization meddra_pt="Senile dementia" meddra_pt_id="10039966" />
      <Normalization meddra_pt="Dementia" meddra_pt_id="10012267" />
    </Mention>
    <Mention id="M782" len="5" reason="general_term" section="S3" start="3471" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M634" len="26" reason="preexisting_condition_or_risk_factor" section="S3" start="3560" type="Not_AE_Candidate">
      <Normalization meddra_llt="Dementia" meddra_llt_id="10012267" meddra_pt="Dementia" meddra_pt_id="10012267" />
    </Mention>
    <Mention id="M708" len="33" reason="AE_from_off_label" section="S3" start="3730" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder cerebrovascular" meddra_llt_id="10013203" meddra_pt="Cerebrovascular disorder" meddra_pt_id="10008196" />
    </Mention>
    <Mention id="M709" len="6" reason="AE_from_off_label" section="S3" start="3771" type="NonOSE_AE">
      <Normalization meddra_llt="Stroke" meddra_llt_id="10042244" meddra_pt="Cerebrovascular accident" meddra_pt_id="10008190" />
    </Mention>
    <Mention id="M710" len="25" reason="AE_from_off_label" section="S3" start="3779" type="NonOSE_AE">
      <Normalization meddra_llt="Transient ischemic attack" meddra_llt_id="10072760" meddra_pt="Transient ischaemic attack" meddra_pt_id="10044390" />
    </Mention>
    <Mention id="M785" len="10" reason="general_term" section="S3" start="3817" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M635" len="26" reason="preexisting_condition_or_risk_factor" section="S3" start="3938" type="Not_AE_Candidate">
      <Normalization meddra_llt="Senile psychosis" meddra_llt_id="10039987" meddra_pt="Senile psychosis" meddra_pt_id="10039987" />
    </Mention>
    <Mention id="M711" len="30" reason="AE_from_off_label" section="S3" start="4042" type="NonOSE_AE">
      <Normalization meddra_llt="Cerebrovascular disorder" meddra_llt_id="10008196" meddra_pt="Cerebrovascular disorder" meddra_pt_id="10008196" />
    </Mention>
    <Mention id="M636" len="26" reason="preexisting_condition_or_risk_factor" section="S3" start="4220" type="Not_AE_Candidate">
      <Normalization meddra_llt="Dementia" meddra_llt_id="10012267" meddra_pt="Dementia" meddra_pt_id="10012267" />
    </Mention>
    <Mention id="M786" len="5" reason="general_term" section="S3" start="4432" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M821" len="35" reason="from_drug_use" section="S3" start="4469" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neuroleptic malignant syndrome" meddra_llt_id="10029282" meddra_pt="Neuroleptic malignant syndrome" meddra_pt_id="10029282" />
    </Mention>
    <Mention id="M712" len="3" reason="AE_only_as_instruction" section="S3" start="4534" type="NonOSE_AE">
      <Normalization meddra_llt="NMS" meddra_llt_id="10029435" meddra_pt="Neuroleptic malignant syndrome" meddra_pt_id="10029282" />
    </Mention>
    <Mention id="M713" len="12" reason="manifestation_or_complication" section="S3" start="4546" type="NonOSE_AE">
      <Normalization meddra_llt="Hyperpyrexia" meddra_llt_id="10020741" meddra_pt="Hyperpyrexia" meddra_pt_id="10020741" />
    </Mention>
    <Mention id="M714" len="15" reason="manifestation_or_complication" section="S3" start="4560" type="NonOSE_AE">
      <Normalization meddra_llt="Muscle rigidity" meddra_llt_id="10028330" meddra_pt="Muscle rigidity" meddra_pt_id="10028330" />
    </Mention>
    <Mention id="M715" len="21" reason="manifestation_or_complication" section="S3" start="4577" type="NonOSE_AE">
      <Normalization meddra_llt="Mental status changes" meddra_llt_id="10048294" meddra_pt="Mental status changes" meddra_pt_id="10048294" />
    </Mention>
    <Mention id="M716" len="21" reason="manifestation_or_complication" section="S3" start="4604" type="NonOSE_AE">
      <Normalization meddra_llt="Autonomic instability" meddra_llt_id="10049218" meddra_pt="Autonomic nervous system imbalance" meddra_pt_id="10003840" />
    </Mention>
    <Mention id="M717" len="15" reason="manifestation_or_complication" section="S3" start="4627" type="NonOSE_AE">
      <Normalization meddra_llt="Irregular pulse" meddra_llt_id="10022994" meddra_pt="Heart rate irregular" meddra_pt_id="10019304" />
    </Mention>
    <Mention id="M718" len="9,14" reason="manifestation_or_complication" section="S3" start="4627,4646" type="NonOSE_AE">
      <Normalization meddra_llt="Blood pressure abnormal" meddra_llt_id="10005728" meddra_pt="Blood pressure abnormal" meddra_pt_id="10005728" />
      <Normalization meddra_pt="Blood pressure fluctuation" meddra_pt_id="10005746" />
    </Mention>
    <Mention id="M719" len="11" reason="manifestation_or_complication" section="S3" start="4662" type="NonOSE_AE">
      <Normalization meddra_llt="Tachycardia" meddra_llt_id="10043071" meddra_pt="Tachycardia" meddra_pt_id="10043071" />
    </Mention>
    <Mention id="M720" len="11" reason="manifestation_or_complication" section="S3" start="4675" type="NonOSE_AE">
      <Normalization meddra_llt="Diaphoresis" meddra_llt_id="10012703" meddra_pt="Hyperhidrosis" meddra_pt_id="10020642" />
    </Mention>
    <Mention id="M721" len="19" reason="manifestation_or_complication" section="S3" start="4692" type="NonOSE_AE">
      <Normalization meddra_llt="Cardiac dysrhythmia, unspecified" meddra_llt_id="10007544" meddra_pt="Arrhythmia" meddra_pt_id="10003119" />
    </Mention>
    <Mention id="M722" len="36" reason="manifestation_or_complication" section="S3" start="4743" type="NonOSE_AE">
      <Normalization meddra_llt="Creatine phosphokinase increased" meddra_llt_id="10011349" meddra_pt="Blood creatine phosphokinase increased" meddra_pt_id="10005470" />
    </Mention>
    <Mention id="M723" len="13" reason="manifestation_or_complication" section="S3" start="4782" type="NonOSE_AE">
      <Normalization meddra_llt="Myoglobinuria" meddra_llt_id="10028629" meddra_pt="Myoglobinuria" meddra_pt_id="10028629" />
    </Mention>
    <Mention id="M724" len="14" reason="manifestation_or_complication" section="S3" start="4797" type="NonOSE_AE">
      <Normalization meddra_llt="Rhabdomyolysis" meddra_llt_id="10039020" meddra_pt="Rhabdomyolysis" meddra_pt_id="10039020" />
    </Mention>
    <Mention id="M725" len="19" reason="manifestation_or_complication" section="S3" start="4817" type="NonOSE_AE">
      <Normalization meddra_llt="Renal failure acute" meddra_llt_id="10038436" meddra_pt="Acute kidney injury" meddra_pt_id="10069339" />
    </Mention>
    <Mention id="M687" len="9" reason="AE_only_as_instruction" section="S3" start="5055" type="NonOSE_AE">
      <Normalization meddra_llt="Pneumonia" meddra_llt_id="10035664" meddra_pt="Pneumonia" meddra_pt_id="10035664" />
    </Mention>
    <Mention id="M688" len="18" reason="AE_only_as_instruction" section="S3" start="5066" type="NonOSE_AE">
      <Normalization meddra_llt="Infection systemic" meddra_llt_id="10021867" meddra_pt="Systemic infection" meddra_pt_id="10077116" />
    </Mention>
    <Mention id="M726" len="38" reason="AE_only_as_instruction" section="S3" start="5130" type="NonOSE_AE">
      <Normalization meddra_llt="Extrapyramidal symptoms" meddra_llt_id="10015835" meddra_pt="Extrapyramidal disorder" meddra_pt_id="10015832" />
    </Mention>
    <Mention id="M689" len="32" reason="AE_only_as_instruction" section="S3" start="5240" type="NonOSE_AE">
      <Normalization meddra_llt="Syndrome anticholinergic" meddra_llt_id="10042788" meddra_pt="Anticholinergic syndrome" meddra_pt_id="10002757" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
    </Mention>
    <Mention id="M690" len="11" reason="AE_only_as_instruction" section="S3" start="5274" type="NonOSE_AE">
      <Normalization meddra_llt="Heat stroke" meddra_llt_id="10019345" meddra_pt="Heat stroke" meddra_pt_id="10019345" />
    </Mention>
    <Mention id="M691" len="10" reason="AE_only_as_instruction" section="S3" start="5287" type="NonOSE_AE">
      <Normalization meddra_llt="Drug fever" meddra_llt_id="10013697" meddra_pt="Pyrexia" meddra_pt_id="10037660" />
    </Mention>
    <Mention id="M727" len="40" reason="AE_only_as_instruction" section="S3" start="5303" type="NonOSE_AE">
      <Normalization meddra_llt="Central nervous system toxicity" meddra_llt_id="10071216" meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M692" len="3" reason="AE_only_as_instruction" section="S3" start="5365" type="NonOSE_AE">
      <Normalization meddra_llt="NMS" meddra_llt_id="10029435" meddra_pt="Neuroleptic malignant syndrome" meddra_pt_id="10029282" />
    </Mention>
    <Mention id="M693" len="3" reason="AE_only_as_instruction" section="S3" start="5756" type="NonOSE_AE">
      <Normalization meddra_llt="NMS" meddra_llt_id="10029435" meddra_pt="Neuroleptic malignant syndrome" meddra_pt_id="10029282" />
    </Mention>
    <Mention id="M694" len="3" reason="AE_only_as_instruction" section="S3" start="5834" type="NonOSE_AE">
      <Normalization meddra_llt="NMS" meddra_llt_id="10029435" meddra_pt="Neuroleptic malignant syndrome" meddra_pt_id="10029282" />
    </Mention>
    <Mention id="M695" len="3" reason="AE_only_as_instruction" section="S3" start="5980" type="NonOSE_AE">
      <Normalization meddra_llt="NMS" meddra_llt_id="10029435" meddra_pt="Neuroleptic malignant syndrome" meddra_pt_id="10029282" />
    </Mention>
    <Mention id="M823" len="18" reason="class_effect" section="S3" start="6013" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyskinesia tardive" meddra_llt_id="10013928" meddra_pt="Tardive dyskinesia" meddra_pt_id="10043118" />
    </Mention>
    <Mention id="M822" len="20" reason="class_effect" section="S3" start="6088" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyskinetic syndrome" meddra_llt_id="10013930" meddra_pt="Dyskinesia" meddra_pt_id="10013916" />
    </Mention>
    <Mention id="M787" len="18" reason="AE_only_as_instruction" section="S3" start="6190" type="NonOSE_AE">
      <Normalization meddra_llt="Dyskinesia tardive" meddra_llt_id="10013928" meddra_pt="Tardive dyskinesia" meddra_pt_id="10043118" />
    </Mention>
    <Mention id="M728" len="18" reason="AE_only_as_instruction" section="S3" start="6580" type="NonOSE_AE">
      <Normalization meddra_llt="Dyskinesia tardive" meddra_llt_id="10013928" meddra_pt="Tardive dyskinesia" meddra_pt_id="10043118" />
    </Mention>
    <Mention id="M696" len="18" reason="AE_only_as_instruction" section="S3" start="7087" type="NonOSE_AE">
      <Normalization meddra_llt="Dyskinesia tardive" meddra_llt_id="10013928" meddra_pt="Tardive dyskinesia" meddra_pt_id="10043118" />
    </Mention>
    <Mention id="M697" len="18" reason="AE_only_as_instruction" section="S3" start="7651" type="NonOSE_AE">
      <Normalization meddra_llt="Dyskinesia tardive" meddra_llt_id="10013928" meddra_pt="Tardive dyskinesia" meddra_pt_id="10043118" />
    </Mention>
    <Mention id="M824" len="17" reason="class_effect" section="S3" start="7941" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Metabolic disorder" meddra_llt_id="10058097" meddra_pt="Metabolic disorder" meddra_pt_id="10058097" />
    </Mention>
    <Mention id="M729" len="17" reason="AE_only_as_instruction" section="S3" start="8020" type="NonOSE_AE">
      <Normalization meddra_llt="Metabolic disorder" meddra_llt_id="10058097" meddra_pt="Metabolic disorder" meddra_pt_id="10058097" />
    </Mention>
    <Mention id="M825" len="13" reason="class_effect" section="S3" start="8046" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperglycemia" meddra_llt_id="10020639" meddra_pt="Hyperglycaemia" meddra_pt_id="10020635" />
    </Mention>
    <Mention id="M826" len="12" reason="class_effect" section="S3" start="8061" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyslipidemia" meddra_llt_id="10058110" meddra_pt="Dyslipidaemia" meddra_pt_id="10058108" />
    </Mention>
    <Mention id="M827" len="16" reason="class_effect" section="S3" start="8079" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight gain" meddra_llt_id="10047896" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M828" len="17" reason="class_effect" section="S3" start="8165" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Metabolic disorder" meddra_llt_id="10058097" meddra_pt="Metabolic disorder" meddra_pt_id="10058097" />
    </Mention>
    <Mention id="M791" len="13" reason="from_drug_use" section="S3" start="8274" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperglycemia" meddra_llt_id="10020639" meddra_pt="Hyperglycaemia" meddra_pt_id="10020635" />
    </Mention>
    <Mention id="M792" len="17" reason="from_drug_use" section="S3" start="8292" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diabetes mellitus" meddra_llt_id="10012601" meddra_pt="Diabetes mellitus" meddra_pt_id="10012601" />
    </Mention>
    <Mention id="M793" len="12" reason="from_drug_use" section="S3" start="8353" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ketoacidosis" meddra_llt_id="10023379" meddra_pt="Ketoacidosis" meddra_pt_id="10023379" />
    </Mention>
    <Mention id="M794" len="17" reason="from_drug_use" section="S3" start="8369" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nonketotic hyperglycaemic-hyperosmolar coma" meddra_llt_id="10029646" meddra_pt="Diabetic hyperosmolar coma" meddra_pt_id="10012669" />
    </Mention>
    <Mention id="M698" len="5" reason="general_term" section="S3" start="8390" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M730" len="21" reason="AE_only_as_instruction" section="S3" start="8563" type="NonOSE_AE">
      <Normalization meddra_llt="Glucose abnormal" meddra_llt_id="10018415" meddra_pt="Blood glucose abnormal" meddra_pt_id="10005554" />
      <Normalization meddra_pt="Blood glucose fluctuation" meddra_pt_id="10049803" />
    </Mention>
    <Mention id="M660" len="17" reason="preexisting_condition_or_risk_factor" section="S3" start="8654" type="Not_AE_Candidate">
      <Normalization meddra_llt="Diabetes mellitus" meddra_llt_id="10012601" meddra_pt="Diabetes mellitus" meddra_pt_id="10012601" />
    </Mention>
    <Mention id="M637" len="13" reason="indication" section="S3" start="8689" type="Not_AE_Candidate">
      <Normalization meddra_llt="Schizophrenia" meddra_llt_id="10039626" meddra_pt="Schizophrenia" meddra_pt_id="10039626" />
    </Mention>
    <Mention id="M685" len="17" reason="preexisting_condition_or_risk_factor" section="S3" start="8735" type="Not_AE_Candidate">
      <Normalization meddra_llt="Diabetes mellitus" meddra_llt_id="10012601" meddra_pt="Diabetes mellitus" meddra_pt_id="10012601" />
    </Mention>
    <Mention id="M731" len="36" reason="AE_only_as_instruction" section="S3" start="8861" type="NonOSE_AE">
      <Normalization meddra_llt="Hyperglycemia" meddra_llt_id="10020639" meddra_pt="Hyperglycaemia" meddra_pt_id="10020635" />
    </Mention>
    <Mention id="M829" len="36" reason="class_effect" section="S3" start="9009" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperglycemia" meddra_llt_id="10020639" meddra_pt="Hyperglycaemia" meddra_pt_id="10020635" />
    </Mention>
    <Mention id="M732" len="36" reason="AE_only_as_instruction" section="S3" start="9127" type="NonOSE_AE">
      <Normalization meddra_llt="Hyperglycemia" meddra_llt_id="10020639" meddra_pt="Hyperglycaemia" meddra_pt_id="10020635" />
    </Mention>
    <Mention id="M638" len="17" reason="preexisting_condition_or_risk_factor" section="S3" start="9276" type="Not_AE_Candidate">
      <Normalization meddra_llt="Diabetes mellitus" meddra_llt_id="10012601" meddra_pt="Diabetes mellitus" meddra_pt_id="10012601" />
    </Mention>
    <Mention id="M733" len="28" reason="AE_only_as_instruction" section="S3" start="9400" type="NonOSE_AE">
      <Normalization meddra_llt="Loss of control of diabetes" meddra_llt_id="10024859" meddra_pt="Diabetes mellitus inadequate control" meddra_pt_id="10012607" />
    </Mention>
    <Mention id="M734" len="17" reason="AE_only_as_instruction" section="S3" start="9461" type="NonOSE_AE">
      <Normalization meddra_llt="Diabetes mellitus" meddra_llt_id="10012601" meddra_pt="Diabetes mellitus" meddra_pt_id="10012601" />
    </Mention>
    <Mention id="M639" len="7" reason="preexisting_condition_or_risk_factor" section="S3" start="9486" type="Not_AE_Candidate">
      <Normalization meddra_llt="Obesity" meddra_llt_id="10029883" meddra_pt="Obesity" meddra_pt_id="10029883" />
    </Mention>
    <Mention id="M640" len="26" reason="preexisting_condition_or_risk_factor" section="S3" start="9495" type="Not_AE_Candidate">
      <Normalization meddra_llt="Family history of diabetes" meddra_llt_id="10064123" meddra_pt="Familial risk factor" meddra_pt_id="10064117" />
    </Mention>
    <Mention id="M699" len="13" reason="AE_only_as_instruction" section="S3" start="9832" type="NonOSE_AE">
      <Normalization meddra_llt="Hyperglycemia" meddra_llt_id="10020639" meddra_pt="Hyperglycaemia" meddra_pt_id="10020635" />
    </Mention>
    <Mention id="M735" len="10" reason="manifestation_or_complication" section="S3" start="9856" type="NonOSE_AE">
      <Normalization meddra_llt="Polydipsia" meddra_llt_id="10036067" meddra_pt="Polydipsia" meddra_pt_id="10036067" />
    </Mention>
    <Mention id="M736" len="8" reason="manifestation_or_complication" section="S3" start="9868" type="NonOSE_AE">
      <Normalization meddra_llt="Polyuria" meddra_llt_id="10036142" meddra_pt="Polyuria" meddra_pt_id="10036142" />
    </Mention>
    <Mention id="M737" len="10" reason="manifestation_or_complication" section="S3" start="9878" type="NonOSE_AE">
      <Normalization meddra_llt="Polyphagia" meddra_llt_id="10036132" meddra_pt="Hyperphagia" meddra_pt_id="10020710" />
    </Mention>
    <Mention id="M738" len="8" reason="manifestation_or_complication" section="S3" start="9894" type="NonOSE_AE">
      <Normalization meddra_llt="Weakness" meddra_llt_id="10047862" meddra_pt="Asthenia" meddra_pt_id="10003549" />
    </Mention>
    <Mention id="M739" len="13" reason="AE_only_as_instruction" section="S3" start="9937" type="NonOSE_AE">
      <Normalization meddra_llt="Hyperglycemia" meddra_llt_id="10020639" meddra_pt="Hyperglycaemia" meddra_pt_id="10020635" />
    </Mention>
    <Mention id="M740" len="13" reason="AE_only_as_instruction" section="S3" start="10087" type="NonOSE_AE">
      <Normalization meddra_llt="Hyperglycemia" meddra_llt_id="10020639" meddra_pt="Hyperglycaemia" meddra_pt_id="10020635" />
    </Mention>
    <Mention id="M661" len="13" reason="indication" section="S3" start="10368" type="Not_AE_Candidate">
      <Normalization meddra_llt="Schizophrenia" meddra_llt_id="10039626" meddra_pt="Schizophrenia" meddra_pt_id="10039626" />
    </Mention>
    <Mention id="M641" len="7" reason="indication" section="S3" start="10432" type="Not_AE_Candidate">
      <Normalization meddra_llt="Bipolar disorder" meddra_llt_id="10057667" meddra_pt="Bipolar disorder" meddra_pt_id="10057667" />
    </Mention>
    <Mention id="M830" len="25,13" reason="from_drug_use" section="S3" start="10901,11052" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Blood glucose fluctuation" meddra_llt_id="10049803" meddra_pt="Blood glucose fluctuation" meddra_pt_id="10049803" />
      <Normalization meddra_pt="Blood glucose abnormal" meddra_pt_id="10005554" />
    </Mention>
    <Mention id="M741" len="39" reason="AE_rate_lteq_placebo" section="S3" start="11242" type="NonOSE_AE">
      <Normalization meddra_llt="Glucose high" meddra_llt_id="10018420" meddra_pt="Blood glucose increased" meddra_pt_id="10005557" />
      <Normalization meddra_pt="Impaired fasting glucose" meddra_pt_id="10056997" />
    </Mention>
    <Mention id="M834" len="22" reason="from_drug_use" section="S3" start="11458" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Blood glucose fluctuation" meddra_llt_id="10049803" meddra_pt="Blood glucose fluctuation" meddra_pt_id="10049803" />
      <Normalization meddra_pt="Blood glucose abnormal" meddra_pt_id="10005554" />
    </Mention>
    <Mention id="M642" len="13" reason="indication" section="S3" start="11637" type="Not_AE_Candidate">
      <Normalization meddra_llt="Schizophrenia" meddra_llt_id="10039626" meddra_pt="Schizophrenia" meddra_pt_id="10039626" />
    </Mention>
    <Mention id="M643" len="13" reason="indication" section="S3" start="11673" type="Not_AE_Candidate">
      <Normalization meddra_llt="Mania" meddra_llt_id="10026749" meddra_pt="Mania" meddra_pt_id="10026749" />
    </Mention>
    <Mention id="M644" len="17" reason="indication" section="S3" start="11712" type="Not_AE_Candidate">
      <Normalization meddra_llt="Autistic disorder" meddra_llt_id="10003808" meddra_pt="Autism spectrum disorder" meddra_pt_id="10063844" />
    </Mention>
    <Mention id="M831" len="25,13" reason="from_drug_use" section="S3" start="12288,12437" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Blood glucose fluctuation" meddra_llt_id="10049803" meddra_pt="Blood glucose fluctuation" meddra_pt_id="10049803" />
      <Normalization meddra_pt="Blood glucose abnormal" meddra_pt_id="10005554" />
    </Mention>
    <Mention id="M832" len="39" reason="from_drug_use" section="S3" start="12623" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Glucose high" meddra_llt_id="10018420" meddra_pt="Blood glucose increased" meddra_pt_id="10005557" />
      <Normalization meddra_pt="Impaired fasting glucose" meddra_pt_id="10056997" />
    </Mention>
    <Mention id="M833" len="30" reason="from_drug_use" section="S3" start="12855" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fasting blood glucose abnormal" meddra_llt_id="10051573" meddra_pt="Blood glucose abnormal" meddra_pt_id="10005554" />
      <Normalization meddra_pt="Blood glucose fluctuation" meddra_pt_id="10049803" />
    </Mention>
    <Mention id="M870" len="12" reason="class_effect" section="S3" start="12927" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dyslipidemia" meddra_llt_id="10058110" meddra_pt="Dyslipidaemia" meddra_pt_id="10058108" />
    </Mention>
    <Mention id="M835" len="33" reason="class_effect" section="S3" start="12944" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Lipids abnormal" meddra_llt_id="10024588" meddra_pt="Lipids abnormal" meddra_pt_id="10024588" />
    </Mention>
    <Mention id="M662" len="13" reason="indication" section="S3" start="13158" type="Not_AE_Candidate">
      <Normalization meddra_llt="Schizophrenia" meddra_llt_id="10039626" meddra_pt="Schizophrenia" meddra_pt_id="10039626" />
    </Mention>
    <Mention id="M663" len="13" reason="indication" section="S3" start="13175" type="Not_AE_Candidate">
      <Normalization meddra_llt="Mania" meddra_llt_id="10026749" meddra_pt="Mania" meddra_pt_id="10026749" />
    </Mention>
    <Mention id="M836" len="11,20" reason="from_drug_use" section="S3" start="13670,13780" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Blood cholesterol abnormal" meddra_llt_id="10005423" meddra_pt="Blood cholesterol abnormal" meddra_pt_id="10005423" />
    </Mention>
    <Mention id="M837" len="13,20" reason="from_drug_use" section="S3" start="14003,14113" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Triglycerides abnormal" meddra_llt_id="10044661" meddra_pt="Blood triglycerides abnormal" meddra_pt_id="10005837" />
    </Mention>
    <Mention id="M838" len="39" reason="from_drug_use" section="S3" start="14415" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cholesterol high" meddra_llt_id="10008661" meddra_pt="Blood cholesterol increased" meddra_pt_id="10005425" />
    </Mention>
    <Mention id="M839" len="41" reason="from_drug_use" section="S3" start="14643" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Triglycerides high" meddra_llt_id="10052373" meddra_pt="Blood triglycerides increased" meddra_pt_id="10005839" />
    </Mention>
    <Mention id="M840" len="42" reason="from_drug_use" section="S3" start="14861" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Blood cholesterol abnormal" meddra_llt_id="10005423" meddra_pt="Blood cholesterol abnormal" meddra_pt_id="10005423" />
    </Mention>
    <Mention id="M841" len="14,11,13" reason="from_drug_use" section="S3" start="14861,14880,14991" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Blood triglycerides abnormal" meddra_llt_id="10005837" meddra_pt="Blood triglycerides abnormal" meddra_pt_id="10005837" />
    </Mention>
    <Mention id="M645" len="13" reason="indication" section="S3" start="15148" type="Not_AE_Candidate">
      <Normalization meddra_llt="Schizophrenia" meddra_llt_id="10039626" meddra_pt="Schizophrenia" meddra_pt_id="10039626" />
    </Mention>
    <Mention id="M646" len="13" reason="indication" section="S3" start="15184" type="Not_AE_Candidate">
      <Normalization meddra_llt="Mania" meddra_llt_id="10026749" meddra_pt="Mania" meddra_pt_id="10026749" />
    </Mention>
    <Mention id="M647" len="17" reason="indication" section="S3" start="15223" type="Not_AE_Candidate">
      <Normalization meddra_llt="Autistic disorder" meddra_llt_id="10003808" meddra_pt="Autism spectrum disorder" meddra_pt_id="10063844" />
    </Mention>
    <Mention id="M842" len="11,20" reason="from_drug_use" section="S3" start="15836,15944" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Blood cholesterol abnormal" meddra_llt_id="10005423" meddra_pt="Blood cholesterol abnormal" meddra_pt_id="10005423" />
    </Mention>
    <Mention id="M843" len="3,20" reason="from_drug_use" section="S3" start="16163,16271" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Low density lipoprotein abnormal" meddra_llt_id="10024901" meddra_pt="Low density lipoprotein abnormal" meddra_pt_id="10024901" />
    </Mention>
    <Mention id="M844" len="3,20" reason="from_drug_use" section="S3" start="16490,16598" type="OSE_Labeled_AE">
      <Normalization meddra_llt="High density lipoprotein abnormal" meddra_llt_id="10020051" meddra_pt="High density lipoprotein abnormal" meddra_pt_id="10020051" />
    </Mention>
    <Mention id="M845" len="13,20" reason="from_drug_use" section="S3" start="16817,16925" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Triglycerides abnormal" meddra_llt_id="10044661" meddra_pt="Blood triglycerides abnormal" meddra_pt_id="10005837" />
    </Mention>
    <Mention id="M846" len="39" reason="from_drug_use" section="S3" start="17221" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cholesterol high" meddra_llt_id="10008661" meddra_pt="Blood cholesterol increased" meddra_pt_id="10005425" />
    </Mention>
    <Mention id="M847" len="31" reason="from_drug_use" section="S3" start="17338" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Increased LDL" meddra_llt_id="10021668" meddra_pt="Low density lipoprotein increased" meddra_pt_id="10024910" />
    </Mention>
    <Mention id="M848" len="29" reason="from_drug_use" section="S3" start="17447" type="OSE_Labeled_AE">
      <Normalization meddra_llt="HDL decreased" meddra_llt_id="10019186" meddra_pt="High density lipoprotein decreased" meddra_pt_id="10020060" />
    </Mention>
    <Mention id="M849" len="41" reason="from_drug_use" section="S3" start="17556" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Mg++ increased" meddra_llt_id="10027521" meddra_pt="Blood magnesium increased" meddra_pt_id="10005655" />
    </Mention>
    <Mention id="M850" len="38" reason="from_drug_use" section="S3" start="17790" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Blood cholesterol abnormal" meddra_llt_id="10005423" meddra_pt="Blood cholesterol abnormal" meddra_pt_id="10005423" />
    </Mention>
    <Mention id="M851" len="14,7,3" reason="from_drug_use" section="S3" start="17790,17809,17875" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Low density lipoprotein abnormal" meddra_llt_id="10024901" meddra_pt="Low density lipoprotein abnormal" meddra_pt_id="10024901" />
    </Mention>
    <Mention id="M852" len="14,7,3" reason="from_drug_use" section="S3" start="17790,17809,17925" type="OSE_Labeled_AE">
      <Normalization meddra_llt="High density lipoprotein abnormal" meddra_llt_id="10020051" meddra_pt="High density lipoprotein abnormal" meddra_pt_id="10020051" />
    </Mention>
    <Mention id="M853" len="14,7,13" reason="from_drug_use" section="S3" start="17790,17809,17979" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Triglycerides abnormal" meddra_llt_id="10044661" meddra_pt="Blood triglycerides abnormal" meddra_pt_id="10005837" />
    </Mention>
    <Mention id="M854" len="11" reason="class_effect" section="S3" start="18050" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight gain" meddra_llt_id="10047896" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M742" len="22" reason="AE_only_as_instruction" section="S3" start="18174" type="NonOSE_AE">
      <Normalization meddra_llt="Weight abnormal" meddra_llt_id="10056814" meddra_pt="Weight abnormal" meddra_pt_id="10056814" />
    </Mention>
    <Mention id="M743" len="11" reason="AE_only_as_instruction" section="S3" start="18238" type="NonOSE_AE">
      <Normalization meddra_llt="Weight gain" meddra_llt_id="10047896" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M648" len="13" reason="indication" section="S3" start="18389" type="Not_AE_Candidate">
      <Normalization meddra_llt="Schizophrenia" meddra_llt_id="10039626" meddra_pt="Schizophrenia" meddra_pt_id="10039626" />
    </Mention>
    <Mention id="M649" len="13" reason="indication" section="S3" start="18406" type="Not_AE_Candidate">
      <Normalization meddra_llt="Mania" meddra_llt_id="10026749" meddra_pt="Mania" meddra_pt_id="10026749" />
    </Mention>
    <Mention id="M855" len="130" reason="from_drug_use" section="S3" start="18882" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight fluctuation" meddra_llt_id="10049040" meddra_pt="Weight fluctuation" meddra_pt_id="10049040" />
    </Mention>
    <Mention id="M856" len="11" reason="from_drug_use" section="S3" start="19104" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight gain" meddra_llt_id="10047896" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M857" len="21" reason="from_drug_use" section="S3" start="19427" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight fluctuation" meddra_llt_id="10049040" meddra_pt="Weight fluctuation" meddra_pt_id="10049040" />
    </Mention>
    <Mention id="M744" len="27" reason="AE_only_as_instruction" section="S3" start="19523" type="NonOSE_AE">
      <Normalization meddra_llt="Weight fluctuation" meddra_llt_id="10049040" meddra_pt="Weight fluctuation" meddra_pt_id="10049040" />
    </Mention>
    <Mention id="M745" len="19" reason="AE_only_as_instruction" section="S3" start="19612" type="NonOSE_AE">
      <Normalization meddra_llt="Weight gain" meddra_llt_id="10047896" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M650" len="13" reason="indication" section="S3" start="19728" type="Not_AE_Candidate">
      <Normalization meddra_llt="Schizophrenia" meddra_llt_id="10039626" meddra_pt="Schizophrenia" meddra_pt_id="10039626" />
    </Mention>
    <Mention id="M651" len="13" reason="indication" section="S3" start="19764" type="Not_AE_Candidate">
      <Normalization meddra_llt="Mania" meddra_llt_id="10026749" meddra_pt="Mania" meddra_pt_id="10026749" />
    </Mention>
    <Mention id="M652" len="17" reason="indication" section="S3" start="19800" type="Not_AE_Candidate">
      <Normalization meddra_llt="Autistic disorder" meddra_llt_id="10003808" meddra_pt="Autism spectrum disorder" meddra_pt_id="10063844" />
    </Mention>
    <Mention id="M664" len="21" reason="preexisting_condition_or_risk_factor" section="S3" start="19848" type="Not_AE_Candidate">
      <Normalization meddra_llt="Psychiatric disorder NOS" meddra_llt_id="10037174" meddra_pt="Mental disorder" meddra_pt_id="10061284" />
      <Normalization meddra_pt="Psychiatric symptom" meddra_pt_id="10061472" />
    </Mention>
    <Mention id="M858" len="128" reason="from_drug_use" section="S3" start="20400" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight fluctuation" meddra_llt_id="10049040" meddra_pt="Weight fluctuation" meddra_pt_id="10049040" />
    </Mention>
    <Mention id="M859" len="11" reason="from_drug_use" section="S3" start="20618" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight gain" meddra_llt_id="10047896" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M860" len="21" reason="from_drug_use" section="S3" start="20951" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight fluctuation" meddra_llt_id="10049040" meddra_pt="Weight fluctuation" meddra_pt_id="10049040" />
    </Mention>
    <Mention id="M653" len="13" reason="indication" section="S3" start="21110" type="Not_AE_Candidate">
      <Normalization meddra_llt="Schizophrenia" meddra_llt_id="10039626" meddra_pt="Schizophrenia" meddra_pt_id="10039626" />
    </Mention>
    <Mention id="M861" len="15" reason="from_drug_use" section="S3" start="21125" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight increase" meddra_llt_id="10047898" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M654" len="13" reason="indication" section="S3" start="21244" type="Not_AE_Candidate">
      <Normalization meddra_llt="Schizophrenia" meddra_llt_id="10039626" meddra_pt="Schizophrenia" meddra_pt_id="10039626" />
    </Mention>
    <Mention id="M871" len="23" reason="from_drug_use" section="S3" start="21261" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight increase" meddra_llt_id="10047898" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M655" len="17" reason="indication" section="S3" start="21621" type="Not_AE_Candidate">
      <Normalization meddra_llt="Autistic disorder" meddra_llt_id="10003808" meddra_pt="Autism spectrum disorder" meddra_pt_id="10063844" />
    </Mention>
    <Mention id="M665" len="21" reason="preexisting_condition_or_risk_factor" section="S3" start="21648" type="Not_AE_Candidate">
      <Normalization meddra_llt="Psychiatric disorder NOS" meddra_llt_id="10037174" meddra_pt="Mental disorder" meddra_pt_id="10061284" />
      <Normalization meddra_pt="Psychiatric symptom" meddra_pt_id="10061472" />
    </Mention>
    <Mention id="M872" len="23" reason="from_drug_use" section="S3" start="21674" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight increase" meddra_llt_id="10047898" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M795" len="11" reason="from_drug_use" section="S3" start="21799" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight gain" meddra_llt_id="10047896" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M666" len="51" reason="indication" section="S3" start="22264" type="Not_AE_Candidate">
      <Normalization meddra_llt="Bipolar I disorder" meddra_llt_id="10004939" meddra_pt="Bipolar I disorder" meddra_pt_id="10004939" />
    </Mention>
    <Mention id="M796" len="24" reason="from_drug_use" section="S3" start="22317" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Weight gain" meddra_llt_id="10047896" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M862" len="44" reason="from_drug_use" section="S3" start="22595" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Body mass index" meddra_llt_id="10005894" meddra_pt="Body mass index" meddra_pt_id="10005894" />
    </Mention>
    <Mention id="M746" len="11" reason="AE_only_as_instruction" section="S3" start="22717" type="NonOSE_AE">
      <Normalization meddra_llt="Weight gain" meddra_llt_id="10047896" meddra_pt="Weight increased" meddra_pt_id="10047899" />
    </Mention>
    <Mention id="M873" len="18" reason="from_drug_use" section="S3" start="22799" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperprolactinemia" meddra_llt_id="10020739" meddra_pt="Hyperprolactinaemia" meddra_pt_id="10020737" />
      <Normalization meddra_pt="Blood prolactin increased" meddra_pt_id="10005780" />
    </Mention>
    <Mention id="M797" len="25" reason="from_drug_use" section="S3" start="22895" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Prolactin levels increased" meddra_llt_id="10036828" meddra_pt="Blood prolactin increased" meddra_pt_id="10005780" />
      <Normalization meddra_pt="Hyperprolactinaemia" meddra_pt_id="10020737" />
    </Mention>
    <Mention id="M798" len="19" reason="from_drug_use" section="S3" start="23031" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Prolactin high" meddra_llt_id="10036825" meddra_pt="Blood prolactin increased" meddra_pt_id="10005780" />
      <Normalization meddra_pt="Hyperprolactinaemia" meddra_pt_id="10020737" />
    </Mention>
    <Mention id="M788" len="18" reason="AE_only_as_instruction" section="S3" start="23086" type="NonOSE_AE">
      <Normalization meddra_llt="Hyperprolactinemia" meddra_llt_id="10020739" meddra_pt="Hyperprolactinaemia" meddra_pt_id="10020737" />
      <Normalization meddra_pt="Blood prolactin increased" meddra_pt_id="10005780" />
    </Mention>
    <Mention id="M747" len="26" reason="manifestation_or_complication" section="S3" start="23109" type="NonOSE_AE">
      <Normalization meddra_llt="Blood gonadotrophin releasing hormone decreased" meddra_llt_id="10063242" meddra_pt="Blood gonadotrophin releasing hormone decreased" meddra_pt_id="10063242" />
    </Mention>
    <Mention id="M748" len="40" reason="manifestation_or_complication" section="S3" start="23150" type="NonOSE_AE">
      <Normalization meddra_llt="Gonadotropin pituitary decreased" meddra_llt_id="10018541" meddra_pt="Blood gonadotrophin decreased" meddra_pt_id="10005562" />
      <Normalization meddra_pt="Secondary hypogonadism" meddra_pt_id="10059594" />
    </Mention>
    <Mention id="M749" len="29" reason="manifestation_or_complication" section="S3" start="23211" type="NonOSE_AE">
      <Normalization meddra_llt="Infertility" meddra_llt_id="10021926" meddra_pt="Infertility" meddra_pt_id="10021926" />
    </Mention>
    <Mention id="M750" len="33" reason="manifestation_or_complication" section="S3" start="23244" type="NonOSE_AE">
      <Normalization meddra_llt="Impaired gonadal steroidogenesis" meddra_llt_id="10078995" meddra_pt="Hypogonadism" meddra_pt_id="10058359" />
    </Mention>
    <Mention id="M874" len="12" reason="class_effect" section="S3" start="23312" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Galactorrhea" meddra_llt_id="10017592" meddra_pt="Galactorrhoea" meddra_pt_id="10017600" />
    </Mention>
    <Mention id="M875" len="10" reason="class_effect" section="S3" start="23326" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Amenorrhea" meddra_llt_id="10001927" meddra_pt="Amenorrhoea" meddra_pt_id="10001928" />
    </Mention>
    <Mention id="M876" len="12" reason="class_effect" section="S3" start="23338" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Gynecomastia" meddra_llt_id="10018801" meddra_pt="Gynaecomastia" meddra_pt_id="10018800" />
    </Mention>
    <Mention id="M877" len="9" reason="class_effect" section="S3" start="23356" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Impotence" meddra_llt_id="10021550" meddra_pt="Erectile dysfunction" meddra_pt_id="10061461" />
    </Mention>
    <Mention id="M752" len="18" reason="AE_only_as_instruction" section="S3" start="23452" type="NonOSE_AE">
      <Normalization meddra_llt="Hyperprolactinemia" meddra_llt_id="10020739" meddra_pt="Hyperprolactinaemia" meddra_pt_id="10020737" />
      <Normalization meddra_pt="Blood prolactin increased" meddra_pt_id="10005780" />
    </Mention>
    <Mention id="M775" len="12" reason="AE_only_as_instruction" section="S3" start="23492" type="NonOSE_AE">
      <Normalization meddra_llt="Hypogonadism" meddra_llt_id="10058359" meddra_pt="Hypogonadism" meddra_pt_id="10058359" />
    </Mention>
    <Mention id="M751" len="22" reason="AE_only_as_instruction" section="S3" start="23517" type="NonOSE_AE">
      <Normalization meddra_llt="Bone density decreased" meddra_llt_id="10049470" meddra_pt="Bone density decreased" meddra_pt_id="10049470" />
    </Mention>
    <Mention id="M753" len="14" reason="AE_only_as_instruction" section="S3" start="23650" type="NonOSE_AE">
      <Normalization meddra_llt="Breast cancer" meddra_llt_id="10006187" meddra_pt="Breast cancer" meddra_pt_id="10006187" />
    </Mention>
    <Mention id="M667" len="13" reason="preexisting_condition_or_risk_factor" section="S3" start="23823" type="Not_AE_Candidate">
      <Normalization meddra_llt="Breast cancer" meddra_llt_id="10006187" meddra_pt="Breast cancer" meddra_pt_id="10006187" />
    </Mention>
    <Mention id="M756" len="15,9" reason="AE_animal" section="S3" start="23853,23911" type="NonOSE_AE">
      <Normalization meddra_llt="Pituitary tumour" meddra_llt_id="10035104" meddra_pt="Pituitary tumour" meddra_pt_id="10035104" />
    </Mention>
    <Mention id="M755" len="13,9" reason="AE_animal" section="S3" start="23870,23911" type="NonOSE_AE">
      <Normalization meddra_llt="Mammary gland tumour" meddra_llt_id="10077561" meddra_pt="Breast neoplasm" meddra_pt_id="10006279" />
    </Mention>
    <Mention id="M754" len="31" reason="AE_animal" section="S3" start="23889" type="NonOSE_AE">
      <Normalization meddra_llt="Pancreatic neoplasm" meddra_llt_id="10061902" meddra_pt="Pancreatic neoplasm" meddra_pt_id="10061902" />
    </Mention>
    <Mention id="M757" len="23" reason="AE_animal" section="S3" start="23922" type="NonOSE_AE">
      <Normalization meddra_llt="Breast cancer" meddra_llt_id="10006187" meddra_pt="Breast cancer" meddra_pt_id="10006187" />
    </Mention>
    <Mention id="M759" len="9,8" reason="AE_animal" section="S3" start="23947,23972" type="NonOSE_AE">
      <Normalization meddra_llt="Pituitary adenoma" meddra_llt_id="10035079" meddra_pt="Pituitary tumour benign" meddra_pt_id="10061538" />
    </Mention>
    <Mention id="M758" len="19" reason="AE_animal" section="S3" start="23961" type="NonOSE_AE">
      <Normalization meddra_llt="Pancreatic adenoma" meddra_llt_id="10058902" meddra_pt="Benign pancreatic neoplasm" meddra_pt_id="10061000" />
    </Mention>
    <Mention id="M700" len="13" reason="negation" section="S3" start="24263" type="NonOSE_AE">
      <Normalization meddra_llt="Carcinogenicity" meddra_llt_id="10007269" meddra_pt="Carcinogenicity" meddra_pt_id="10007269" />
    </Mention>
    <Mention id="M799" len="23" reason="from_drug_use" section="S3" start="24431" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Orthostatic hypotension" meddra_llt_id="10031127" meddra_pt="Orthostatic hypotension" meddra_pt_id="10031127" />
    </Mention>
    <Mention id="M800" len="9" reason="from_drug_use" section="S3" start="24471" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M801" len="11" reason="from_drug_use" section="S3" start="24482" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tachycardia" meddra_llt_id="10043071" meddra_pt="Tachycardia" meddra_pt_id="10043071" />
    </Mention>
    <Mention id="M802" len="7" reason="from_drug_use" section="S3" start="24517" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Syncope" meddra_llt_id="10042772" meddra_pt="Syncope" meddra_pt_id="10042772" />
    </Mention>
    <Mention id="M803" len="7" reason="from_drug_use" section="S3" start="24645" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Syncope" meddra_llt_id="10042772" meddra_pt="Syncope" meddra_pt_id="10042772" />
    </Mention>
    <Mention id="M656" len="13" reason="indication" section="S3" start="24760" type="Not_AE_Candidate">
      <Normalization meddra_llt="Schizophrenia" meddra_llt_id="10039626" meddra_pt="Schizophrenia" meddra_pt_id="10039626" />
    </Mention>
    <Mention id="M804" len="23" reason="from_drug_use" section="S3" start="24787" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Orthostatic hypotension" meddra_llt_id="10031127" meddra_pt="Orthostatic hypotension" meddra_pt_id="10031127" />
    </Mention>
    <Mention id="M805" len="7" reason="from_drug_use" section="S3" start="24815" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Syncope" meddra_llt_id="10042772" meddra_pt="Syncope" meddra_pt_id="10042772" />
    </Mention>
    <Mention id="M669" len="5,10" reason="preexisting_condition_or_risk_factor" section="S3" start="24996,25013" type="Not_AE_Candidate">
      <Normalization meddra_llt="Renal impairment" meddra_llt_id="10062237" meddra_pt="Renal impairment" meddra_pt_id="10062237" />
    </Mention>
    <Mention id="M668" len="18" reason="preexisting_condition_or_risk_factor" section="S3" start="25005" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hepatic impairment" meddra_llt_id="10052254" meddra_pt="Liver disorder" meddra_pt_id="10024670" />
      <Normalization meddra_pt="Hepatotoxicity" meddra_pt_id="10019851" />
    </Mention>
    <Mention id="M701" len="11" reason="AE_only_as_instruction" section="S3" start="25223" type="NonOSE_AE">
      <Normalization meddra_llt="Hypotension" meddra_llt_id="10021097" meddra_pt="Hypotension" meddra_pt_id="10021097" />
    </Mention>
    <Mention id="M670" len="22" reason="preexisting_condition_or_risk_factor" section="S3" start="25321" type="Not_AE_Candidate">
      <Normalization meddra_llt="Cardiovascular disease, unspecified" meddra_llt_id="10007648" meddra_pt="Cardiovascular disorder" meddra_pt_id="10007649" />
      <Normalization meddra_pt="Cardiovascular symptom" meddra_pt_id="10075534" />
    </Mention>
    <Mention id="M671" len="21" reason="preexisting_condition_or_risk_factor" section="S3" start="25356" type="Not_AE_Candidate">
      <Normalization meddra_llt="Myocardial infarction" meddra_llt_id="10028596" meddra_pt="Myocardial infarction" meddra_pt_id="10028596" />
    </Mention>
    <Mention id="M672" len="8" reason="preexisting_condition_or_risk_factor" section="S3" start="25381" type="Not_AE_Candidate">
      <Normalization meddra_llt="Ischemia" meddra_llt_id="10054438" meddra_pt="Ischaemia" meddra_pt_id="10061255" />
    </Mention>
    <Mention id="M673" len="13" reason="preexisting_condition_or_risk_factor" section="S3" start="25391" type="Not_AE_Candidate">
      <Normalization meddra_llt="Heart failure" meddra_llt_id="10019279" meddra_pt="Cardiac failure" meddra_pt_id="10007554" />
    </Mention>
    <Mention id="M674" len="24" reason="preexisting_condition_or_risk_factor" section="S3" start="25409" type="Not_AE_Candidate">
      <Normalization meddra_llt="Conduction disorder" meddra_llt_id="10010276" meddra_pt="Conduction disorder" meddra_pt_id="10010276" />
    </Mention>
    <Mention id="M675" len="23" reason="preexisting_condition_or_risk_factor" section="S3" start="25436" type="Not_AE_Candidate">
      <Normalization meddra_llt="Unspecified cerebrovascular disease" meddra_llt_id="10045652" meddra_pt="Cerebrovascular disorder" meddra_pt_id="10008196" />
    </Mention>
    <Mention id="M760" len="11" reason="AE_only_as_instruction" section="S3" start="25511" type="NonOSE_AE">
      <Normalization meddra_llt="Hypotension" meddra_llt_id="10021097" meddra_pt="Hypotension" meddra_pt_id="10021097" />
    </Mention>
    <Mention id="M676" len="11" reason="preexisting_condition_or_risk_factor" section="S3" start="25530" type="Not_AE_Candidate">
      <Normalization meddra_llt="Dehydration" meddra_llt_id="10012174" meddra_pt="Dehydration" meddra_pt_id="10012174" />
    </Mention>
    <Mention id="M677" len="11" reason="preexisting_condition_or_risk_factor" section="S3" start="25546" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hypovolemia" meddra_llt_id="10021139" meddra_pt="Hypovolaemia" meddra_pt_id="10021137" />
    </Mention>
    <Mention id="M776" len="11" reason="AE_from_drug_interaction" section="S3" start="25582" type="NonOSE_AE">
      <Normalization meddra_llt="Hypotension" meddra_llt_id="10021097" meddra_pt="Hypotension" meddra_pt_id="10021097" />
    </Mention>
    <Mention id="M789" len="27" reason="AE_only_as_instruction" section="S3" start="25656" type="NonOSE_AE">
      <Normalization meddra_llt="Drug therapy" meddra_llt_id="10063370" meddra_pt="Drug therapy" meddra_pt_id="10063370" />
      <Normalization meddra_pt="Immunoglobulin therapy" meddra_pt_id="10069534" />
    </Mention>
    <Mention id="M806" len="10" reason="from_drug_use" section="S3" start="25704" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Somnolence" meddra_llt_id="10041349" meddra_pt="Somnolence" meddra_pt_id="10041349" />
    </Mention>
    <Mention id="M807" len="20" reason="from_drug_use" section="S3" start="25716" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Postural hypotension" meddra_llt_id="10036433" meddra_pt="Orthostatic hypotension" meddra_pt_id="10031127" />
    </Mention>
    <Mention id="M863" len="5,11" reason="from_drug_use" section="S3" start="25738,25756" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Motor deficit" meddra_llt_id="10079471" meddra_pt="Motor dysfunction" meddra_pt_id="10061296" />
    </Mention>
    <Mention id="M808" len="19" reason="from_drug_use" section="S3" start="25748" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sensory aberrations" meddra_llt_id="10040020" meddra_pt="Sensory disturbance" meddra_pt_id="10040026" />
    </Mention>
    <Mention id="M761" len="5" reason="manifestation_or_complication" section="S3" start="25865" type="NonOSE_AE">
      <Normalization meddra_llt="Fall" meddra_llt_id="10016173" meddra_pt="Fall" meddra_pt_id="10016173" />
    </Mention>
    <Mention id="M762" len="9" reason="manifestation_or_complication" section="S3" start="25890" type="NonOSE_AE">
      <Normalization meddra_llt="Ill-defined fractures of bones of trunk" meddra_llt_id="10021350" meddra_pt="Fracture" meddra_pt_id="10017076" />
    </Mention>
    <Mention id="M763" len="21" reason="manifestation_or_complication" section="S3" start="25909" type="NonOSE_AE">
      <Normalization meddra_llt="Injury" meddra_llt_id="10022116" meddra_pt="Injury" meddra_pt_id="10022116" />
    </Mention>
    <Mention id="M764" len="5" reason="AE_only_as_instruction" section="S3" start="26070" type="NonOSE_AE">
      <Normalization meddra_llt="Fall" meddra_llt_id="10016173" meddra_pt="Fall" meddra_pt_id="10016173" />
    </Mention>
    <Mention id="M809" len="10" reason="from_drug_use" section="S3" start="26317" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Leukopenia" meddra_llt_id="10024384" meddra_pt="Leukopenia" meddra_pt_id="10024384" />
    </Mention>
    <Mention id="M810" len="11" reason="from_drug_use" section="S3" start="26328" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M811" len="15" reason="from_drug_use" section="S3" start="26431" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Agranulocytosis" meddra_llt_id="10001507" meddra_pt="Agranulocytosis" meddra_pt_id="10001507" />
    </Mention>
    <Mention id="M765" len="10" reason="AE_only_as_instruction" section="S3" start="26499" type="NonOSE_AE">
      <Normalization meddra_llt="Leukopenia" meddra_llt_id="10024384" meddra_pt="Leukopenia" meddra_pt_id="10024384" />
    </Mention>
    <Mention id="M766" len="11" reason="AE_only_as_instruction" section="S3" start="26510" type="NonOSE_AE">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M678" len="31" reason="preexisting_condition_or_risk_factor" section="S3" start="26543" type="Not_AE_Candidate">
      <Normalization meddra_llt="White blood cell count low" meddra_llt_id="10051617" meddra_pt="White blood cell count decreased" meddra_pt_id="10047942" />
    </Mention>
    <Mention id="M679" len="12,11" reason="preexisting_condition_or_risk_factor" section="S3" start="26591,26615" type="Not_AE_Candidate">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M686" len="23" reason="preexisting_condition_or_risk_factor" section="S3" start="26591" type="Not_AE_Candidate">
      <Normalization meddra_llt="Leukopenia" meddra_llt_id="10024384" meddra_pt="Leukopenia" meddra_pt_id="10024384" />
    </Mention>
    <Mention id="M657" len="7" reason="preexisting_condition_or_risk_factor" section="S3" start="26680" type="Not_AE_Candidate">
      <Normalization meddra_llt="WBC decreased" meddra_llt_id="10056731" meddra_pt="White blood cell count decreased" meddra_pt_id="10047942" />
    </Mention>
    <Mention id="M680" len="23" reason="preexisting_condition_or_risk_factor" section="S3" start="26693" type="Not_AE_Candidate">
      <Normalization meddra_llt="Leukopenia" meddra_llt_id="10024384" meddra_pt="Leukopenia" meddra_pt_id="10024384" />
    </Mention>
    <Mention id="M681" len="12,11" reason="preexisting_condition_or_risk_factor" section="S3" start="26693,26717" type="Not_AE_Candidate">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M702" len="14" reason="AE_only_as_instruction" section="S3" start="26940" type="NonOSE_AE">
      <Normalization meddra_llt="WBC dec" meddra_llt_id="10047859" meddra_pt="White blood cell count decreased" meddra_pt_id="10047942" />
    </Mention>
    <Mention id="M767" len="11" reason="AE_only_as_instruction" section="S3" start="27037" type="NonOSE_AE">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M703" len="5" reason="manifestation_or_complication" section="S3" start="27083" type="NonOSE_AE">
      <Normalization meddra_llt="Fever" meddra_llt_id="10016558" meddra_pt="Pyrexia" meddra_pt_id="10037660" />
    </Mention>
    <Mention id="M768" len="9" reason="manifestation_or_complication" section="S3" start="27119" type="NonOSE_AE">
      <Normalization meddra_llt="Infection" meddra_llt_id="10021789" meddra_pt="Infection" meddra_pt_id="10021789" />
    </Mention>
    <Mention id="M769" len="11" reason="AE_only_as_instruction" section="S3" start="27204" type="NonOSE_AE">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M770" len="37" reason="AE_only_as_instruction" section="S3" start="27217" type="NonOSE_AE">
      <Normalization meddra_llt="Absolute neutrophil count decreased" meddra_llt_id="10059234" meddra_pt="Neutrophil count decreased" meddra_pt_id="10029366" />
    </Mention>
    <Mention id="M864" len="9,10" reason="from_drug_use" section="S3" start="27361,27381" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Cognitive impairment" meddra_llt_id="10009846" meddra_pt="Cognitive disorder" meddra_pt_id="10057668" />
    </Mention>
    <Mention id="M812" len="10" reason="from_drug_use" section="S3" start="27395" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Somnolence" meddra_llt_id="10041349" meddra_pt="Somnolence" meddra_pt_id="10041349" />
    </Mention>
    <Mention id="M813" len="10" reason="from_drug_use" section="S3" start="27722" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Somnolence" meddra_llt_id="10041349" meddra_pt="Somnolence" meddra_pt_id="10041349" />
    </Mention>
    <Mention id="M814" len="10" reason="from_drug_use" section="S3" start="27950" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Somnolence" meddra_llt_id="10041349" meddra_pt="Somnolence" meddra_pt_id="10041349" />
    </Mention>
    <Mention id="M815" len="15" reason="from_drug_use" section="S3" start="28028" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Judgement impaired" meddra_llt_id="10023236" meddra_pt="Judgement impaired" meddra_pt_id="10023236" />
    </Mention>
    <Mention id="M865" len="6,8" reason="from_drug_use" section="S3" start="28028,28045" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Difficulty thinking" meddra_llt_id="10012805" meddra_pt="Mental impairment" meddra_pt_id="10027374" />
    </Mention>
    <Mention id="M866" len="6,12" reason="from_drug_use" section="S3" start="28028,28058" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Motor dysfunction" meddra_llt_id="10061296" meddra_pt="Motor dysfunction" meddra_pt_id="10061296" />
    </Mention>
    <Mention id="M682" len="13" reason="indication" section="S3" start="28329" type="Not_AE_Candidate">
      <Normalization meddra_llt="Schizophrenia" meddra_llt_id="10039626" meddra_pt="Schizophrenia" meddra_pt_id="10039626" />
    </Mention>
    <Mention id="M816" len="8" reason="from_drug_use" section="S3" start="28344" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Seizures" meddra_llt_id="10039910" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M790" len="12" reason="AE_only_as_instruction" section="S3" start="28441" type="NonOSE_AE">
      <Normalization meddra_llt="Hyponatremia" meddra_llt_id="10021038" meddra_pt="Hyponatraemia" meddra_pt_id="10021036" />
    </Mention>
    <Mention id="M683" len="8" reason="preexisting_condition_or_risk_factor" section="S3" start="28527" type="Not_AE_Candidate">
      <Normalization meddra_llt="Seizures" meddra_llt_id="10039910" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M869" len="9" reason="from_drug_use" section="S3" start="28547" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dysphagia" meddra_llt_id="10013950" meddra_pt="Dysphagia" meddra_pt_id="10013950" />
    </Mention>
    <Mention id="M867" len="22" reason="from_drug_use" section="S3" start="28560" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Oesophageal motility disorder" meddra_llt_id="10072419" meddra_pt="Oesophageal motility disorder" meddra_pt_id="10072419" />
    </Mention>
    <Mention id="M868" len="10" reason="from_drug_use" section="S3" start="28587" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Aspiration" meddra_llt_id="10003504" meddra_pt="Aspiration" meddra_pt_id="10003504" />
    </Mention>
    <Mention id="M771" len="20" reason="AE_only_as_instruction" section="S3" start="28648" type="NonOSE_AE">
      <Normalization meddra_llt="Aspiration pneumonia" meddra_llt_id="10003525" meddra_pt="Pneumonia aspiration" meddra_pt_id="10035669" />
    </Mention>
    <Mention id="M658" len="20" reason="preexisting_condition_or_risk_factor" section="S3" start="28740" type="Not_AE_Candidate">
      <Normalization meddra_llt="Dementia Alzheimer's type" meddra_llt_id="10012271" meddra_pt="Dementia Alzheimer's type" meddra_pt_id="10012271" />
    </Mention>
    <Mention id="M772" len="20" reason="AE_only_as_instruction" section="S3" start="28858" type="NonOSE_AE">
      <Normalization meddra_llt="Aspiration pneumonia" meddra_llt_id="10003525" meddra_pt="Pneumonia aspiration" meddra_pt_id="10035669" />
    </Mention>
    <Mention id="M817" len="8" reason="from_drug_use" section="S3" start="28967" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Priapism" meddra_llt_id="10036661" meddra_pt="Priapism" meddra_pt_id="10036661" />
    </Mention>
    <Mention id="M773" len="8" reason="AE_only_as_instruction" section="S3" start="29036" type="NonOSE_AE">
      <Normalization meddra_llt="Priapism" meddra_llt_id="10036661" meddra_pt="Priapism" meddra_pt_id="10036661" />
    </Mention>
    <Mention id="M818" len="41" reason="class_effect" section="S3" start="29121" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Temperature regulation disorder" meddra_llt_id="10061376" meddra_pt="Temperature regulation disorder" meddra_pt_id="10061376" />
    </Mention>
    <Mention id="M819" len="12" reason="from_drug_use" section="S3" start="29213" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hyperthermia" meddra_llt_id="10020843" meddra_pt="Hyperthermia" meddra_pt_id="10020843" />
    </Mention>
    <Mention id="M820" len="11" reason="from_drug_use" section="S3" start="29230" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypothermia" meddra_llt_id="10021113" meddra_pt="Hypothermia" meddra_pt_id="10021113" />
    </Mention>
  </Mentions>
</GoldLabel>